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Summary 
Allergic rhinitis (AR) is a common respiratory allergic condition characterised by 
sneezing, itching, rhinorrhoea and/or nasal congestion, affecting 16% of the 
Australian population. Although it is not a life threatening disease, it has a significant 
impact on patients’ quality of life in terms of physical, psychological and social 
aspects. There is also a substantial economic burden on sufferers and the health 
care system associated with AR.  
 
Current Western medical management of AR includes pharmacotherapy, allergen-
specific immunotherapy and others. These therapies usually do not completely 
relieve all AR symptoms, with some unwanted side effects. Chinese medicine, 
including acupuncture and Chinese herbal medicine (CHM), has a long history of 
treating AR in China. Ear-acupressure is a subtype of acupuncture. Previous clinical 
studies suggested that ear-acupressure was effective and safe for AR management. 
However, there was insufficient evidence to confirm the claims of clinical efficacy for 
ear-acupressure in AR. The aim of this study was to investigate the efficacy and 
safety of ear-acupressure for the clinical management of AR by conducting 
systematic reviews and randomised controlled trials (RCTs). The study consists of 
two systematic reviews, two pilot RCTs and one main RCT:  
 
Systematic review 1: Ear-acupuncture/ear-acupressure for AR 
This systematic review was conducted prior to designing the clinical trial protocol. By 
systematically reviewing previous RCTs on ear-acupuncture/ear-acupressure for AR, 
it was concluded that ear-acupressure might be effective and safe for AR. However, 
the previous RCTs in this area suffered methodological weakness and a rigorously 
designed RCT was required (Appendix A4.2, publication 2). 
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Systematic review 2: Sham control methods in ear-acupuncture/ear-
acupressure RCTs 
In order to determine the sham control method for the RCT, a systematic review on 
all previous ear-acupuncture/ear-acupressure RCTs was conducted. There were four 
types of control methods that had been used in previous ear-acupuncture/ear-
acupressure RCTs: 
 Type I: non-specific ear points for the condition treated;  
 Type II: non-ear points;  
 Type III: placebo needles or adhesive patches; and  
 Type IV: pseudo-interventions  
Among these four types of sham control methods, type I method (non-specific ear 
points) was the most commonly used sham/placebo control. Based on the findings of 
this systematic review, type I sham control was employed in RCTs. 
 
Ear-acupressure for AR RCT: Pilot study I (feasibility study) 
The trial protocol and ethics application were finalised and approved in November 
2007. In order to assess the feasibility of the trial protocol, a pilot study was 
conducted between May and November 2008 at RMIT University’s Bundoora 
campus. Eighteen (18) perennial allergic rhinitis (PAR) participants were included in 
this pilot study with 17 of them completed the pilot trial. No serious adverse event 
was reported.  
 
It was demonstrated that ear-acupressure as an intervention could be effectively 
employed in a trial setting including participants recruitment, initial assessment, 
delivery of treatment and data collection. The pilot study also identified several areas 
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of improvement which were incorporated into the amended trial protocol that was 
submitted to and approved by the RMIT Human Research Ethics Committee in 
August 2008. 
 
Ear-acupressure for AR RCT: Pilot study II (efficacy study) 
Pilot study II (efficacy study) was conducted between September and December 
2008 to investigate the efficacy of ear-acupressure for seasonal allergic rhinitis (SAR) 
and to provide data for sample size estimation for the main trial. Sixty-three (63) SAR 
participants were included in this pilot, of whom 57 completed the study. At the end of 
the eight-week treatment period, significant differences between the two groups were 
found in terms of sneezing, total nasal symptoms, global nasal and non-nasal 
symptoms and regular activities at home and work. No severe adverse event was 
reported (Appendix A4.3, publication 3). Based on the findings of this study, the 
sample size of the main trial was calculated using G. Power 3.0.5 Software. It was 
estimated that the main trial requires 116 participants in each group and 232 in total. 
 
Ear-acupressure for AR RCT: the main trial 
The ear-acupressure for the AR main trial was conducted in 2009 and 2010 
according to the amended protocol, at two trial centres: Melbourne, Australia and 
Guangzhou, China. This PhD project was to investigate the efficacy and safety of 
ear-acupressure for allergic rhinitis at the Australia centre of the multi-centre trial. 
Therefore, only the results from Australian trial centre (n=117) are reported in this 
thesis. Data from the other Centre will be handled separately, but may be combined 
in publications. The trial lasted for 22 weeks including a two-week run-in period, an 
eight-week treatment period and a 12-week follow-up period. Assessment of the 
treatment outcomes included symptom severity scores using a four point scale, 
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seven-point visual analogue scale (VAS) and a quality-of-life questionnaire, relief 
medication scores, and patients’ opinion during the run-in period, treatment and 
follow-up period.  Significant differences between two groups were found in the 
following items: total nasal symptom, sneezing, blocked nose, itchy nose, watery 
eyes, global nasal and non-nasal symptoms, global quality of life, activity and sleep 
domain at the end of treatment period; and total nasal symptoms, blocked nose 
symptom and sleep domain at the end of follow-up period. Some mild and moderate 
discomforts were reported by participants during the treatment period. However, 
these discomforts were short-term and effectively managed by refinement of the 
pressing techniques by participants. No medical treatment was required for the 
management of these events. 
 
Findings from this main trial suggested that ear-acupressure is effective and safe for 
symptomatic control and quality of life improvement in AR.   
 
Conclusion 
This thesis presents outcomes of two systematic reviews that address key research 
questions concerning the methodology and current state of evidence of ear-
acupressure for AR, followed by findings from two trials that determine the efficacy 
and safety of ear-acupressure for AR. This is the first comprehensive examination of 
the potential role of a semi-self-administered traditional medicine technique in the 
management of a highly prevalent clinical condition. Further evaluation in different 
population is needed, and particularly, cost-effectiveness analysis is required to 
determine the value for money in the healthcare system that will facilitate further 
translation of clinical evidence into practice.  
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Chapter 1: General Introduction  
1.1 Background  
AR was initially described in 1929 as “the three cardinal symptoms in nasal reactions 
occurring in allergy are sneezing, nasal obstruction and mucous discharge” (Hansel, 
1929). Currently, the definition of AR is “a symptomatic disorder of the nose induced 
after allergen exposure by an immunoglobulin E (IgE)-mediated inflammation” 
(Bousquet, Khaltaev, et al., 2008). It is an immune response triggered by nasal 
membrane exposure to specific allergens such as pollens, moulds, animal dander 
and dust mites. The main symptoms of AR are nasal symptoms such as sneezing, 
itching, rhinorrhoea and/or nasal congestion. These symptoms are provoked by a 
complicated network involving mediators, cytokines, chemokines, neuropeptides, 
adhesion molecules and cells.  
 
AR is a major chronic respiratory disease due to its high prevalence and significant 
impact on patients’ quality of life. The prevalence of AR is high worldwide and it has 
been increasing in the last decades (Bousquet, Khaltaev, et al., 2008). The increase 
in prevalence may be caused by the change in people’s life style, the environment 
and the weather. In Australia, AR is one of the most common long-term conditions 
and it affects approximately 16% of the Australian population (Australian Institute of 
Health and Welfare (AIHW), 2006). The prevalence of AR in the Melbourne area is 
also reported as very high due to the local botanical environment (Bousquet, 
Leynaert, et al., 2008).  
 
Although AR symptoms are reversible spontaneously with reduction of allergen 
exposure or can be controlled under proper treatment, they significantly impact on 
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patients’ quality of life through causing sleep disturbance, learning disability or work 
impairment (Juniper, 2001). In addition, AR is considered a risk factor for asthma, 
sinusitis and other co-morbidities such as conjunctivitis. Therefore, AR leads to a 
substantial burden on health and the economy (Bousquet, Van Cauwenberge, & 
Khaltaev, 2001). 
 
The current conventional medical managements of AR include allergen avoidance, 
pharmacotherapy and immunotherapy. However, these treatments have limitations. 
Firstly, the inhalant allergens such as pollens, moulds, animal dander and dust mites 
exist in the air. For AR sufferers, to totally avoid those allergens is not feasible. 
Secondly, the current pharmacologic managements for AR usually do not provide 
complete symptomatic relief and often cause unwanted side effects. For example, 
anti-histamines are the most commonly prescribed medications for AR as histamine 
is the major mediator involved in the pathophysiology of allergic symptoms. The first 
generation of anti-histamine medications had severe central nervous system side 
effects. Although the second generation of anti-histamine medications avoid the 
central nervous system side effects, other side effects have been reported (such as 
cardiac side effects). Another type of drug prescribed for AR is the 
glucocorticosteroids due to their anti-inflammatory and other effects. Local and 
systemic side effects caused by glucocorticosteroids are also commonly reported.  
Thirdly, specific immunotherapy may cause serious adverse events such as systemic 
allergic reactions. Due to the side effects or the inability to completely relive all 
symptoms for all patients of the conventional medical approaches, there has been an 
increasing trend among AR sufferers towards seeking complementary and alternative 
medicine (CAM) treatments for AR (Schafer, Riehle, Wichmann, & Ring 2002; Xue, 
Thien, Zhang, Da Costa, & Li, 2003; Xue et al., 2007). 
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The use of CAM has been increasing in recent years in the Western countries 
(Eisenberg et al., 1998; Eisenberg et al., 1993; Ramsay, Walker, & Alexander, 1999; 
Thomas, Nicholl, & Coleman, 2001). In Australia, more than two-thirds of the 
population used CAM therapies (68.9%) (Xue, Zhang, Lin, Da Costa, & Story, 2007). 
Chinese medicine, including Chinese herbal medicine (CHM) and acupuncture 
therapy, is considered a part of CAM. It has also been used in China for a great 
variety of conditions for thousands of years. In the Western countries, CHM and 
acupuncture are also commonly used. The philosophy of Chinese medicine is to 
restore balance of the human body and thus overcome the disease. Recently, clinical 
researchers have provided quality data concerning the efficacy and safety of CHM for 
AR (Chui, Shek, Fong, Szeto, & Chan, 2010; Matkovic et al., 2010; Xue, Thien, 
Zhang, Da Costa, & Li, 2003) and acupuncture for AR (Magnusson, Svensson, 
Leirvik, & Gunnarsson, 2004; Ng et al., 2004; Xue et al., 2007). Based on the 
reported evidence of acupuncture for AR, needling process with skin penetration is a 
hurdle for wider acceptance of acupuncture in the AR population. Therefore, a non-
invasive ear-acupressure technique would be advantageous for AR sufferers, 
however, data on its benefit and safety is lacking.  
 
Ear-acupuncture/ear-acupressure is an alternative form of the traditional body 
acupuncture. It originated in ancient China and was further developed in France in 
the 1950’s. It views the ear as a microcosm of the body in which each part of the 
body is projected on the ear (Frank & Soliman, 2006). Instead of stimulating the 
acupoints on the body, ear-acupuncture/ear-acupressure stimulates acupoints on the 
ears. To generate stimulation on the ear acupoints, ear-acupuncture with needle 
insertion or ear-acupressure using ear-pellets attached to ear acupoints are both 
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commonly used in clinical practice. These methods have a long history of clinical 
practice in the Western world and China for a range of conditions. Generally 
speaking, ear-acupressure is safer compared with needling as it does not involve 
skin penetration (Frank & Soliman, 2006). Furthermore, when applying the treatment 
of ear-acupressure by attaching pellets or seeds to ear points, patients are requested 
to periodically press the pellets themselves. Therefore, patients are also involved in 
the administration of the treatment and the stimulation intensity on the ear points is 
controlled by the patients, not the practitioner alone.  
 
As a microsystem, each part of the whole body has a corresponding location on the 
ear, so there are ear points that relate to the nose, the eyes and also to allergy. 
Stimulating these points aims to produce therapeutic effects on AR symptoms. In 
recent years, researchers have conducted clinical trials on ear-acupressure/ear-
acupuncture for AR to investigate the efficacy and safety of these methods (Gao, Liu, 
& Zhou, 2008; Qi & Wang, 2008; Rao & Han, 2006; Ye, Luo & Xia, 2008). All these 
clinical studies have provided positive results. However, at the commencement of this 
study there was not, as yet, any systematic review to assess the current evidence in 
this area.  
 
Therefore, we conducted this study to determine clinical evidence for the efficacy and 
safety of ear-acupressure for AR.  
  
 
1.2 Study design  
Randomised controlled trials (RCTs) are considered powerful tools in clinical 
research for testing the efficacy and safety of healthcare services since they can 
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separate the “specific” from the “unspecific” or “placebo” effects of an intervention 
(Dincer & Linde, 2003). This study is designed as an RCT to evaluate the efficacy 
and safety of ear-acupressure for AR.  
 
Prior to designing the trial protocol, it was considered important to conduct a 
systematic review to evaluate all currently available RCTs on this topic. The aim of 
this review was to provide evidence for the design of the ear-acupressure for AR 
RCT. This review followed the methods specified in the Cochrane Handbook for 
Systematic Reviews of Interventions 4.2.6 (Higgins & Green, 2006). All types of ear-
acupuncture/ear-acupressure for all types of AR RCTs were included in the 
systematic review. The findings from this review provided evidence on the 
effectiveness and safety of these interventions as well as data that informed the 
design of the RCTs of ear-acupressure for AR discussed below.  
 
For designing a RCT, if the intervention is a physical procedure, the placebo control 
is not possible to be an inert one. In this case, sham control methods will be 
employed. Hence, the question arises: how to design an appropriate sham control for 
an ear-acupressure RCT? In order to develop a well-designed RCT on ear-
acupressure, another systematic review focussing on all the sham control methods 
used in previous ear-acupuncture/ear-acupressure studies was undertaken. This 
review also followed the methods specified in the Cochrane Handbook for Systematic 
Reviews of Interventions 4.2.6 (Higgins & Green, 2006). All the available sham 
controlled RCTs of any type of ear-acupuncture or ear-acupressure for any type of 
clinical conditions were included in this review. 
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Based on the findings from above two systematic reviews, the protocol of a 
randomised, single-blinded, sham controlled clinical trial on ear-acupressure for AR 
was finalised.  
 
In order to test the feasibility of the trial protocol, a small sized pilot study (Pliot study 
I (feasibility study)) was conducted in 2008. As a result of completing this pilot study, 
some minor methodological weaknesses were found. Consequently, amendments 
were made to the protocol for the main RCT. Furthermore, due to the lack of reliable 
data for sample size calculation for the main trial, Pilot study II (efficacy study) was 
conducted in 2008. The effect size in this pilot study was used for sample size 
calculation for the main trial. 
 
The main trial was an international, multi-centre, adequately powered, randomised, 
single-blinded, sham controlled clinical trial. It was conducted at two trial centres: one 
in Australia and one in China, between 2009 and 2010. The results from Australian 
centre are reported in this thesis. 
 
The main structure of this study is shown in Figure 1: 
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Figure 1: Structure of ear-acupressure for AR study 
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1.3 Aims and Objectives 
The aims of the study were to investigate whether ear-acupuncture/ear-acupressure 
treatment may provide effective symptomatic relief for AR and whether ear-
acupuncture/ear-acupressure treatment is safe in the management of AR, by 
conducting two systematic reviews and a rigorously-designed RCT.  
 
The objectives of two systematic reviews are: 
a. To evaluate  whether ear-acupuncture/ear-acupressure is effective for the 
management of AR according to currently available studies; 
b. To evaluate  whether ear-acupuncture/ear-acupressure is safe for the 
management of AR according to current available RCTs; 
c. To summarise the designs of sham control methods from currently available 
ear-acupuncture/ear-acupressure RCTs. 
 
The objectives of the RCTs are:  
a. To evaluate whether ear-acupressure can relieve AR symptoms, including 
nasal symptoms, non-nasal symptoms and global nasal and non-nasal 
symptoms; 
b. To test whether ear-acupressure can improve AR sufferers’ quality of life; 
c. To assess whether ear-acupressure can reduce AR medication usage; and 
d. To investigate whether ear-acupressure is a safe treatment for the AR 
management. 
 
The hypotheses tested in the RCTs are: 
a.  Null hypothesis: 
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There was no statistically significant difference at post treatment between the 
intervention and control groups. 
b. Alternative hypothesis: 
There was a statistically significant difference at post treatment between the 
intervention and control groups. 
 
1.4 Location of the study  
The main trial was an international, multi-centre, clinical trial conducted at two clinical 
trial centres: 
 Australian centre 
The Australian centre is in the Discipline of Chinese Medicine, School of 
Health Sciences, RMIT University, Victoria, Australia. 
 China centre 
The centre in China is located in Guangdong Provincial Academy of Chinese 
Medical Sciences, Guangzhou, China. 
Prior to the commencement of the main trial, the two systematic reviews and two pilot 
studies were conducted at the Australian centre only. 
 
This thesis only reports the findings from the Australian centre, in addition to two 
systematic reviews, and two pilot studies. 
 
1.5 Organisation of the thesis 
This thesis consists of nine chapters, as follows:  
14 
 
 Chapter 1 briefly introduces the background of AR and ear-acupressure, and 
the aims and objectives of this study. The study structure and the organisation 
of the thesis are also introduced in this chapter.  
 Chapter 2 provides a descriptive review, from the Western medicine 
perspective, on AR with respect to its definition, epidemiology, classification, 
diagnosis and clinical management.  
 Chapter 3 addresses AR from Chinese medicine point of view. It explains the 
Chinese medicine managements including CHM and acupuncture for AR, as 
well as the current clinical research in this area.  
 Chapter 4 introduces ear-acupuncture/ear-acupressure treatment methods, 
systematically reviews the current research on ear-acupuncture/ear-
acupressure for AR, and the sham control designs used in all ear-
acupuncture/ear-acupressure sham-controlled RCTs.  
 Chapter 5 presents the details of the methodology of the RCT including 
recruitment, selection criteria, trial procedures, outcome measures, data 
collection and data analysis.  
 Chapter 6 reports the procedure and results of Pilot study I (feasibility study). . 
Upon the completion of this pilot study, some minor changes in the trial 
methods were made for the further trials.  
 Chapter 7 reports the procedure and results of Pilot study II (efficacy study). 
The sample size of the main trial was calculated based on the results of this 
pilot study.  
 Chapter 8 reports the procedure and results of the ear acupressure for the AR 
main trial conducted at the Australian centre.  
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 Finally, Chapter 9 discusses the strengths and limitations of the whole project, 
outlines the overall evidence and provides recommendations for future 
research on ear-acupressure for AR and the implications for clinical practice.   
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Chapter 2: Literature review on allergic rhinitis from the 
Western medicine perspective 
This chapter provides a review, from the Western medicine perspective, of allergic 
rhinitis (AR) with respect to its definition, epidemiology, classification, diagnosis and 
clinical management. The drawbacks of current mainstream treatments for AR are 
elaborated to address the need to seek additional approaches to AR management. 
 
Rhinitis, characterised mainly by nasal symptoms, is a condition of irritation and 
inflammation of the nose lining. Due to its different causes, rhinitis is classified as: 
infectious rhinitis, AR, occupational rhinitis, drug-induced rhinitis, hormonal rhinitis 
and others (Bousquet, Khaltaev, et al., 2008; Bousquet, Van Cauwenberge, & 
Khaltaev, 2001). Among them, AR is the most common non-infectious rhinitis.  
 
AR is a major chronic respiratory disease due to its high prevalence, impact on 
quality of life, impact on work/school performance and productivity, significant 
economic burden (Juniper et al., 2005) and its links with asthma (Scadding, 2008).   
 
2.1 Definition of AR 
AR, commonly called “hay fever”, is a disorder induced by inflammation of the nasal 
membranes. Exposure to specific allergens such as pollens, moulds, animal dander 
and dust mites leads to an IgE-mediated immune response and induces inflammation 
of the nose lining. Clinically, AR is defined as a “symptomatic disorder of the nose 
induced after allergen exposure by the IgE-mediated inflammation” (Bousquet, 
Khaltaev, et al., 2008). 
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AR is characterised by one or more nasal symptoms including sneezing, itching, 
rhinorrhoea and/or nasal congestion. In addition, AR nasal symptoms are frequently 
accompanied by symptoms involving the eyes, ears and throat, such as itchy and 
watery eyes, redness and tearing of the eyes, ear fullness and popping, itchy throat, 
post nasal drip, chronic cough, and feeling of pressure over the cheeks and forehead. 
Malaise, weakness and fatigue may also be present in AR sufferers (Dykewicz et al., 
1998; Skoner, 2001). 
 
2.2 Epidemiology of AR 
2.2.1 Prevalence in global general population 
AR has a high prevalence at 10% to 45% globally. The results of recent prevalence 
studies in a number of countries are summarised in Table 1. 
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Table 1: Prevalence of AR in specific countries 
Country Prevalence of AR Reference Country 
Prevalence 
of AR Reference 
Australia 16.1%  (ABS, 2006) Japan 44.2% (Sakashita et al., 2009) 
Belgium 28.5%  (Bauchau & Durham, 2004) Lebanon  38.6% 
(Musharrafieh 
et al., 2009) 
France 24.5% (Bauchau & Durham, 2004) Poland 22.54% 
(Samolinski et 
al., 2009) 
Germany 20.6% (Bauchau & Durham, 2004) Spain 21.5% 
(Bauchau & 
Durham, 2004) 
Gulf Arab 
population 32% 
(Alsowaidi, 
Abdulle, 
Shehab, 
Zuberbier, & 
Bernsen, 
2010) 
Turkey 23.1% (Cingi et al., 2009) 
Italy 16.9% (Bauchau & Durham, 2004) UK 26% 
(Bauchau & 
Durham, 2004) 
 
Using a conservative estimate, it is suggested that AR occurs in approximately 500 
million people in the world (Bousquet, Khaltaev, et al., 2008). The relative proportions 
of AR sufferers in different areas are shown in Figure 2. 
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Figure 2: Worldwide AR prevalence  
 
Among all the areas, the Asia-Pacific area has the highest AR population (over 150 
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trends in prevalence. Comparing the results from Phase I and Phase III of this study, 
it was found that there was a global increase in AR prevalence in the 6 to 7 years 
age group and in the 13 to 14 years group across most countries (Asher et al., 2006; 
Bousquet, Khaltaev, et al., 2008). 
 
2.2.3 AR prevalence in Australia and China 
In Australia, the AR prevalence in the total population has increased from 13.9% in 
1995 to 16.1% in 2004-05 (ABS, 2006; Australian Institute of Health and Welfare 
(AIHW), 2006) with a per annum increase of 0.22% (Australasian Society of Clinical 
Immunology and Allergy (ASCIA), 2007). The National Health Survey conducted in 
2002 reported that there were 2.9 million people suffering from AR (Australian 
Institute of Health and Welfare (AIHW), 2005), while in 2007 there were in total 
3,342,870 Australian AR sufferers of all ages including 15.6% of the total male 
population (1,613,432) and 16.6% of the female population (1,729,438) (Australasian 
Society of Clinical Immunology and Allergy (ASCIA), 2007). Considering the growth 
of population and the trend of increasing prevalence, it is estimated that there will be 
7.86 million AR sufferers in Australia by 2050 (Australasian Society of Clinical 
Immunology and Allergy (ASCIA), 2007). The results of the ISAAC study proved that 
in Australia, the prevalence of AR among children aged 6-7 years old has increased 
from 9.8% to 12.9% from 1994-5 to 2001-3 (Asher et al. 2006). 
 
The prevalence of AR in Australia varies by region. According to a self-reported 
survey in 2001, the Australian Capital Territory had the highest prevalence of AR 
(25.3%) whilst the lowest AR prevalence was found in New South Wales (13.1%) 
(Public and Environmental Health Service, 2003) (Figure 3). 
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(Asher et al., 2006; Bousquet, Khaltaev, et al., 2008). Another survey conducted 
between December 2009 and January 2010 in Asia-Pacific area (Allergies In Asia-
Pacific: A Landmark Survey of Nasal Allergy Sufferers (AIAP)) concluded that 9% of 
the population in China had been diagnosed with nasal allergies, which is equal to 
the average AR prevalence of the entire Asia-Pacific area. 
 
2.2.4 Factors impacting on AR prevalence 
The factors which cause variation in AR prevalence may differ from one location to 
another and from one age-group to another. They can be related to aspects of 
lifestyle, dietary habits, microbial exposure, economic status, indoor or outdoor 
environment, climatic variation, awareness of the disease and the management of 
symptoms (Asher et al., 2006).  
 
Firstly, the geographic factors cause differences in the AR prevalence. For example, 
in Western and developed countries such as the United States, Australia, New 
Zealand and United Kingdom, the prevalence of AR is higher than that in developing 
countries. These differences may not be simply caused by the difference between 
ethnic groups. In fact, whether genetic, environmental, socio-economic or cultural 
factors contributed to this difference is yet to be confirmed (Bousquet, Van 
Cauwenberge, & Khaltaev, 2001). 
 
Secondly, the life style differences between rural and urban areas may have an 
impact on the AR prevalence. Studies have shown that AR prevalence is higher in 
urban than in rural areas (Gergen & Turkeltaub, 1992; Nicolaou, Siddique, & 
Custovic, 2005; Soto-Quiros, Silverman, Hanson, Weiss, & Celedon, 2002). This 
difference may be caused by the fact that the pollen counts differ in urban and rural 
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areas or the countryside lifestyle could possibly protect children from the allergy 
development (Kilpelainen, Terho, Helenius, & Koskenvuo, 2002; Leynaert et al., 2001; 
Riikjarv, Annus, Braback, Rahu, & Bjorksten, 2000; Wickens et al., 2002). Therefore, 
adoption of an urbanised “Western” lifestyle such as having indoor animals, sharing a 
bedroom with a smoker, poor house ventilation and exposure to motor vehicles may 
lead to an increase the AR prevalence in developing countries (Gerez, Lee, van 
Bever, & Shek, 2010; Yemaneberhan et al., 1997).  
 
Thirdly, age also influences the AR prevalence. There is a significant variation in the 
prevalence of AR among different age groups. Although AR may occur in persons of 
all ages, it peaks between the ages of 6 and 20 (Bellanti & Wallerstedt, 2000). That is, 
the onset of AR is more common in childhood, adolescence and early adult years. 
On average, 40% of AR patients experience AR symptoms between 8 and 11 years 
of age, and up to 80% of AR patients experience symptoms by the age of 20 
(Skoner, 2001). 
 
In addition, there are other factors that relate to increases in AR prevalence, such as 
traffic-related air pollution which may play a role in the high prevalence in urban 
areas (Lindgren et al., 2009). Global climate change may also have an impact on the 
increasing AR prevalence due to the growth of atmospheric carbon dioxide (Beggs & 
Bambrick, 2005). Also, higher temperatures may expand the pollen quantity and 
induce longer pollen seasons (Sheffield, Weinberger, & Kinney, 2011; Ziska et al., 
2011).   
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2.3 Mechanisms of AR  
AR is a disease of nasal membrane inflammation mediated by IgE after allergen 
exposure. Symptoms of AR are provoked by a complicated network involving 
mediators, cytokines, chemokines, neuropeptides, adhesion molecules and cells. 
Understanding the mechanisms of the complex inflammatory reactions of AR 
provides a framework for rational therapy. This section introduces the 
pathophysiology of AR and the mechanisms of nasal inflammation resulting from an 
IgE mediated allergy. 
 
Briefly, when the nasal mucosa is exposed to a very small quantity of allergens, the 
antigens are phagocytosed by antigen presenting cells in the mucosal epithelium. 
The antigen presenting cells process and break antigens down into peptide 
fragments which bind to the antigen recognition sites of major histocompatibility 
complex class II molecules (Baraniuk, 1997). This membrane-bound complex is now 
presented to T cell antigen specific receptors. In an allergic person, the antigen-
specific T-cell receptors of Th0 cells recognise the antigenic peptides and differentiate 
into Th2 lymphocytes. Th2 cells release their characteristic combination of cytokines, 
which activate B cells to form IgE-secreting plasma cells. The IgE molecules bind to 
high affinity IgE-specific Fc-receptors on the membrane of mast cells and basophils 
(Mygind, 1996). With later exposure to the same allergen, the cross-link of bound IgE 
causes cell degranulation and triggers the release of various inflammatory mediators 
(Kuby, 1997) which is a critical event in acute AR. Histamine, tryptase, prostaglandin 
and bradykinin are rapidly released during this immediate allergic (Baraniuk, 1997) 
causing sneezing, nasal itch and rhinorrhoea. The late phase response usually 
occurs four to twelve hours after the immediate response during which there is a 
large increase of eosinophils, basophils and other leukocytes in response to 
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2.3.1 Nasal mucosa 
Firstly, understanding the structure of the nasal mucosa helps with understanding the 
nasal symptoms caused by inflammation. Inside the nose, there is a bony framework 
covered with mucosa which consists of three layers. There is also a thin layer of 
mucus on the surface of the nasal mucosa. Being an unspecific protection against 
infection, nasal fluid consists of the secretions produced by the submucosal gland 
and goblet cells, derived from the eyes or from the paranasal sinuses (Mygind et al., 
1987). In rhinitis, the hypersecretion from nasal mucous glands is important because 
an active secretory process in the nose appears to be the main cause of watery 
rhinorrhoea (Brofeldt, Mygind, Sorensen, Readman, & Marriott, 1986).  
 
Allergic inflammation can also decrease the mucociliary clearance function of the 
ciliated epithelium. The nasal mucosa has a high degree of vascularisation. The 
arteries in the nose microvasculature are surrounded by a smooth muscle layer 
which controls the blood supply. The nasal mucosa can expand or shrink rapidly by 
changing the blood volume (Holmberg, Bake, & Pipkorn, 1988). Therefore, the 
capacitance vessels or sinuses can be distended to block the nasal lumen or be 
emptied to open the nasal passages (Holmberg, Bake, & Pipkorn, 1988).  
 
2.3.2 Nasal inflammation  
In the nasal inflammation caused by an IgE-mediated allergy reaction, cells, 
mediators, cytokines, chemokines and adhesion molecules all cooperate in a 
complex network provoking specific symptoms and nonspecific nasal hyperreactivity 
(Bousquet, Khaltaev, et al., 2008).  
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Mast cells release histamine and granule protein, arachidonic acid metabolites and 
cytokines (Bradding et al., 1993). Therefore, mast cells play an important role in 
immediate-phase allergic response, late-phase response and ongoing allergic 
inflammation (Bousquet, Van Cauwenberge, & Khaltaev, 2001). Basophils and 
eosinophils also release cytokines during allergic reaction. Other cells such as T-
lymphocytes, B-lymphocytes, macrophages, dendritic cells, epithelial cells, 
endothelial cells and fibroblasts are all involved in allergic reactions (Costa, Weller, & 
Galli, 1997; Foresi et al., 1997; Naclerio, 1997).  
 
Histamine has been recognised as the main mediator in allergic disorders since the 
1920s (Bachert, 1998). Histamine is quantitatively the major mediator released after 
the IgE activation on mast cells and basophils. It can cause many AR symptoms 
such as rhinorrhoea, sneezing, itchiness and nasal obstruction (Bachert, 1998; 
Beaven, 1978; Corrado, Gould, Kassab, & Davies, 1986) through its effects on 
sensory nerves, glands or vessels and its pro-inflammatory effects. Other mediators 
such as the Arachidonic acid metabolic pathway and the Kinins system are also 
considered to have effects on AR (Naclerio, 1997). 
 
Pro-inflammatory cytokines such as IL-1, tumour necrosis factor (TNF), IL-6 and IL-
18 are multifunctional unspecific enhancers of inflammation; while Th2-cytokines 
such as IL-4 and IL-3 are important in the regulation of IgE; and IL-3, GM-CSF and 
IL-5 are related to the production of eosinophils.  Chemokines are a family of small 
cytokines or proteins secreted by cells. The major role of chemokines in AR is to act 
as a chemoattractant to guide the migration of cells (Bousquet, Van Cauwenberge, & 
Khaltaev, 2001). 
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Cellular adhesion molecules are an essential part in binding circulating leukocytes to 
the vascular endothelium at sites of inflammation (Baroody, Lee, Lim, & Bochner, 
1995).  
 
In short, the nasal inflammatory reaction results from an increased recruitment of 
inflammatory cells and a prolonged survival of these cells in the nasal mucosa. This 
is due to interactions with adhesion molecules and probably altered apoptosis 
(Bousquet, Van Cauwenberge, & Khaltaev, 2001). 
 
2.3.3 Neurotransmitters 
Neuropeptides, the non-adrenergic, non-cholinergic system peptide 
neurotransmitters, are presumed to be involved in the allergic reaction (Joos, 
Germonpre, Kips, Peleman, & Pauwels, 1994). However, the mechanism of the 
specific involvement of neuropeptides in AR needs to be further investigated.  
 
Nitric oxide is an endogenous soluble gas acting as an intercellular transmitter. Nitric 
oxide has been observed to increase in the nose of AR patients (Kawamoto, Takeno, 
& Yajin, 1999; Martin, Bryden, Devoy, & Howarth, 1996), and sinusitis patients (Arnal 
et al., 1999). Nitric oxide may be an important mediator of the effector arm of the 
naso-nasal reflex that increases vascular permeability (Lane, Prazma, Baggett, 
Rose, & Pillsbury, 1997). Further studies are necessary to confirm the role of nitric 
oxide in AR.  
 
2.3.4 The IgE immune response 
Allergy is caused by a sustained overproduction of IgE in response to allergens. 
Increased serum IgE level is characteristic of atopic (inherited allergic condition) 
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diseases like AR. IgE production results from complex interactions between B-cells, 
T-cells, mast cells and basophils. It involves a series of surface molecules, as well as 
the presence of the IL-4 and IL-3 cytokines. In view of the location of the tissue 
distribution of these various types of cells, it is likely that IgE synthesis takes place 
not only in the germinal centres of the lymph node, but also in the nasal mucosa 
(Bousquet, Van Cauwenberge, & Khaltaev, 2001).  
 
IgE provokes immune response by binding to receptors found on the surface of mast 
cells and basophils, eosinophils, monocytes, macrophages and platelets in humans. 
There are two types of IgE receptors: FcεRI (the high-affinity IgE receptor) and 
FcεRII (CD23), (the low-affinity IgE receptor). IgE can upregulate the expression of 
both Fcε receptors. FcεRI is expressed only on mast cells and/or basophils. 
Aggregation of antigens and binding of IgE to the FcεRI on mast cells causes 
deregulations and the release of mediators from the cells, while basophils cross-
linked with IgE release cytokines like interleukin-4 (IL-4) and interleukin-13 (IL-13) 
and other inflammatory mediators. The low affinity receptor (FcεRII) is always 
expressed on B cells, but its expression can be induced on the surfaces of 
macrophages, eosinophils, platelets and some T cells by IL-4. FcεRII allows the 
occurrence of facilitated antigen presentation, an IgE-dependent mechanism 
(Bousquet, Van Cauwenberge, & Khaltaev, 2001).  
 
2.3.5 From nasal challenge to chronic rhinitis 
The allergic reaction after nasal challenge includes early and late-phase reactions. 
 The early-phase reaction 
Patients present symptoms such as rhinorrhoea, obstruction, sneezing and itchiness 
within minutes of a nasal challenge with pollen grains (Lebel et al., 1988). At this 
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stage, mast cells are activated, several mediators including histamine are released 
that induce symptoms of itchiness and sneezing, nasal mucosal blood flow 
decreases and plasma exudation causes nasal hypersecretion and congestion. 
 The late-phase reaction 
About 30-40% of patient will have a late-phase reaction in 4 to 12 hours after allergen 
challenge (Naclerio et al., 1985). Nasal obstruction is the main symptom at this stage, 
while rhinorrhoea and sneezing are less severe. The late-phase reaction is caused 
by the migration of other leukocytes such as neutrophils, lymphocytes, eosinophils 
and macrophages to the allergy site.  
 
Another important phenomenon is called the “priming effect”. It has been found that 
during a single nasal challenge with pollen, the number of grains required to induce 
symptoms is much more than that inhaled during the pollen season (Lebel et al., 
1988; Naclerio et al., 1983). On the other hand, in the second challenge the number 
of pollen grains required for inducing a positive result is much less than that in the 
first challenge. This is called a “priming effect” which can be mimicked by using 
challenge with very low repeated doses of allergen. The priming effect of nasal 
mucosa explains why once the nasal mucosa is primed by a high pollen count, a low 
pollen count later will also induce symptoms (Bousquet et al., 1991).    
 
In summary, AR is an allergic reaction characterised by varying degrees of morbidity 
due to upper respiratory tract symptoms including sneezing, nasal congestion, 
rhinorrhoea and nasal itching. These symptoms are due to the interaction between 
the allergen and IgE causing immediate mast cell release of histamine and other 
mediators. Mediators, cytokines, chemokines, neuropeptides, adhesion molecules 
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and cells all co-operate in a complex network to induce the above symptoms of AR. 
This complicated process establishes the early and late-phase reactions of AR. 
 
2.4 Allergens and other risk factors 
AR is a multifactorial disease resulting from several factors including genetic factors, 
life style and environmental factors such as allergens. This section introduces factors 
in the development of AR to explain the high and increasing prevalence of this 
disease. 
 
2.4.1 Allergens  
AR can be triggered by many kinds of allergens which are antigens inducing and 
reacting with specific IgE antibodies. Allergens include a range of animals, insects, 
plants, fungi and small molecular weight chemicals. Most of these allergens are 
proteins or glycoproteins (Savolainen, Viander, & Koivikko, 1990). They are classified 
as inhalant allergens, food allergens and occupational allergens as explained below 
(Bousquet, Khaltaev, et al., 2008). 
 
2.4.1.1 Inhalant allergens  
Inhalant allergens are usually classified as indoor and outdoor agents. The most 
commonly seen inhalant allergens are as follows: 
a. Dust mites 
House dust mites such as Dermatophagoides and Euroglyphus which feed on human 
skin dander are particularly abundant in mattresses, bed bases, pillows, carpets, 
furniture and fluffy toys (Bousquet, Van Cauwenberge, & Khaltaev, 2001). Patients 
who are allergic to these house dust mites have symptoms all year round with an 
aggravation during humid periods as these mites grow more in hot and humid 
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environments (Chan-Yeung et al., 1995). Furthermore, in very damp houses, storage 
mites may grow in stocked grains and flour and are usually present in the dust 
(Bernd, Ambrozio, & Baggio, 1996).  
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b. Pollens 
The pollen grain is the mail sex cell of the vegetable kingdom. The anemophilous 
pollens which are transported by wind can travel hundreds of kilometres. Most 
patients are allergic to many different types of pollens. Pollen allergy is higher in rural 
areas than in urban area as per the pollen counts (Nicolaou, Siddique, & Custovic, 
2005). The size of pollens varies from 10 to 100 µm in diameter. Therefore, pollen 
may deposit not only in the nostrils but also in the eyes. This explains the reason why 
pollen allergic patients usually have rhinitis and conjunctivitis (Suphioglu et al., 1992). 
The pollens causing most allergies are found among: grasses; certain weeds such as 
mugwort and ragweed; trees such as birch and other Betulaceae species, Oleaceae 
species (ash and olive trees), oak, plane tree, cypress tree, etc. In Melbourne, 
Australia, grass pollen especially that of ryegrass, has been proven to be the major 
source of airborne allergens causing AR (Schappi et al., 1999).  
 
c. Animal dander 
Cat and dog allergens are the major animal allergens for asthma, AR and 
rhinoconjunctivitis (Bousquet, Khaltaev, et al., 2008). Other animals such as rabbits, 
guinea pigs, rats or horses are also associated with AR symptoms (Bousquet, 
Khaltaev, et al., 2008). The most important allergen sources from animals are the 
sebaceous glands, saliva and the peri-anal glands. These allergens can be found in 
animal’s fur, saliva and urine and are transported in the air and remain airborne for a 
prolonged period. They are also adherent so that they can exist in the environment 
for weeks or months even after the animals have been taken away. Additionally, 
these allergens can be carried by clothing and transported to the areas where 
animals have no access such as schools and public buildings or even homes without 
animals (Bousquet, Khaltaev, et al., 2008).  
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d. Fungal allergens 
Superior fungi, moulds and yeast release large quantities of allergenic spores into the 
indoor and outdoor environment (Bousquet, Khaltaev, et al., 2008). Fungi and 
moulds grow particularly well in hot and humid areas while yeast can be found in 
foods as well. The major outdoor moulds which cause allergy are Cladosporium, 
Alternaria and Stemphylium. In addition, domestic moulds which are mainly abundant 
in bathrooms and kitchens or in the areas which are watered frequently for plant 
growth also play an important role. Mould spores are able to enter deeply into the 
respiratory tract due to their small size. Therefore, AR as well as asthma can be 
triggered by mould allergens (Bousquet, Khaltaev, et al., 2008). 
 
e. Insects 
Once insect waste is inhaled into the respiratory tract, an IgE immune response can 
also been induced. Wastes of insects, such as cockroaches, usually are found in 
apartments or low-income houses (Cohn, Arbes, Jaramillo, Reid, & Zeldin, 2006; 
Leaderer et al., 2002; Lewis, Weiss, Platts-Mills, Syring, & Gold, 2001). Among the 
household allergens, in some hot and humid regions, allergies caused by cockroach 
waste, can have the same frequency as, or even a higher frequency than that caused 
by house dust mites (Barnes & Brenner, 1996; Lan, Lee, Wu, Chang, & Yeh, 1988; 
Sakaguchi et al., 1994). 
 
2.4.1.2 Food allergens 
Food allergens usually cause allergy with multiple organ involvement or even severe 
systemic anaphylaxis. Rhinitis is one of the common symptoms of food allergy. Milk, 
egg and soy are the major allergens for infants less than six months old while 
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peanuts, tree nuts, fish, egg, milk, sesame, celery and some fruits are the common 
allergens for adults (Bousquet, Bjorksten, et al., 1998). 
 
Cross-reaction allergens between food and inhalant allergens are common. For 
example, patients who are allergic to birch or other Betulaceae pollens may also be 
allergic to tree nuts, fruits and vegetables (Eriksson, Formgren, & Svenonius, 1982; 
Geroldinger-Simic et al., 2011); ragweed or grass pollen sensitive patients may also 
present symptoms when eating banana or melon (Enberg, Leickly, McCullough, 
Bailey, & Ownby, 1987; Garcia Ortiz, Cosmes Martin, & Lopez-Asunolo, 1995). 
 
2.4.1.3 Occupational agents 
Occupational rhinitis is caused by agents in workplaces. For example, bakery 
allergens such as flour and grain may cause rhinitis to bakers; laboratory animals 
may induce AR symptoms in laboratory personnel (Bousquet, Khaltaev, et al., 2008). 
Latex allergy has become an increasing concern to cause occupational allergy due to 
the increasing use for industrial products and household items or medical devices 
(Bousquet, Flahault, et al., 2006).  
 
2.4.2 Pollutants 
Outdoor pollutants such as automobile pollution and organic chemical agents are 
associated with rhinitis symptoms (Hwang, Jaakkola, Lee, Lin, & Guo, 2006; Keles, 
Ilicali, & Deger, 1999). Indoor pollutants include biomass fuels, gas pollutants and 
compounds utilised during the manufacturing process of furniture may also cause AR 
(Karol, 1991). Similarly, tobacco smoke aggravates AR because smoking 
inconstantly increases the total and specific IgE (Wuthrich, Schindler, Medici, 
Zellweger, & Leuenberger, 1996).  
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2.4.3 Other risk factors of AR 
In addition, other risk factors are related to AR. For example, a genetic component 
has been well established as a risk factor in AR (Bahna, 1992). People with a parent 
who has AR have an increased risk of developing AR themselves. The risk increases 
significantly if both parents have AR. Previous studies have demonstrated that there 
is a close association between childhood allergic disease and parental allergic history 
in populations (Barnes & Marsh, 1998). Furthermore, the ethnic origin may affect the 
AR prevalence. Surveys demonstrated that there are differences in AR prevalence 
between different ethnic populations in the same area in England (Gillam, Jarman, 
White, & Law, 1989) and New Zealand (Pattemore et al., 1989). However, this 
difference perhaps is caused by lifestyle and environmental factors. In contrast, 
another study showed that in the United States, there is a similar prevalence of AR in 
both Caucasian and black population (Sly, 2002). Furthermore, in recent years, 
climate changes became one of the factors caused the increasing of allergic disease 
(Beggs, 2010; Sheffield, Weinberger, & Kinney, 2011; Ziska et al., 2011). 
 
In summary, an increasing worldwide prevalence in AR has been observed over the 
last few decades. The reasons for this phenomenon are still not understood 
completely. Many factors may be involved in the high and increasing prevalence of 
AR.  
 
2.5 Classification of AR 
There are two systems of classification of AR: 1. seasonal allergic rhinitis (SAR) and 
perennial allergic rhinitis (PAR); and 2. intermittent allergic rhinitis (IAR) and 
persistent allergic rhinitis (PER). 
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2.5.1 SAR/PAR classification 
This classification is based on the seasonality character of symptoms and allergens 
(Dykewicz et al., 1998). Symptoms of AR may occur only during specific seasons, be 
perennial without seasonal exacerbation, be perennial with seasonal exacerbation or 
may occur sporadically after specific exposures. Thus, AR is subdivided into SAR 
and PAR based on the tune of allergen exposure: 
a. SAR is caused by an IgE-meditated reaction to seasonal aeroallergens. 
Typical seasonal aeroallergens are pollens. The length of seasonal exposure 
to these allergens depends on geographic location. 
b. PAR is caused by an IgE-mediated reaction to perennial environmental 
aeroallergens. These allergens may include dust mites, moulds, animal 
allergens or certain occupational allergens, as well as pollen in areas where 
pollen is prevalent perennially.  
However, this traditional SAR/PAR classification is not entirely satisfactory as 
(Bousquet, Van Cauwenberge, & Khaltaev, 2001): 
a. To differentiate between seasonal and perennial symptoms is often difficult; 
b. Some pollen allergens exposure may be long standing instead of being 
seasonal in some areas; 
c. The nasal inflammation can be prolonged for weeks after pollen exposure in 
patients with SAR; 
d. The exposure to some perennial allergens cannot be similar over the whole 
year, therefore, symptoms caused by such perennial allergens can be short 
term; and 
e. The majority of patients are sensitised to both pollens and perennial allergens. 
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2.5.2 IAR/PER classification 
Another classification which was introduced by Allergic Rhinitis and its Impact on 
Asthma (ARIA) in 2001 is based on the duration of symptoms and quality of life in the 
assessment of severity instead of the allergens. Therefore AR is divided into IAR or 
PER. 
 
According to this classification, “Intermittent” AR (IAR) means the symptoms present 
less than four days a week or last for less than four consecutive weeks, while 
“Persistent” (PER) refers to symptoms present for more than four days a week and 
last for more than four consecutive weeks (Bousquet, Van Cauwenberge, & Khaltaev, 
2001). 
 
With this classification, the severity of AR is categorised as “mild” or “moderate –
severe” based on the quality of life (Bousquet, Van Cauwenberge, & Khaltaev, 2001). 
“Mild” means that none of the following items are present: 
o Sleep disturbance, 
o Impairment of daily activities, leisure and/or sport, 
o Impairment of school or work, 
o Troublesome symptoms. 
“Moderate–severe” means that one or more of the above-mentioned items present. 
 
A two-step cross-sectional, population-based, epidemiologic study in six Western 
European countries showed that the proportion for IAR/PER and SAR/PAR is quite 
consistent (Bauchau & Durham, 2005). Another study found that the classic types of 
SAR/PAR classification cannot be used interchangeably with the new classification of 
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IAR/PER because they do not represent the same stratum of disease (Alyasin & 
Amin, 2007). 
 
Since the introduction of the IAR/PER classification, questions have arisen such as: 
a. This classification must be performed in patients who are not under treatment. 
Therefore, how should we classify the AR patients who are under treatment 
(Valero et al., 2007)? 
b. For the patients who are classified as “persistent” with symptoms presenting 
more than 4 days a week and lasting for more than 4 consecutive weeks, is 
there any difference between suffering symptoms for 6, 24, or 36 weeks 
(Valero et al., 2007)? 
c. Is it really necessary to differentiate patients classified as moderate-severe? 
Does it help with the clinical management of AR (Valero et al., 2007)? 
 
The mild/moderate–severe classification system of the symptom severity may not be 
adequate as most AR patients would be classified as the moderate-severe type 
based on this method. Some studies have analysed the prevalence of mild and 
moderate-severe rhinitis in different population samples and found that 69% of 
patients with rhinitis who attend an ear-nose-throat (ENT) or allergy clinic and 90% of 
the patients who attend a primary care centre are classified as Moderate-Severe 
(Bachert, van Cauwenberge, Olbrecht, & van Schoor, 2006; Bousquet et al., 2005; 
Bousquet, Neukirch, et al., 2006; Valero et al., 2007). 
 
Therefore, the “British Society for Allergy and Clinical Immunology (BSACI) 
guidelines for the management of allergic and non-allergic rhinitis” recommends 
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using the clinical classification of SAR/PAR alongside the ARIA’s IAR/PER 
classification (Scadding, 2008).  
 
In Australia, the SAR/PAR classification is well-known and accepted by clinical 
practitioners and patients. With a cool temperate climate, the Melbourne area has a 
clearly high pollen count period during spring and summer. Hence, in the pollen 
season every year, scientists in the School of Botany, Melbourne University take 
daily measurements of the pollen levels in Melbourne, which are combined with the 
weather forecast to produce a pollen forecast. Pollen counts and predictions are 
rated as low, moderate, high or extreme levels (Schäppi, Taylor, Kenrick, Staff, & 
Suphioglu, 1998). On the days with high or extreme pollen counts, it is likely that 
people who are grass-pollen-sensitive will experience AR symptoms and they are 
suggested to stay indoors (Schäppi, Taylor, Kenrick, Staff, & Suphioglu, 1998).  
 
Due to the above mentioned reasons, in this study, the SAR/PAR classification 
method was adopted for the recruitment of participants. That is, the study lasted for a 
whole year, during the pollen season, SAR patients were recruited and outside the 
pollen season, PAR patients were recruited. 
 
2.6 Co-morbid conditions of AR  
AR often coexists with other disorders, such as asthma, allergic conjunctivitis, 
sinusitis, nasal polyps and otitis media (Bousquet, Khaltaev, et al., 2008). The co-
morbidity of AR also has an impact on patients’ quality of life and economic burden. 
This section introduces the relationship between AR and other co-morbid conditions. 
 
41 
 
2.6.1 Asthma  
Epidemiological studies have concluded that most asthmatics have rhinitis and also 
many rhinitis patients have asthma (American Thoracic Society Workshop, 1999; 
Vignola, Chanez, Godard, & Bousquet, 1998). The prevalence of asthma has 
increased in rhinitis, especially in persistent rhinitis. It is suggested that “one airway 
one disease” be used to describe the close relationship between asthma and AR. 
The principle is that the two conditions are manifestations of one syndrome in two 
parts of the respiratory tract and that the more severe the rhinitis, the more severe 
the asthma (Bachert et al., 2004; Bousquet, Jacot, Vignola, Bachert, & Van 
Cauwenberge, 2004; Togias, 2003).  
 
Asthma and AR share common risk factors. Allergens such as house mite or animal 
dander and occupational agents can cause both of these two conditions. Asthma and 
rhinitis have commonalities in mechanisms such as eosinophilic inflammation in the 
nasal and bronchial mucosa. Besides the inflammatory process, the nose plays the 
role of a protector for the lungs through warming and humidification, filtering, 
mucociliary clearance and air conditioning of the lower airways. These protective 
functions of the nose may explain some of the links between rhinitis and asthma 
(Bousquet, Khaltaev, et al., 2008).  
 
The close relationship between asthma and rhinitis is due to the similarities of the 
nasal and bronchial mucosa (Togias, 2003). Both nasal and bronchial mucosa are 
characterised by a pseudostratified epithelium with columnar, ciliated cells resting on 
a basement membrane. In the submucosa underneath the epithelium, there are 
vessels, mucosa glands, some inflammatory cells and nerves. In asthma and rhinitis, 
inflammation of the nasal and bronchial mucosa is sustained by a similar 
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inflammatory infiltrate including eosinophils, mast cells, T lymphocytes, cells of the 
monocytic lineage, similar pro-inflammatory mediators, Th2 cytokines and 
chemokines.  The presence of AR commonly aggravates asthma, and increases the 
risk of asthma attacks, emergency visits and hospitalisations for asthma (Bousquet, 
Khaltaev, et al., 2008). The inflammatory reaction of the nose can cause a worsening 
of asthma. This may be due to two reasons:  
a. the nasal challenge induces the release of mediators, and 
b. the post-nasal mucosa drip may induce inflammation of the lower airways. 
 
Clinically, nasal symptoms occur early in the pollen season and reach a maximum 
level with peak pollen count or just after it while bronchial symptoms usually begin 
after the onset of the pollen season, peak later than the peak pollen counts period 
and persist for some time after (Welsh et al., 1987).  
 
Moreover, AR is not only correlated to but is also a risk factor for asthma (Bousquet, 
Van Cauwenberge, & Khaltaev, 2001). Asthma develops more commonly in patients 
with AR than others who have no AR. On the other hand, the prevention or early 
treatment of AR may help to prevent the occurrence of asthma (Bousquet, Khaltaev, 
et al., 2008). It has been recommended by the 1999 World Health Organisation 
(WHO) workshop “ARIA” (Bousquet, Van Cauwenberge, & Khaltaev, 2001) that: 
a. Patients with PER should be evaluated for asthma; 
b. Patients with asthma should have examination of the upper respiratory tract 
for AR; and  
c. A combination treatment for both the upper and lower airway disease is 
suggested.  
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In terms of treatment, intranasal glucocorticosteroids are the most effective topically 
administered drugs for the treatment of both rhinitis and asthma. Oral-H1-
antihistamines are the first-line treatment for AR, however, are less effective for 
asthma (Bousquet, Khaltaev, et al., 2008).  
 
2.6.2 Allergic conjunctivitis  
Allergic conjunctivitis is a common co-morbidity of AR characterised as “red eye”. 
Allergic conjunctivitis is more common with outdoor allergens than indoor allergens; 
thus, it is usually seen in SAR.  
 
The occurrence of conjunctivitis can be explained through the naso-conjunctival 
reflexes mechanism (Bousquet, Van Cauwenberge, & Khaltaev, 2001). It is also 
because the nose and eyes share a common pathophysiological background. 
Therefore, it is suggested that eye examination should be part of the clinical 
assessment of AR.  
 
2.6.3 Sinusitis and nasal polyposis   
Rhinosinusitis is a common complication of AR. This is possibly due to allergens 
entering the sinuses resulting in a similar allergic inflammation to that in the nasal 
mucosa (Karlsson & Holmberg, 1994). Although the role of allergy in sinus diseases 
remains unclear, adding antiallergic therapy to the treatment of chronic sinus disease 
is still helpful (Bousquet, Khaltaev, et al., 2008). Nasal polyps are considered as a 
chronic inflammatory disease of the sinonasal mucosa. The mucosa swelling and the 
sinonasal mucosa’s protrusion into the nasal cavity caused by allergic reaction may 
result in nasal polyps.  
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2.6.4 Otitis media with effusion 
Otitis media with effusion is an inflammatory disease of the middle ear mucosa. 
Anatomically, the nose and middle ears are situated in a system of contiguous 
organs. Both cavities are covered by respiratory mucosa and there is continuity 
between these two cavities through the Eustachian tube. Respiratory allergy 
symptoms are risk factors for the development of otitis media with effusion (Chantzi 
et al., 2006).  
 
2.6.5 Chronic cough  
Chronic cough (over eight weeks) can be caused by a number of factors including 
AR. Of the AR symptoms, post nasal drip may be the most common cause of chronic 
cough (Pratter, 2006). Treatment with steroid nasal spray (Gawchik, Goldstein, 
Prenner, & John, 2003) or oral H1-antihistamine is effective for chronic cough on AR 
patients (Ciprandi et al., 1997).  
 
Apart from the conditions described above, other disorders such as adenoid 
hypertrophy, tubal dysfunction, laryngitis, and gastro oesophageal reflux are also 
considered to be associated with AR (Bousquet, Khaltaev, et al., 2008).  
 
2.7 Impacts of AR 
This section provides details of the impacts of AR on patients’ quality of life and the 
broader social and economic impacts. 
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2.7.1 Impacts on quality of life 
It has been reported that allergic reaction causes significant fatigue and mood 
changes (Marshall, O'Hara, & Steinberg, 2002), some impairment of cognitive 
function (Kremer, den Hartog, & Jolles, 2002; Marshall, O'Hara, & Steinberg, 2000), 
depression and anxiety (Cuffel, Wamboldt, Borish, Kennedy, & Crystal-Peters, 1999; 
Bavbek, Kumbasar, Tugcu, & Misirligil 2002). AR not only results in the classical 
symptoms of sneezing, rhinorrhoea and nasal obstruction, but also is associated with 
impairments in how patients function in daily life (Kirmaz et al., 2005). AR affects 
patients’ quality of life in several important domains, reduces sufferers’ work 
productivities and limits social activities (Bousquet et al., 1994). A study on “health-
related quality of life” of AR patients reported that the most common complaints for 
adults with rhinitis were: being not able to sleep well at night, often feeling tired and 
worn out during the day, practical problems and being limited in daily activities. For 
adolescents, the major problem caused by AR was lack of concentration with school 
and work, whilst for children, being bothered by symptoms and impaired learning, 
memory and behaviour were the main difficulties caused by AR (Juniper, 2001). The 
main ways in which AR has an impact on quality of life are as follows: 
 Sleep disturbance 
Poorly controlled AR may lead to sleep loss or disturbance. On the other hand, using 
sedative treatment may increase patients’ daytime sleepiness.   
 Learning disability  
Children with uncontrolled AR may have learning problems during school hours 
either by direct interference or by sleep loss resulting in daytime fatigue (Craig, Teets, 
Lehman, Chinchilli, & Zwillich, 1998; Simons, 1996). 
 Work impairment 
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AR may induce work absenteeism and reduce work productivity. Patients may suffer 
from fatigue, poor performance and loss of concentration at work; headaches and 
conjunctivitis may impair vision or vision-related activities. In addition, some 
medications such as sedating antihistamines may reduce workers’ functioning. 
 
2.7.2 Economic burden of AR 
AR causes significant economic impacts on the affected persons and their families, 
on the health care systems and on the whole society. In evaluating the economic 
burden, the cost of illness approach included both direct costs such as the expenses 
associated with medical care for the illness, and indirect costs such as the costs 
resulting from non-medical losses as a consequence of the illness. The economic 
impact of AR is often underestimated for the reason that the substantial indirect costs 
of the disease are not well evaluated (Bousquet, Khaltaev, et al., 2008). 
 
In Australia, the financial burden of allergies is significant. According to the data from 
Australasian Society of Clinical Immunology and Allergy, in 2007 the total annual cost 
of allergies was calculated as $7.8 billion. It was broken down into: the cost due to 
lower productivity ("presenteeism" $4.2 billion), direct medical costs ($1.2 billion), 
lower employment rates ($1.1 billion), absenteeism and lost household productivity 
($0.2 billion) and premature death ($83 million). Forty-nine per cent (49%) of the 
financial costs of allergic disease were borne by individuals with allergies and their 
families. Overall, patients with allergies spend over $120 million/year on over-the-
counter allergy medications. If the cost of wellbeing is included, allergic patients 
would bear 86% of the costs (Australasian Society of Clinical Immunology and 
Allergy (ASCIA), 2007).   
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However, much of the costs associated with rhinitis may be underestimated due to 
the frequent use of over-the-counter medications (Malone, Lawson, Smith, Arrighi, & 
Battista, 1997). A recent survey in the United States concluded that the burden of AR 
in children has been significantly underestimated as the health care practitioners 
overestimate patients’ and parents’ satisfaction with disease management (Meltzer et 
al., 2009).  
 
2.7.3 Cost-effectiveness study  
As AR significantly impairs patients’ quality of life, quality of life measurements need 
to be taken into consideration in clinical trials and when treating patients. Recently, 
there is an increasing interest in cost-effectiveness studies due to the high 
prevalence of AR and concern about health care costs. For example, it has been 
found that the first generation oral H1-antihistamine is not cost-effective because of 
the cost of associated sedation (Sullivan, Follin, & Nichol, 2004). Recently, a study 
investigated the cost-effectiveness of acupuncture for AR transformed the value of 
the Short Form 36 Health Survey (SF-36) into health-status utilities for cost-
effectiveness analysis (Witt, Reinhold, Jena, Brinkhaus, & Willich, 2009). 
 
2.8 Diagnosis of AR 
The diagnosis of AR is based on the concordance between a typical history of 
allergic symptoms and diagnostic tests.  
 
2.8.1 Symptoms 
Major symptoms of AR include sneezing, anterior rhinorrhoea and bilateral nasal 
obstruction. For patients with pollen-induced AR, eye symptoms are also very 
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common. Patients who have two or more of the following symptoms need to be 
considered for a diagnosis of AR: watery rhinorrhoea, sneezing, nasal obstruction, 
nasal pruritus and with or without conjunctivitis (ARIA, 2001).  
 
Rhinitis patients are usually divided into “sneezers and runners” and “blockers” 
groups. In AR, “sneezers and runners” are more commonly seen in SAR while 
“blockers” are more common in PAR (Bousquet, Van Cauwenberge, & Khaltaev, 
2001).  
 
Some associated symptoms should also be taken into account in AR diagnosis. 
These are: decreased sense of smell, snoring, sleeping problems, headache, 
postnasal drip or chronic cough and sedation, all of which may be caused by the 
rhinitis itself. 
 
2.8.2 Case history 
A typical clinical history of AR symptoms is important for the diagnosis of AR and for 
the assessment of its severity as well. Usually patients would have a conjecture 
regarding the substances causing their AR symptoms. The case history should focus 
on the evidence of the origin of this condition, whether it is allergic or non-allergic, 
identification of the possible allergens and time period of worsening or any trigger 
factors of occurrence to support the diagnosis. This history should also include 
questions about the symptom frequency, severity, duration, persistence or 
intermittence and seasonality (Bousquet, Khaltaev, et al., 2008). 
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2.8.3 Family history 
It is documented that family history is an important risk factor for AR. For a child 
whose parents both have a history of atopy (inherited allergic condition), the chance 
of developing AR is greater than those with only one parent who is atopic (Dykewicz 
et al., 1998).  
 
2.8.4 General ENT examination 
For AR patients, a nasal examination is optimal. When needed, anterior rhinoscopy 
examination or nasal endoscopy should be applied to describe the anatomical 
situation in the nose, the colour of the mucosa and the amount and aspect of the 
mucus. In AR cases, bilateral but not always symmetrical swelling can be observed; 
the mucosa of the middle meatus may be seen; the mucosa is usually of a common 
pale colour. Sometimes a major oedema of the nasal mucosa can make the study of 
the nose impossible and an increase in vascularity is also commonly seen. There is 
usually no increase in abnormal anatomical structure in the noses of AR patients. On 
the other hand, without allergen exposure, AR patients’ nasal mucosa may seem 
normal (Bousquet, Van Cauwenberge, & Khaltaev, 2001).  
 
2.8.5 Skin tests 
Skin allergy tests are a procedure that involves applying a microscopic amount of an 
allergen to patients’ skin by various means: scratch tests, prick and puncture tests, 
intradermal skin tests, prick-prick tests and atopy patch tests. If an immune-response 
is seen in the form of a rash, hives or even anaphylaxis, it can be concluded that the 
patient has an allergy to the particular allergen. Among these skin tests, the modified 
skin prick test introduced by Pepys (Nelson, 2009) is currently recommended for the 
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clinical diagnosis of IgE-mediated allergic diseases. In the skin prick test, a small 
drop of the purified allergen is placed on to the skin surface (usually the forearm) with 
a gentle prick on the skin. This test is usually performed in order to identify allergies 
to pet dander, dust, pollen, foods or dust mites. It is suggested that the skin prick test 
is the simplest and most convenient test to perform and currently has the highest 
sensitivity to ascertain the AR diagnosis (Bernstein & Storms, 1995; Bousquet, Van 
Cauwenberge, & Khaltaev, 2001). However, its high sensitivity also brings the 
problem of low specificity. It may induce some false positive reactions (Dreborg, 
1989). Other skin tests such as scratch tests are not recommended to be used any 
longer due to poor reproducibility; skin puncture tests may decrease the variability of 
skin prick test but need greater skill; intradermal skin tests are more sensitive than 
prick tests, however, they may induce some false reactions and they are less well 
correlated with symptoms (Bousquet, Van Cauwenberge, & Khaltaev, 2001). 
 
The skin tests should be performed by trained personnel following a rigorous 
methodology. When skin tests are applied, negative and positive controls are 
necessary to reduce false reactions. In addition, the proper interpretation of results 
requires a thorough knowledge of the history and physical findings. Therefore, skin 
prick test on its own cannot be used to confirm a definite clinical reactivity to an 
allergen.  
 
2.8.6 IgE tests  
IgE tests can be applied by testing serum-total IgE, serum-specific IgE and nasal-
specific IgE. The measurement of serum-total IgE should no longer be used for 
screening or diagnosis as allergic, parasitic diseases and many other conditions 
increase the levels of total IgE in serum. The measurement of serum-specific IgE is 
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important as its results correlate closely to those of skin tests and nasal challenges. 
A radioallergosorbent test (RAST test) is a blood test to detect specific IgE antibodies 
to certain allergens. It has been used as an alternative to the skin tests to clarify an 
allergy. Some AR patients may have a local IgE immune response without any 
systemic release of IgE. Skin tests or serum-specific IgE tests may have negative 
results in these cases, therefore a further nasal-specific IgE test will be needed 
(Bousquet, Van Cauwenberge, & Khaltaev, 2001). 
 
2.8.7 Nasal challenge tests 
For standardised allergens, challenges are not usually necessary to confirm the 
diagnosis of common inhalant allergy. However, challenge tests are more important 
in the diagnosis of occupational rhinitis. 
 
In summary, the diagnostic approach introduced by WHO is as below: for most 
patients, a precise and complete history of allergic symptoms, a nasal examination 
and a limited number of skin tests are all required for diagnosing allergic aetiology 
and the relevant allergen exposure. If there is discordance between the history and 
the skin prick test, further tests are suggested (Bousquet, Van Cauwenberge, & 
Khaltaev, 2001).   
 
2.9 Current management of AR  
Many AR patients do not consult with medical doctors and only use over-the-counter 
drugs. Some commonly seek self-treatment for symptomatic relief or use unproven 
alternative therapies. Hence their symptoms do not always get well managed. It is 
important to understand an appropriate initial treatment strategy of AR so that a 
treatment plan can be tailored to individual needs of the patients in clinical practice. 
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The current management of AR consists of allergen avoidance, pharmacotherapy 
and allergen-specific immunotherapy (Bousquet, Khaltaev, et al., 2008).  
 
2.9.1 Allergen avoidance 
As AR symptoms are caused by inflammation of the nasal mucus membrane after 
exposure to specific allergens, the avoidance of the allergens may reduce provoking 
AR symptoms. For example, for the patients who are allergic to animal fur, avoidance 
of animals is effective for symptom relief.  
 
Improving indoor air quality is also important. Recommendations include improving 
ventilation, refining cleaning methods and housing hygiene, avoiding wall-to-wall 
carpeting, using moisture control to prevent the accumulation of mould and 
controlling the sources of pollution such as tobacco smoke and emissions from 
buildings and consumer products (Franchi et al., 2006). 
 
However, to completely avoid the inhalant allergens such as pollen, dust, and 
pollutants which exist in the air is impossible in people’s daily life. For instance, 
patients who are allergic to animals may benefit from allergen avoidance at home; 
but they may encounter allergens in public transportation, schools and public places 
(Bousquet, Khaltaev, et al., 2008). 
 
2.9.2 Pharmacotherapy 
Pharmacologic treatment should take the following factors into account: efficacy, 
safety, cost-effectiveness of medications, patient’s preference, objective of the 
treatment, likely adherence to recommendations and the presence of co-morbidities.  
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Rhinitis medications are administered intranasally or orally in most cases. Intranasal 
medications have high concentrations and can be used directly into the nose thus 
avoiding or minimising systemic effects. In patients who also have conjunctivitis 
and/or asthma, medications need to be used to address these aspects, not only to 
relieve the nasal symptoms (Bousquet, Khaltaev, et al., 2008). Details on the current 
pharmaceutical management for AR are provided in 2.9.2.1 to 2.9.2.4 below. 
 
2.9.2.1 Antihistamines 
Although a number of mediators are involved in the pathophysiology of allergic 
symptoms, histamine still remains the major one. Therefore, the most commonly 
prescribed medications for AR are antihistamines. Antihistamine can be applied 
through oral and topical pathways.  
 
Antihistamines were discovered in 1937 by Bovet and Staub at the Institute Pasteur 
(Emanuel, 1999) and were first used for human treatment of allergic diseases in 
1942. Clinically, antihistamines can be administered orally or topically. When 
administered orally, an H1-antihistamine exerts its effects on both nasal and non-
nasal symptoms such as conjunctivitis. The first generation of antihistamines (before 
1980) had more severe side effects compared with the second generation of 
antihistamines and thus the first generation is no longer recommended for the 
treatment of AR. The most common side effect is sedation. The second generation 
H1-antihistamines are highly selective to the H1-receptors and are therefore effective 
in reducing itching, sneezing and watery rhinorrhoea. Most of the second generation 
H1-antihistamines have an acute onset of action and their effects last for up to 24 
hours. Therefore, the second generation oral or intranasal H1-antihitamines are 
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recommended for the treatment of AR and conjunctivitis in adults and children. 
However, the second generation of antihistamines are less effective on nasal 
obstruction as they do not reduce vasodilatation (van Cauwenberge et al., 2000). On 
the other hand, not all second generation anti-histamines are free from side effects, 
even though they are mostly devoid of central nervous system side effects. Some 
side effects have been observed such as: cardiac side effects, carcinogenic effects, 
appetite stimulation and weight gain, and gastrointestinal disturbances (van 
Cauwenberge et al., 2000). 
 
2.9.2.2 Glucocorticosteroids 
Glucocorticosteroids are the most effective drugs available for the clinical 
management of AR. They can be administered through both systemic and topical 
routes. Since the risk of adverse effects from systemic glucocorticosteroids is related 
to the duration of treatment, it is suggested that only infrequent short-term courses 
should be prescribed for rhinitis. Clinically, topical glucocorticosteroids are more 
frequently used for rhinitis. Topical glucocorticosteroids were first applied as a nasal 
spray for SAR in 1973 when beclomethasone was introduced (Mygind, 1973). 
Currently, intranasal glucocorticosteroids are the most potent medication available for 
allergic and non-allergic rhinitis. In three international reports, intranasal 
glucocorticosteroids are considered as a first-line therapy for adults in moderate and 
severe cases of AR (Dykewicz, 1998; International Rhinitis Management Working 
Group, 1994; van Cauwenberge, 2000).  
 
The effects of glucocorticosteroids on AR are caused by the anti-inflammatory and 
other effects. Side effects of intranasal glucocorticosteroids are mainly local effects 
such as crusting, dryness, minor epistaxis or medication-dependence (Bousquet, 
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Van Cauwenberge, & Khaltaev, 2001; Holm et al., 1998; LaForce, 1999). Also, the 
intranasal medication cannot be given when the nostril is completely blocked 
(Bousquet, Van Cauwenberge, & Khaltaev, 2001).  
 
2.9.2.3 Chromones 
Mast cells have an important role in both the early and late phase of allergic 
responses of AR. Mast cell stabiliser such as Chromones has been shown to be 
effective in improving sneezing, watery rhinorrhoea and nasal itching. However, they 
are not superior to topical glucocorticosteroids or H1-antihistamine (van 
Cauwenberge 2000). Chromones were discovered from the medical plant Ammi 
visnaga. Chromones can be administered via nasal and ocular route. In adults, 
chromones are not a major therapeutic option due to being less effective than H1-
antihistimine or intranasal glucocorticosteroids (Meltzer, 2002; Schuller et al., 1990).  
 
2.9.2.4 Decongestants 
Decongestants, also known as vasoconstrictor drugs, can rapidly relieve nasal 
obstruction due to the function of vasoconstriction by their action on α-adrenergic 
receptors. They can be administered either orally or topically. Clinically, 
decongestants are always applied in combination with anti-histamine (Anolik, 2009; 
Grubbe, Lumry, & Anolik, 2009).  
 
Decongestants are associated with systemic side effects such as heart diseases, 
hypertension, insomnia, irritability, renal failure, psychosis, stroke etc. Therefore, it is 
recommended that the use of decongestants should be limited to within one week. 
Other nasal side effects including nasal burning, stinging, dryness or mucosal 
 ulce
deco
 
It is 
tailo
avai
Khal
(Ada
the p
Figu
 
The 
sum
rations and
ngestants
recommen
red accord
lability and
taev, et al
pted from 
harmacy”
re 5: Man
commonly
marised in
Mild 
intermitt
Oral H1-blocke
Or nasal H1-b
Or decongesta
Or nasal crom
Or nasal salin
 even sep
 (Bousque
ded by the
ing to the 
 affordabil
., 2008) (S
“ARIA in t
 (ARIA, 20
agement 
 used med
 the Table
Sy
ent 
r 
locker 
nt 
one 
e 
tal perfora
t, Van Cau
 ARIA gui
individual 
ity of treat
ee Figure 
he pharma
04)) 
of AR in t
ications w
 2 below.
mptoms o
Mild 
Mode
inte
Oral H1-b
Or nasal 
And/or de
Or nasal 
Or nasal 
If after
No im
tions may
wenberge
delines th
patient’s s
ment and 
5). 
cy: manag
he pharm
ith their m
f allergic
persistent 
rate-severe 
rmittent 
locker 
H1-blocker 
congestant 
steroid 
cromone 
 7–15 days 
provement 
 occur afte
, & Khalta
at the treat
ymptom s
patient’s p
ement of 
acy  
echanism
 rhinitis 
r the use o
ev, 2001).
ment for A
everity, co
reference 
allergic rh
s and side
Moderate-s
persiste
Refer to doc
f intranas
 
R should 
-morbiditie
(Bousquet
initis symp
 effects ar
evere 
nt 
tor 
56
al 
be 
s, the 
, 
 
toms in 
e 
 
57 
 
Table 2: Glossary of medications used in AR 
Name and also  
known as Generic name Mechanism of action Side effects Comments 
Oral H1-antihistamines Second generation 
Acrivastine, Azelastine, 
Cetirizine, Desloratadine,  
Ebastine, Fexofenadine, 
Levocetirizine, Loratadine, 
Mequitazine, Mizolastine, 
Rupatadine 
Blockage of H1 receptor 
Some anti-allergic activity  
New generation drugs can 
be used OD 
No development of 
tachyphylaxis 
Second generation 
No sedation for most 
drugs  
No anticholinergic effect 
No cardiotoxicity for 
products still available 
Acrivastine has sedation 
effects 
Mequitazine has an 
anticholinergic effect 
First generation 
Sedation is common 
and/or anticholinergic 
effect 
Second generation H1-
antihistamine should be 
preferred for their 
favourable efficacy/safety 
ratio and pharmacokinetics 
Rapid effective (<1h) on 
nasal and ocular 
symptoms 
Moderately effective on 
nasal congestion 
Cardiotoxic drugs are no 
longer marketed in most 
countries 
First generation 
Chlorphenyramine, 
Clemastine, Dimethindene 
maleate, Hydroxyzine, 
Ketotifen, Oxatomine 
Cardiotoxic 
Astemizole, Terfenadine 
Local H1-antihistamine 
(intranasal, intraocular) 
Azelastine, Levocabastine, 
Olopatadine 
Blockage of H1 receptor  
Some anti-allergic activity 
for azelasine 
Minor local side effects 
Azelastine: bitter taste 
Rapidly effect (<30min) on 
nasal or ocular symptoms 
Intranasal 
glucocorticosteroids 
Beclomethasone 
dipropionate, Budesonide, 
Ciclesonide, Flunisolide, 
Flunticasone propionate, 
Fluticasone furoate, 
Mometasone furoate, 
Triamcinolone acetonide 
Potently reduce nasal 
inflammation 
Reduce nasal 
hyperreactivity 
Minor local side effects 
Wide margin for systemic 
side effects 
Growth concerns with 
beclomethasone 
dipropionate  only in 
young children  
The most effective 
pharmacologic treatment 
of AR 
Effective on nasal 
congestion 
Effective on smell  
Effect observed after 12 h 
but maximal effect after a 
few days 
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Name and also  
known as Generic name Mechanism of action Side effects Comments 
Leukptriene antagonists Montelukast, Pranlukast, 
Zafirlukast 
Block CystLT receptor Excellent tolerance Effective on rhinitis and 
asthma 
Effective on all symptoms 
of rhinitis and on ocular 
symptoms 
Local cromones 
(intranasal, intraocular) 
Cromoglycate, Nedocromil, 
NAAGA 
Mechanism of action 
poorly known 
Minor local side effects Intraocular cromones are 
very effective  
Intranasal cromones are 
less effective and their 
effect is short lasting  
Overall excellent safety 
Oral decongestants Ephedrine, Phenylephrine, 
Phenyl propanolamine, 
Pseudoephedrine, Oral H1-
antihistamine-decongestant 
combinations 
Sympathomimetic drugs  
Relieve symptoms of 
nasal congestion 
Hypertension 
Palpitations 
Restlessness 
Agitation 
Tremor 
Insomnia 
Headache 
Dry mucous membrane 
Urinary retention 
Exacerbation of glaucoma 
or thyrotoxicosis 
Use oral decongestants 
with caution in patients 
with heart disease 
Oral H1-antihistamine-
decongestant combination 
products may be more 
effective than either 
product alone but side 
effects are combined 
Intranasal 
decongestants 
Oxymethazoline, 
Xylomethazoline, others 
Sympathomimetic drugs  
Relieve symptoms of 
nasal congestion 
Same side effects as oral 
decongestants but less 
intense  
Rhinitis medicamentosa is 
a rebound phenomenon 
occurring with prolonged 
use (over 10 days) 
Act more rapidly and more 
effectively than oral 
decongestants 
Limit duration of treatment 
to <10 days to avoid 
rhinitis medicamentosa 
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Name and also  
known as Generic name Mechanism of action Side effects Comments 
Oral/IM 
glucocorticosteroids 
Dexamethasone, 
Hydrocortisone, 
Prednisolone, Prednisone, 
Triamcinolone 
Potently reduce nasal 
inflammation 
Reduce nasal 
hyperreactivity 
Systemic side effects 
common in particular for 
IM drugs 
Depot injections may 
cause local tissue atrophy 
When possible, intranasal 
glucocorticosteroids 
should replace oral or IM 
drugs 
However, a short course of 
oral glucocorticosteroids 
may be needed if 
moderate/severe 
symptoms 
Intranasal 
anticholinergics 
Ipratropium Anticholinergics block 
almost exclusively 
rhinorrhoea 
Minor local side effects  
Almost no systemic 
anticholinergic activity 
Effective on allergic and 
nonallergic patients with 
rhinorrhoea 
 
(Adapted from “ARIA Executive summary of the workshop report” (Bachert, van Cauwenberge, & Khaltaev, 2002))
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2.9.3 Allergen-specific immunotherapy 
Allergen specific immunotherapy is the practice of administering gradually increasing 
quantities of an allergen vaccine to an allergic subject in order to reduce symptoms 
associated with subsequent exposure to allergens. Allergen immunotherapy was 
introduced in 1911 by Noon and Freeman to treat “pollinosis” or AR (Noon, 1911). 
There has been some evidence that immunotherapy using inhalant allergens to treat 
SAR or PAR is clinically effective (Bousquet, Lockey, et al., 1998). This method can 
induce clinical and immunologic tolerance therefore has a long-term effect and may 
prevent the allergic diseases’ progressing.  
 
Guidelines and indications for specific immunotherapy with inhalant allergens have 
been published over the past years by WHO, the European Academy of Allergy and 
Clinical Immunology, the International Consensus Report on Asthma, the Global 
Strategy for Asthma Management and Prevention, the International Consensus 
Report on Rhinitis, the British Society for Allergy and Clinical Immunology, the 
American Academy of Allergy, Asthma and Immunology and the American College of 
Allergy, Asthma and Immunology (Bousquet, Khaltaev, et al., 2008). These reports 
provide guidelines for a better understanding of the use of allergen specific 
immunotherapy. It is suggested that immunotherapy should be initiated early in the 
disease process to reduce the risk of side effects and to prevent the further 
development of severe diseases. 
 
Traditionally, the allergen specific immunotherapy is administered subcutaneously. It 
has been well established for both rhinitis and asthma. The efficacy of subcutaneous 
immunotherapy has been proven (Calderon et al., 2007). However, applying 
subcutaneous immunotherapy should be under a strict strategy as it is burdened with 
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the risk of causing systemic side effects. These side effects may be life-threatening 
(Bousquet, Khaltaev, et al., 2008).  
 
Another approach of specific immunotherapy currently available in some countries is 
sublingual immunotherapy. However, the efficacy and safety of sublingual 
immunotherapy is still controversial. More studies comparing these two routes of 
immunotherapy are needed. 
 
2.9.4 Anti-IgE 
Anti-IgE forms complexes with free IgE, blocking its interaction with mast cells and 
basophils and lowering free IgE levels. Anti-IgE may induce rare but potentially 
severe anaphylactic reactions (Price & Hamilton, 2007). It is suggested that this 
therapy should be administered only in a healthcare setting with direct medical 
supervision (Bousquet, Khaltaev, et al., 2008).  
 
2.9.5 Surgical treatment of rhinitis 
Surgical treatment is not a part of standard AR management as it does not reduce 
allergy. For the patients with PAR, an inferior turbinates and some increase in 
glandular structure may occur. Therefore, the surgical reduction of the inferior 
turbinate body and mucosal surface will be helpful for reducing nasal obstruction and 
secretion. However, nasal surgery should only be considered when drug treatment is 
not effective and anatomical structure variations are present (Bousquet, Khaltaev, et 
al., 2008).   
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2.9.6 Alternative therapies for AR 
Complementary and alternative medicine (CAM) has been widely used in Australia 
and many patients appear to be satisfied with the effectiveness of these therapies 
(Xue et al., 2008). AR is one of the conditions for which people seek CAM therapies, 
including acupuncture and CHM (Xue, English, Zhang, Da Costa, & Li, 2002). It has 
been reported by the WHO that acupuncture is regarded as effective for AR (World 
Health Organization (WHO), 1995).  
 
A survey conducted in Germany (Schafer, Riehle, Wichmann, & Ring, 2002) found 
that among the participants who used alternative medicine for allergic conditions, the 
motivations or seeking alternative medicine included the assumption of few side-
effects (78.3%), wish to try everything (71.7%) and unsatisfying results from 
conventional therapies (66.3%). This survey also reported that among all the allergic 
conditions, AR was the one most commonly treated by CAM therapies, and 
acupuncture was frequently used as a CAM therapy. 
 
More details of the acupuncture and CHM management for AR are included in the 
reviews in Chapter 3. 
 
2.10 Assessment of treatment effects 
In clinical management and clinical research of AR, there are a number of 
instruments that are used to compare the severity of symptoms or patients’ quality of 
life before and after treatment in order to evaluate the treatment effects. The main 
instruments are detailed below. 
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2.10.1 Instruments for assessing symptom severity 
Scoring systems are commonly used to record the severity of AR symptoms. By 
comparing the scores before and after treatment, the treatment effects are 
determined. Some scoring systems were recommended by ARIA (Bousquet, 
Khaltaev, et al., 2008). 
 
2.10.1.1 Simple rating scale 
A simple rating scale from 0 to 4 (0 = none; 1 = mild; 2 = moderate; 3 = severe; 4 = 
very severe) of symptom severity assessment has been often used as an outcome 
measure in AR clinical trials since 1996 (Prenner et al., 1996; Xue, English, Zhang, 
Da Costa, & Li, 2002; Xue et al., 2007). Another 4 point scale (0 to 3) has also been 
frequently employed in clinical studies (Chui, Shek, Fong, Szeto, & Chan, 2010; Ng 
et al., 2004; Yang, Yu, Chen, Chiao, & Chen, 2010). It is suggested by Juniper et al. 
(Juniper et al., 2005) that the following simple rating scales can be used for clinical 
trials. It has defined criteria to enable assignment of the appropriate rating, as follows:  
 0 = no symptoms;  
 1 = mild symptoms (symptoms that are present but not particularly 
bothersome);  
 2 = moderate symptoms (symptoms that are bothersome but do not 
interfere with daily activities) and  
 3 = severe symptoms (symptoms that are bothersome and interfere 
with daily activities or disturb sleep). 
This simple rating scale can be used to assess the severity of symptoms such as 
sneezing, nasal itch, nasal discharge and nasal obstruction (Juniper et al., 2005).  
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2.10.1.2 Visual Analogue Scale (VAS) 
Two developed VAS questionnaires are also recommended by ARIA as outcome 
measures for AR (Bousquet, Khaltaev, et al., 2008). 
a. Spector 7 point VAS (Spector et al., 2003) 
This 7 point VAS was proposed by the Joint Task Force on Practice Parameters for 
the symptom severity assessment of AR. The questionnaire consists of several VAS 
for assessment of nasal symptom severity (individually for sneezing, running nose, 
congestion, itchy nose, and postnasal drip), non-nasal symptoms (individually for eye 
symptoms, throat symptoms, chronic cough, ear symptoms, headache and mental 
function), global assessment of overall nasal and non-nasal symptoms severity, as 
well as global quality of life assessment of rhinitis severity. The scale used for 
assessment of all individual symptom severity is as follows: 1 = none; 2 = between 1 
and 3; 3 = mild; 4 = between 3 and 5; 5 = moderately bothersome; 6 = between 5 
and 7; 7 = unbearably severe. When assessing the global nasal symptom and global 
nasal and non-nasal symptoms, a reverse scale from 1 to 7 is employed. In addition, 
when assessing the global quality of life in this questionnaire, the scale is: 1= Quality 
of life is terribly affected in terms of sleep disturbance at night and/or impairment of 
social and/or recreational activities; 2 = Quality of life is affected almost all the time in 
terms of sleep disturbance at night and/or impairment of social and/or recreational 
activities; 3 = Quality of life is affected often in terms of sleep disturbance at night 
and/or impairment of social and/or recreational activities; 4 = Quality of life is affected 
occasionally but it is tolerable in terms of sleep disturbance at night and/or 
impairment of social and/or recreational activities; 5 = Quality of life is hardly affected 
in terms of sleep disturbance at night and/or impairment of social and/or recreational 
activities; 6 = Quality of life is hardly noticed in terms of sleep disturbance at night 
and/or impairment of social and/or recreational activities; 7 = Excellent quality of life 
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in terms of sleep disturbance at night and/or impairment of social and/or recreational 
activities. 
 
This VAS instrument has been found to correlate well with the severity of rhinitis, as 
assessed by the ARIA (Bousquet, Combescure, Klossek, Daures, & Bousquet, 2009; 
Bousquet, Combescure, et al., 2007). 
 
b. VAS ranging from 0 to 10 cm  
A VAS ranging from 0 (nasal symptoms, not at all bothersome) to 10cm (nasal 
symptoms, extremely bothersome) is designed to assess the severity of combined 
nasal symptoms (Bousquet, Van Cauwenberge, & Khaltaev, 2001) (Figure 6). 
 
 
 
Figure 6: Visual analogue scale 
 
This simple method was validated to be used for the quantitative evaluation of 
severity of AR (Bousquet, Combescure, et al., 2007). 
 
 
2.10.2 Questionnaires for assessing quality of life  
Quality of life is a complicated concept and can be affected by many factors such as 
finances, spirituality and health. Health-related quality of life is defined as the part of 
quality of life being affected by the person’s health condition and that can be affected 
by clinical management (Juniper et al., 2005). There are several different outcome 
measures that have been used to assess the AR related quality of life in clinical 
studies. 
 
Not bothered at all Extremely bothered  
10 cm
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2.10.2.1 Generic quality of life questionnaires 
Generic quality of life questionnaires such as the Short Form (36) Health Survey (SF-
36) (Stewart, Hays, & Ware, 1988) are designed for assessing the health of patients 
with all kinds of medical conditions. SF-36 contains 36 items, in eight domains about 
patients’ physical and mental functions. The eight domains are: 
 Physical functioning, limitations in physical activities due to health problems; 
 Social functioning, limitations in social activities because of physical or 
emotional problems; 
 Role physical limitations in usual role activities because of health problems; 
 Bodily pain; 
 Mental health, general emotional health (psychological distress and well-
being); 
 Role emotional, limitations in usual role activities because of emotional 
problems; 
 Vitality (energy and fatigue); and 
 General health perceptions. 
Although the SF-36 is not a disease specific questionnaire, it is commonly used in 
health economics as a variable in the quality-adjusted life year (QALY) calculation to 
determine the cost-effectiveness of a health treatment. Recently, it was employed in 
a large size cost-effectiveness study of acupuncture for AR (Witt, Reinhold, Jena, 
Brinkhaus, & Willich, 2009).  
 
2.10.2.2 Specific quality of life questionnaires  
The Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) was designed to 
evaluate patients’ quality of life impairment by the specific condition of AR. This 
questionnaire contains 28 questions covering 7 domains: activities, sleep, non-
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nose/eye symptoms, practical problems, nasal symptoms, eye symptoms and 
emotional problems. Participants are required to score the questions using a 7 point 
scale: 0= not troubled; 1= hardly troubled at all; 2= somewhat troubled; 3= 
moderately troubled; 4= quite a bit troubled; 5= very troubled; 6= extremely troubled 
(Juniper & Guyatt, 1991). The Rhinoconjunctivitis Quality of Life Questionnaire with 
Standardised Activities (RQLQ(S)) (Juniper, Thompson, Ferrie, & Roberts, 1999) is 
an updated version of RQLQ. In the activities domain, instead of letting patients 
select their own activities, in RQLQ(S), three questions about activities are defined as 
“regular activities at home and at work”, “social activities” and “outdoor activities”. The 
RQLQ(S) has been regarded as a more responsive instrument for measuring health 
related quality of life in rhinitis patients than other generic instruments (Juniper et al., 
2005). The Mini Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ) is an 
abbreviated version of RQLQ, with 14 questions in 5 domains (activity limitations, 
practical problems, nose symptoms, eye symptoms, and other symptoms) (Juniper, 
Thompson, Ferrie, & Roberts, 2000). 
 
2.10.3 Other assessment 
Besides symptoms and quality of life assessment, other measurements are also 
included in clinical management or clinical research of AR, such as measurements of 
nasal obstruction, measurements of inflammation, reactivity measurements and 
measurements of the sense of smell (Juniper et al., 2005).  
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Chapter 3: Literature review on allergic rhinitis from 
Chinese medicine perspective 
Chinese medicine originated in ancient China and consists of a range of traditional 
medical practices such as CHM and acupuncture. The earliest practice of 
acupuncture may date back to the Stone Age based on the discovery of ancient 
stone needles (Chiu, 1993). The earliest and most fundamental Chinese medicine 
text, published during the Spring and Autumn period (300-100 BC), is Huangdi’s 
Internal Classic (Huangdi Neijing). Further progress was made in the Eastern Han 
Dynasty (150-219 BC) when the Treatise on Cold-Attack and Miscellaneous 
Diseases (Shang Han Za Bing Lun) written by Zhang Zhong Jing strengthened the 
traditional Chinese medicine theoretical system. Chinese medicine steadily 
developed over subsequent centuries (Cheng, 1999). Since the late 20th century, 
Chinese medicine has been enhanced through systematisation and research of the 
basic theories of Chinese medicine in combination with the application of modern 
science and technology to further develop both theory and practice (Zhu & 
Woerdenbag, 1995). In Western countries Chinese medicine is regarded as part of 
CAM and has been widely used in many countries including Australia (Xue et al., 
2008). 
 
This chapter briefly introduces the fundamental theory of Chinese medicine and the 
understanding of AR according to Chinese medicine concepts. It also reviews the 
current clinical research on CHM and acupuncture for treating AR. Ear-
acupuncture/ear-acupressure is a subtype of acupuncture. The treatment methods 
and current research on ear-acupuncture/ear-acupressure for AR will be detailed 
separately in Chapter 4.  
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3.1 The fundamental theory of Chinese medicine  
Unlike Western medicine, Chinese medicine was developed based on ancient 
Chinese philosophical framework of Yin and Yang, and the Five-Elements theory. Yin 
and Yang, and the Five-Elements theory were concepts derived from the observation 
of nature and they were fundamental to all natural sciences in ancient China 
(Wiseman, 1996). Other key concepts of Chinese medicine include the classification 
of organs into Zang and Fu organs (solid organs and hollow organs or bowels); 
bodily substances into Qi, Blood, Fluid and Humour, and the Meridian theory that 
forms the basis of acupuncture (Cheng, 1999; B. Zhu & Wang, 2010). The following 
sections introduce the key concepts of CM fundamental theory and the treatment 
principles.  
 
3.1.1 Key concepts of Chinese medicine theory 
3.1.1.1 Yin and Yang 
The Yin and Yang concept represents the two opposite aspects within natural 
phenomena. This theory was first mentioned in the Book of Changes (Yi Jing) in 
about 700 BC. Yin was classified on the basis of having the characteristics of 
darkness, descending, inward, coldness and stillness whilst Yang was classified as 
having the opposite characteristic of brightness, ascending, outward, heat and 
movement. Yin and Yang are two stages of a cyclical movement, one constantly 
changing into the other, such as the day giving way to night and vice versa. Yin and 
Yang can represent not only two opposite objects but also two opposite states of one 
thing. These two states are not independent of each other and they change into each 
other. Yin and Yang are in a constant state of change, so that when one increases 
the other is consumed, to keep the balance.  
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The balance between these two forces maintains the normal physiological functions 
of the human body. Conversely, if either of these two sides becomes excessive or 
deficient, the human body will lose its balance and become dysfunctional leading to a 
disease state. Chinese medicine treatments therefore focus on rebalancing Yin and 
Yang by reinforcing deficiency and reducing excess in order to restore normal human 
physiological functions in one or more parts or systems (Cheng, 1999; B. Zhu & 
Wang, 2010). 
 
3.1.1.2 Five-Elements theory 
Together with Yin-Yang theory, the Five-Elements theory constitutes the basis of 
Chinese medicine theory. Basically, the Five-Elements are Wood, Fire, Earth, Metal 
and Water symbolising five different inherent qualities and states of natural 
phenomena. The Five-Elements are not independent, each element inter-promotes 
another and also restrains another following certain sequences. Five-Elements may 
also overwhelm or rebel against each other when one element is extremely strong.  
 
Five-Elements theory is mainly applied to analyse and study the characteristics of the 
human organs and their associated tissues and meridians based on a series of 
correspondences with the basic properties of the Five-Elements. It also explains the 
physiological functions of the organs, meridians and their interconnections by 
applying the inter-promotion and restraining relationships of Five-Elements as well as 
their pathological changes by applying the overacting and counteracting relationships. 
By combining the Five-Elements theory with Yin-Yang theory and the Zang-Fu 
organs theory, a model of a functioning human being’s body can be created which 
helps to explain the mechanisms of health and disease and the diagnosis of clinical 
disorders (Cheng, 1999; B. Zhu & Wang, 2010). 
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3.1.1.3 Vital substances (Qi, Blood, Fluid and Humour) 
The understanding of the human body’s function also relies on the vital substances 
inside the body. Qi is the vital energy in the human body which performs the normal 
physiological functions including movement, warming, defense and transformation. 
Blood maintains vital activity through its nourishing and moistening functions. Fluid 
and Humour (Jin and Ye) are the bodily fluids within Zang-Fu organs, the tissues and 
the normal secretions. The main functions of Fluid and Humour (Jin and Ye) are 
moistening and nourishing (Cheng, 1999; B. Zhu & Wang, 2010).  
 
3.1.1.4 Meridian system 
According to Chinese medicine theory, all Zang-Fu organs and associated structures 
of the body are connected by the Meridian system, which is also known as the 
Channels and Collaterals (jing-luo). Also, the organs of the body can be influenced 
via the Meridian system. This theory is a major component of Chinese medicine and 
forms the basis of acupuncture treatment. Meridians are the pathways throughout the 
whole body, through which the Blood and Qi that support life functions flow. These 
channels are not analogous to any tangible channel in the human body in Western 
medicine, they are more invisible rather than visible (Liu, Vian, & Eckman, 1998).  
 
All the meridians form a network in which the Qi and Blood circulate. The Qi and 
Blood flowing in these meridians control and regulate every part of the body. The 
main trunks of the meridian system are the twelve Regular meridians. Among the 
twelve Regular meridians, each meridian is associated with either a Zang or a Fu 
organ and they contain acupuncture points along their length (Cheng, 1999; B. Zhu & 
Wang, 2010).  
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3.1.2 Occurrence of disease and treatment principles of CM 
The breakdown of the different levels of normal physiological activities (such as the 
disturbance of Zang-Fu organs and meridians, balance of Yin and Yang, Qi and 
Blood etc.) results in various clinical manifestations. The factors causing the 
disequilibrium are termed aetiological factors. These factors include the Six External 
Excessive pathogenic factors (Wind, Cold, Dryness, Dampness, Summer Heat and 
Fire Heat), the Seven Excessive Emotions (Anger, Overjoy, Anxiety, Worry, Grief, 
Fright and Apprehension) and non-internal non-external factors (such as parasites, 
insect or animal bites, trauma, improper diet, excessive sexual activity, fatigue or lack 
of exercise), as well as secondary pathological products (such as blood stagnation 
and phlegm-fluid retention). Any of the above factors can cause imbalance of Yin and 
Yang and affect the functions of various organs or meridians (Wiseman, 1996).   
 
The main target of Chinese medicine treatment is to reinforce the anti-pathogenic Qi 
and eliminate the pathogenic factor. Therefore, based on the differentiation of 
syndromes, the main Chinese medicine therapeutic principles include (Wiseman, 
1996): 
 Treating the primary cause and the secondary aspect of a disease; 
 Reinforcing the healthy Qi and eliminating the pathogenic factor; 
 Regulating Yin and Yang; 
 Regulating the functions of the Zang and Fu organs; 
 Regulating the relationship between Qi and Blood; and 
 Treating a disease according to season, environment and individual 
constitution. 
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The next section will introduce AR from the Chinese medicine perspective based on 
the understanding of the fundamental theory of Chinese medicine.  
 
3.2 AR in Chinese medicine 
AR is a specific concept in Chinese medicine in regard to its definition, aetiology and 
pathogenesis, differential diagnosis and treatment.  
 
3.2.1 Definition of AR in Chinese medicine 
AR is the medical term for a Western medicine category. However, in Chinese 
medicine, there is no single condition that matches all the symptoms of AR. The most 
similar disease in Chinese medicine is “Bi Qiu 鼻鼽” (Wang & Gan, 1985). Bi refers to 
the nose and Qiu means clear rhinorrhoea. Qiu also refers to Qiu Ti 鼽嚏 and Qiu 
Shui 鼽水. Ti is sneezing and Shui means discharge. Therefore, the term Bi Qiu 鼻鼽
covers the symptoms of sneezing and runny nose, which are the major symptoms of 
AR (Wang & Gan, 1985). 
 
A condition with clear nasal discharge was first documented in the literature in the 
11th Century BC (Xizhou Dynasty), and the description was further developed in the 
text Huangdi’s Internal Classic (Huangdi Neijing) between 475 to 221 BC; In 610 AD, 
the physician Chao Yuan Fang explained that excessive nasal discharge was caused 
by deficiency of Fei (Lung) Qi combining with cold pathogens. Liu Wan Su (1182 to 
1209) clarified that symptoms such as rhinorrhoea, itchy nose and sneezing were the 
result of Fei (Lung) Qi deficiency in the book titled The Pattern and Mechanism of 
Causation of Diseases from Basic Questions (Su Wen Xuan Ji Yuan Bing Shi). In 
1249, Li Dong Yuan concluded that deficiency of the Pi (Spleen) and Wei (Stomach) 
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was also related to these symptoms according to the theory of Five-Phases in 
Comments on Spleen and Stomach (Piwei Lun). Furthermore, Chinese medicine 
described this condition’s occurrence as induced by the invasion of Wind-cold (Wang 
& Gan, 1985). 
 
3.2.2 Aetiology and pathogenesis of AR in Chinese medicine 
According to Chinese medicine theory, respiration is dominated by the Fei (Lung) 
organ. The concept of Fei (Lung) in Chinese medicine is similar to the lungs in 
western medicine but it is much broader than the anatomical lungs since it includes 
the nose and skin. Fei (Lung)’s main role is performing respiration, dominating the 
function of dispersion and depuration, descending Qi and regulating both Qi activity 
and the metabolism of Body Fluid. The Fei (Lung) Qi controls the defensive Qi which 
is distributed to the body surface to protect it from attack by external factors. Fei 
(Lung) has a close relationship with the nose. Fei (Lung) opens into the nose and the 
nose is the portal of Fei (Lung). If Fei (Lung) Qi is harmonised, the nose will be 
unobstructed, the respiration will be smooth and the sense of smell will be acute. 
Once the Fei (Lung) is attacked by pathogenic factors, it will fail to disperse and 
regulate the Body Fluid, therefore, symptoms like nasal obstruction, watery nose and 
decrease in smell sensation will occur (Maciocia, 2005). In addition, Pi (Spleen) and 
Shen (Kidney) also play an important role in AR due to their functions associated with 
Qi. When Pi (Spleen/digestive system) Qi is impaired, Fei (Lung) Qi will be deficient 
as a result of losing aid from Pi (Spleen) Qi. When Shen (Kidney) does not store the 
essence of Qi properly, Fei (Lung) will lose the function of governing Qi (Maciocia, 
2005). 
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The occurrence of Bi Qiu is due to the invasion of the exterior pathogen Wind-cold 
and is associated with deficiency of Fei (Lung) Qi, Pi (Spleen) Qi and/or Shen 
(Kidney) Qi. Wind-cold is the external pathogen which invades the body while the 
deficiency of Qi represents the failure of internal factors to repel the invasion. Wind-
cold invasion is similar to the inhalation of an allergen while deficiency of Qi is similar 
to dysfunction of the immune system in the western medicine view (Maciocia, 2005). 
 
When the defence Qi is weak, the pathogenic Wind-cold can invade the body and 
cause a loss of balance between Yin and Yang leading to a disease state 
characterised by either Fei (Lung) Qi, Pi (Spleen) Qi and/or Shen (Kidney) Qi 
deficiency (Maciocia, 2005). 
 
3.2.2.1 Fei (Lung) Qi deficiency 
Fei (Lung) Qi is the reflection of the overall function of the Fei (Lung). Fei (Lung) Qi is 
originally produced by the Shen (Kidney) and constantly replenished by the Pi 
(Spleen). When the Fei (Lung) Qi is over consumed due to long-term cough, 
congenital deficiency or insufficient provision from the digestive system (Pi Wei, 
Spleen & Stomach), the Fei (Lung) and its associated structures (the nose and skin) 
will be susceptible to invasion by pathogenic factors. Wind-cold is one pathogenic 
factor that easily invades the human body through the nose and the mouth. Sneezing 
is due to the invasion of Cold while itchiness in nose, eye and throat is the symptom 
caused by the Wind. When the impaired Fei (Lung) Qi fails to maintain the normal 
function of the nasal passages and the water metabolism, nasal blockage and watery 
rhinorrhoea will occur (Maciocia, 2005). 
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3.2.2.2 Pi (Spleen) Qi deficiency 
In Chinese medicine, Pi (Spleen) and Wei (Stomach) refer to the digestive system 
and are described as the postnatal foundation of life which provides all the nutrients 
to the entire body. The Pi (Spleen) Qi may be impaired if the person is under stress, 
suffering from overthinking and/or imbalanced diet. In addition, dysfunction of other 
organs such as the Gan (Liver) and Shen (Kidney) may also indirectly affect the Pi 
(Spleen) function. Once the Pi (Spleen) Qi is deficient, it is not able to generate 
adequate nutrients to replenish the Fei (Lung) Qi and this can cause Fei (Lung) Qi 
deficiency. It will also affect the water metabolism due to dysfunction in its role of 
distributing Body Fluid, so that rhinitis symptoms can occur (Maciocia, 2005). 
 
3.2.2.3 Shen (Kidney) Qi deficiency 
According to the Chinese medicine theory, the Shen (Kidney) is the congenital 
foundation for the entire body in relation to its function of providing the primary Qi at 
conception and birth. Furthermore, the Shen (Kidney) has the function of warming 
and nourishing the Pi (Spleen). It also has a close relationship with Fei (Lung) 
function in order to descend the Qi derived from breathing and thereby maintain the 
proper functioning of the respiratory tracts. Via its control over urination Shen (Kidney) 
has an important role in balancing water metabolism. Therefore, when the Shen 
(Kidney) Qi is deficient, Fei (Lung) and Pi (Spleen) may not be able to function well 
and this may contribute to rhinitis symptoms (Maciocia, 2005). 
 
The aetiology and pathogenesis of AR in Chinese medicine is illustrated in the Figure 
7. 
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Table 3: Chinese medicine differential diagnosis of AR 
 Key symptoms Tongue Pulse 
Common 
symptoms 
Sudden onset of continuous sneezing, nose itch, watery rhinorrhoea and 
nasal congestion may be associated with impairment of smell, eye itch 
and itchy palate.  
Fei (Lung) Qi 
deficiency 
Easily catches cold, 
spontaneously sweats and 
reduced sense of smell 
Pale tongue and 
white coating Superficial & weak 
Pi (Spleen) Qi 
deficiency 
Heavy-headed, tired or 
exhausted,  heavy limbs, 
loss of appetite and loose 
bowels 
Pale tongue or 
enlarged with teeth 
marks, white coating 
Weak & thready 
Shen (Kidney) Qi 
deficiency 
Cold limbs, weakness in 
the lumbar area and 
knees, frequent nocturnal 
urination and shortness of 
breath after light physical 
exercise 
Pale tongue with 
white coating Deep & weak 
 
 
3.3 CHM and acupuncture management for AR 
The principle of Chinese medicine treatment is based on the diagnosis, which 
determines the nature of a condition as deficiency or excess. The aim of treatment is 
to restore the balance of Qi and Blood, Yin and Yang, and the Zang-Fu organs. 
Tonification means using an enhancing and strengthening method for treating 
deficient syndromes. Reduction means the elimination and dispelling of excessive 
pathogens. Therefore, warming the Fei (Lung) and dispelling Cold is the principle of 
treatment for the Wind-cold syndrome; tonifying Fei (Lung) Qi to strengthen the 
superficial resistance is for the treatment of Fei (Lung) Qi deficiency; strengthening Pi 
(Spleen) Qi to supplement Qi is the treatment principle for Pi (Spleen) Qi deficiency; 
and tonifying the Shen (Kidney) to promote Qi is the treatment principle for Shen 
(Kidney) Qi deficiency (Maciocia, 2005). 
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CHM and acupuncture are the commonly used modalities of Chinese medicine. This 
section introduces the CHM and acupuncture treatment for AR and current clinical 
research in this area.  
 
3.3.1 CHM for AR 
Based on Chinese medicine theory, Chinese herbs have characters of five Flavours 
and four Energies. Five Flavours in nature are Sour, Bitter, Sweet, Pungent and Salty 
and the Four Energies are Cold, Hot, Warm and Cool. The five Flavours are related 
to the Five-Zang Organs through their association with the Five-Elements. The 
function of four Energies is to work on the nature of the imbalance, for example 
Warm and Hot can warm the Yang, while Cold and Cool can clear the Heat, and 
flush out the Fire. Each CHM has specific functions based on its Flavour and 
Energies. Using the proper CHMs according to the differential diagnosis will restore 
balance to the functioning of the relevant organs (Maciocia, 2005).  
 
In clinical practice, CHM formulas can be chosen according to the differential 
diagnosis of patients’ syndrome. The selection of CHM formulations is based on the 
traditional therapeutic effects of the individual herbal medicines and the interaction 
among the various herbal substances. An individualised treatment plan can be 
provided through modifying the formulas. The CHM formulas related to AR treatment 
are summarised in Table 4 (Liu, 1988).  
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Table 4: CHM formulas and individual herbs for AR 
Syndrome Treatment principle Formula Herbal medicine 
Fei (Lung) Qi 
deficiency 
Tonify Fei 
(Lung) Qi and 
strengthen the 
superficial 
resistance 
Yu Ping Feng 
San 
Huang Qi (Radix Astragali seu Hedysari) 
Fang Feng (Saposhnikvia divaricata) 
Bai Zhu (Rhizoma Atractylodis 
Macrocephalae) 
Pi (Spleen) Qi 
deficiency 
Nourish Pi 
(Spleen) and 
benefit Fei 
(Lung) 
Bu Zhong Yi 
Qi Tang 
Huang Qi (Radix Astragali seu Hedysari) 
Zhi Gan Cao (Radix Glycyrrhizae 
Preparata) 
Ren Shen (Radix Ginseng) 
Chen Pi (Pericarpium Citri Reticulatae) 
Sheng Ma (Rhizoma Cimicifugae) 
Chai Hu (Radix Bupleuri) 
Bai Zhu (Rhizoma Atractylodis 
Macrocephalae) 
Shen (Kidney) 
Qi deficiency 
Tonify Shen 
(Kidney) 
Jin Gui Shen 
Qi Wan 
Shu Di (Radix Rehmaniae Praeparata) 
Shan Yao (Rhizoma Dioscoreae) 
Shan Zhu Yu (Fructus Corni) 
Fu Ling (Poria) 
Ze Xie (Rhizoma Alismatis) 
Dan Pi (Cortex Moutan Radicis) 
Fu Zi (Radix Aconiti Praeparata) 
 
3.3.2 Acupuncture for AR 
Acupuncture is a technique that involves inserting metal needles into certain points of 
the human body. The mechanism of acupuncture is based on the meridian theory of 
Chinese medicine. This method has been used in clinical practice for thousands of 
years.  
 
The practice of acupuncture can perhaps be traced as far back as the Stone Age 
(approximately three million years ago), with the Bian shi, or sharpened stones being 
used in ancient China. The fact that stimulating certain points on the body could 
relieve pain or other illnesses was observed, then people started to discover the 
relationships between internal parts and external parts of the human body and 
eventually formed the meridian theory (Cheng, 1999).  
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The earliest available written record about acupuncture is Huangdi’s Internal Classic 
(Huangdi Neijing), which was compiled around 475–221 BC. The technique of 
acupuncture was applied using different types of needles or instruments to stimulate 
certain points. By activating the circulation of Qi and Blood in the flow of the meridian 
system, the physiological function of the human body could be adjusted and diseases 
could be cured. 
 
During thousands of years of clinical practice, the acupuncture system played an 
important role in the clinical diagnosis and management of a variety of conditions 
(Cheng, 1999). Acupuncture has been adopted by western societies such as 
Australia as one of the most popular treatments of the CAM therapies (Xue et al., 
2008). 
 
In the treatment for AR with acupuncture, the principles of tonifying the deficient Fei 
(Lung), Pi (Spleen) or Shen (Kidney) and eliminating the Wind and Cold are applied 
through selecting relevant points and using manipulation techniques during the 
treatment process (Table 5) (Liu, 1988).  
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Table 5: Acupuncture points selection for AR 
Treatment principle Points 
Local points around the nose area Yingxiang (LI 20), Kouheliao (LI 19) 
To tonify the Fei (Lung) Qi Taiyuan (LU 9) 
To tonify the Pi (Spleen) Qi Zusanli (ST 36) 
To tonify the Shen (Kidney) Taixi (KI 3) 
To eliminate the Wind and Cold Fengchi (GB 20) 
 
Similar to the the CHMs for treating AR, the acupuncture points for AR should be 
selected by following the principles listed in the table above and can be combined or 
modified according to the differential diagnosis.  
 
In fact, the Chinese medicine treatments mainly rely on experience and empiricism 
handed down from generation to generation. The knowledge and experience in both 
CHM and acupuncture have accumulated over centuries of practice and clinical 
observations. However, from a research methodological point of view, more scientific 
evidence is needed to substantiate the claim of the clinical benefit. Therefore, a 
critical review of the clinical trial literature for CHM and acupuncture was carried out 
in order to obtain a clearer picture regarding the current state of the clinical research 
in the area of CHM and acupuncture and their roles in the clinical management of AR.  
 
3.4 Existing reviews on CHM and acupuncture for AR  
The number of RCTs on CHM and acupuncture has increased significantly in recent 
years (Xue, Zhang, Greenwood, Lin, & Story, 2010). In the field of CHM and 
acupuncture for AR, some systematic reviews and overviews of RCTs have been 
conducted to evaluate the current evidence (Guo, Pittler, & Ernst, 2007; Lee, Pittler, 
Shin, Kim, & Ernst, 2009; Roberts, Huissoon, Dretzke, Wang, & Hyde, 2008; Witt & 
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Brinkhaus, 2010). In order to define the clinical effectiveness and safety of CHM and 
acupuncture for AR, this section reviews and summarises all the RCTs included in 
current existing systematic reviews and overviews.  
 
Literature search was carried out in the following databases: Pubmed, Embase, and 
Cochrane Library from their inceptions to April 2008 and updated in January 2011. 
Search terms used were: allergic rhinitis, Chinese herbal medicine, herbal medicine, 
acupuncture, complementary and alternative medicine, randomised controlled trial, 
systematic review, overview, meta-analysis. Systematic reviews (including or not 
including meta-analysis) or overviews of RCTs of all types of CAM therapies for AR 
were included. Only the RCTs of CHM and acupuncture for AR published in the 
language of English were extracted from the included RCTs. As a result of the search, 
five systematic reviews and overviews on the RCTs of CHM and acupuncture (Lee, 
Pittler, Shin, Kim, & Ernst, 2009; Roberts, Huissoon, Dretzke, Wang, & Hyde, 2008; 
Witt & Brinkhaus, 2010), herbal medicine (Guo, Pittler, & Ernst, 2007), and CAM 
therapies (Passalacqua et al., 2006) for AR were considered, and their included 
RCTs are reviewed in this section. Study selection procedure is summarised in 
Figure 8. 
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Figure 8: Flow chart of the study selection process of CHM and acupuncture 
for AR 
 
Two RCTs of CHM for AR (Hu et al., 2002; Xue et al., 2003), nine RCTs of 
acupuncture for AR (Brinkhaus et al., 2008; Y. M. Li, Zhuang, Lai, & Jiang, 2007; 
Magnusson, Svensson, Leirvik, & Gunnarsson, 2004; Ng et al., 2004; Petti, Liguori, & 
Ippoliti, 2002; Rao & Han, 2006; Williamson et al., 1996; Xue, English, Zhang, Da 
Costa, & Li, 2002; Xue et al., 2007) and one RCT (Brinkhaus et al., 2004) of the 
combination of CHM and acupuncture for AR were included and extracted. Details 
are listed in Table 6 below. 
 
Included RCTs of 
CHM for AR 
n=2 
Included RCTs of 
CHM and 
acupuncture for AR 
n=1
Included RCTs of 
acupuncture for AR 
n=9 
Included systematic 
reviews and overviews 
n=5 
RCTs of CHM for AR 
n=3 
RCTs of non-CHM or 
acupuncture for AR 
n=25
RCTs of CHM and 
acupuncture for AR 
n=1
RCTs of acupuncture 
for AR 
n=15
Excluded 
RCTs of 
CHM for AR 
n=1 
(Published in 
German) 
 
Excluded 
RCTs of 
acupuncture 
for AR 
n=5 
(In German) 
n=1 
(Duplication)
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Table 6: Included reviews and RCTs extracted from reviews 
Review 
Review focus 
and included 
studies (n=) 
RCTs extracted from included reviews Reviewer’s comments 
RCTs of 
CHM for 
AR 
RCTs of 
acupuncture for 
AR 
RCTs of CHM 
combined with 
acupuncture for 
AR 
Efficacy Adverse events Overall trial quality 
Passalacqua 
2006 
Systematic review 
on CAM for rhinitis 
and asthma 
(n=46) 
Hu 2002, 
Xue 2003 
Williamson 1996, 
Ng 2004, 
Xue 2002 
Brinkhaus 2004 No clear evidence 
for the efficacy of 
acupuncture in 
rhinitis. 
Not discussed. The 
methodology of 
clinical trials with 
CAM was 
frequently 
inadequate.  
Guo 2007 Systematic review 
on herbal 
medicine for AR 
(n=16) 
Hu 2002, 
Xue 2003 
  All RCTs on CHM 
for AR generated 
positive results. 
Mild and moderate 
adverse events 
were reported. 
Methodological 
quality score 
was 4-5. 
Robert 2008 Systematic review 
on acupuncture for 
AR (n=7) 
 Williamson 1996, 
Petti 2002, 
Xue 2002, 
Ng 2004,  
Magnusson 2004, 
 Meta-analysis failed 
to show any 
summary benefits of 
acupuncture for AR.  
Acupuncture was 
not associated 
with any additional 
adverse events in 
the trials. 
The quality of 
included studies 
was generally 
poor. 
Lee 2009 Systematic review 
on acupuncture for 
AR (n=12) 
 Williamson 1996, 
Petti 2002, 
Xue 2002, 
Ng 2004,  
Magnusson 2004, 
Rao 2006, 
Xue 2007 
 No specific effects of 
acupuncture SAR; 
suggestive evidence 
of acupuncture for 
PAR was provided. 
Mild adverse 
events were 
reported. 
Most of included 
studies were 
high quality. 
Witt 2010 Overview on 
acupuncture for 
AR (n=8) 
 Williamson 1996, 
Xue 2002, 
Magnusson 2004, 
Li 2007, 
Xue 2007,  
Brinkhaus 2008 
Brinkhaus 2004 The trials on efficacy 
and on effectiveness 
of acupuncture are 
very heterogeneous. 
Not discussed. Not discussed. 
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All these RCTs were summarised with regard to methodological quality, 
intervention/control method, efficacy and safety.  
 
The Jadad scale (Jadad et al., 1996) was used to assess the methodological quality 
of included studies as it was commonly employed in these reviews for 
methodological quality assessment (Guo, Pittler, & Ernst, 2007; Lee, Pittler, Shin, 
Kim, & Ernst, 2009; Passalacqua et al., 2006; Roberts, Huissoon, Dretzke, Wang, & 
Hyde, 2008). This is a six-point scale that assesses methodological quality of clinical 
trials with respect to randomisation, blinding and dropouts/withdrawals. The scoring 
method is as follows: if the study describes details of randomisation, blinding and 
methods dealing with withdrawals, one point is given to each of the three items. If the 
randomisation method is appropriate and the blinding is adequate, one additional 
point is allocated to each of the above two items. However, if a study has 
inappropriate randomisation and/or inadequate blinding, one point is deducted for 
each of these two items (Jadad et al., 1996).    
 
All included studies are categorised in three groups: CHM for AR, acupuncture for 
AR and acupuncture combined with CHM for AR (sections 3.4.1 to 3.4.3). 
 
3.4.1 CHM for AR 
Two studies (Hu et al., 2002; Xue et al., 2003) that focused on CHM for AR were 
included in this category. They were both conducted in Australia and published in 
English. The sample size of these two studies is small: 55 (Xue et al., 2003) and 58 
(Hu et al., 2002). Conditions treated in these two studies are SAR (Xue et al., 2003) 
and PAR (Hu et al., 2002). When assessing the methodological quality of these two 
studies with the 6 point (0 to 5) Jadad scale, they both were assessed as high quality 
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RCTs (Jadad score 5). The characteristics of these two RCTs are summarised in 
Table 7. 
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Table 7: Characteristics of the two included RCTs (CHM for AR) 
Notes: PAR: perennial allergic rhinitis; SAR: seasonal allergic rhinitis; T: treatment group; C: control group.  
 
 
Author, Year  Country Condition 
Analysed 
Sample Size 
(Groups T/C)
Treatment 
duration Intervention Control Outcome measures Results 
Jadad 
Score 
Xue 2003 Australia SAR 55 (28/27) 
 
8 weeks 
CHM  in 
capsules, 
made from 
18 Chinese 
medicine 
herbs 
Placebo  
capsules 
Nasal and non-nasal symptoms 
score, RQLQ, overall individual 
response to treatment, relief 
medication score, patients’ 
opinion and blood tests. 
T>C, 
p<0.01 5 
Hu 2002 Australia PAR 58 (26/32) 12 weeks 
Biminne 
in capsules,  
made from 
11 Chinese 
medicine 
herbs 
Placebo  
capsules 
Symptoms score, QOL, patients’ 
evaluation of improvement VAS, 
physician’s overall evaluation.  
total serum IgE 
T>C, 
p<0.05 5 
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Both of these studies used capsules made from CHM formulas extraction as the 
intervention with placebo capsules as the control. The formula used in Xue (2003) 
study included 18 Chinese herbs (Dang Gui, Xi Xin, Huang Qi, Bai Zhu, Chai Hu, 
Sheng Ma, Dang Shen, Gan Cao, Chuan Xiong, Xin Yi, Bo He, Chen Pi, Che Qian Zi, 
Wu Wei Zi, Jing Jie, Fang Feng, He Zi, Cang Er Zi) while that in Hu (2002) study 
included 11 Chinese herbs (Di Huang, Huang Qin, Huang Jing, Yin Xing Ye, Yin 
Yang Huo, Bu Gu Zhi, Wu Wei Zi, Wu Mei, Fang Feng, Bai Zi, Huang Qi). Treatment 
duration was eight weeks (Xue et al., 2003) and 12 weeks (Hu et al., 2002). Both 
studies employed similar outcome measures such as symptom scores, quality of life 
assessment and blood tests. In addition, Xue (2003) also included a relief medication 
score as an outcome measure.  
 
In terms of efficacy, both studies reported that the specific CHM formula was more 
effective compared with placebo in reducing the symptom severity and in improving 
patients’ quality of life. In the study by Xue (2003), no significant difference was found 
in the relief medication score between the CHM and placebo groups. However, this 
may have been caused by the variety of medications used for AR symptoms (Xue et 
al., 2003). Due to multiplicity of herbs involved in these two studies, a firm conclusion 
regarding to the efficacy of CHM in the clinical management of AR could not be 
drawn. 
 
With regard to the safety of CHM for AR, one study (Xue et al., 2003) reported some 
mild gastrointestinal side effects such as bloating, indigestion and mild stomach-ache 
by the patients in both groups. These mild discomforts were tolerable and did not 
require medical treatment. Another adverse event reported in this study was skin 
rash and leg oedema from the real treatment group which required medical attention 
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and led to withdrawal from the study. However, it is not clear whether these 
gastrointestinal discomforts were caused by certain herbs in the formula or the intake 
of 12 capsules per day (Xue et al., 2003). The other study (Hu et al., 2002) reported 
two adverse events (stomach upset and dull abdominal pain) involving two patients in 
the placebo group, which led these two patients to withdraw from the trial.  
 
3.4.2 Acupuncture for AR 
Nine studies (Brinkhaus et al., 2008; Li, Zhuang, Lai, & Jiang, 2007; Magnusson, 
Svensson, Leirvik, & Gunnarsson, 2004; Ng et al., 2004; Petti, Liguori, & Ippoliti, 
2002; Rao & Han, 2006; Williamson et al., 1996; Xue, English, Zhang, Da Costa, & 
Li, 2002; Xue et al., 2007) focussing on acupuncture for AR were extracted from the 
identified reviews. They were conducted in Europe (Germany, Sweden, and Italy), 
Australia, mainland China and Hong Kong. The sample size of these studies varied 
from 20 to over 981. Conditions treated in these studies included SAR (Magnusson, 
Svensson, Leirvik, & Gunnarsson, 2004; Xue, English, Zhang, Da Costa, & Li, 2002), 
PAR (Li, Zhuang, Lai, & Jiang, 2007; Petti, Liguori, & Ippoliti, 2002), SAR and/or PAR 
(Brinkhaus et al., 2008) or PER (Ng et al., 2004; Xue et al., 2007). However, two 
studies did not specify the classification of AR (Rao & Han, 2006; Williamson et al., 
1996). In fact, the study by Williamson (1996) mentioned the “hay fever season”, 
hence it seems that this study was targeting SAR patients. The characteristics of 
these RCTs are summarised in Table 8. 
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Table 8: Characteristics of the nine included RCTs (Acupuncture for AR) 
Author, Year  Country Condition 
Analysed 
Sample Size 
(Groups T/C)
Treatment 
duration Intervention Control Outcome measures Results 
Jadad 
Score 
Brinkhaus 2008 Germany 
SAR 
and/or 
PAR 
981 
(487/494) 3 months 
Usual care 
plus 
acupuncture 
10 sessions 
Usual care 
alone Cost; SF-36; QALYs 
T>C, 
p<0.001 3 
Xue 2007 Australia PER 80 (42/38) 
8 weeks 
treatment, 
12 weeks 
follow-up 
Acupuncture 
16 sessions 
Sham 
acupuncture 
16 sessions 
Daily nasal symptoms score; 
weekly symptom score and 
total nasal symptom scores 
(TNSS); seven-day relief 
medication scores 
T>C, 
short- 
term and 
long-term 
p=0.001, 
0.02 
4 
Li 2007 China PAR 100 (50/50) 30 days 
Electro- 
acupuncture, 
30 sessions 
Cetirizine 
Percentage of effectiveness 
based on symptom score; 
plasma vasoactive intestinal 
peptide, substance P 
T>C, 
p<0.05 1 
Rao 2006  China AR 93 (47/46) 
28 days 
treatment, 
6 months 
follow-up 
Acupuncture, 
24 sessions Cetirizine 
Symptom score. serum total 
IgE, IFN-r, IL-4  
T>C,  
long term 
only, 
p<0.05 
2 
Ng 2004 
Hong 
Kong, 
China 
PER 72 (35/37) 
8 weeks 
treatment, 
12 weeks 
follow-up 
Acupuncture 
16 sessions 
Sham 
acupuncture 
16 sessions, 
Daily rhinitis scores, 
Symptom-free days. VAS 
score for immediate 
improvement after 
acupuncture; 
Relief medication score; 
Treatment preferences of 
participants; 
Blood eosinophil counts; 
Nasal eosinophil counts; 
Serum IgE levels 
T>C, 
short- 
term and 
long-term, 
p<0.05 
5 
Magnusson 
2004 Sweden SAR 
32 
(14/18) 
3 months 
treatment, 
12 
months 
follow-up 
 
 
Acupuncture 
12 sessions 
Sham 
acupuncture 
12 sessions 
Symptoms VAS; 
Reduction of levels of specific 
IgE; 
Reduction in skin test reaction 
T>C, 
short- 
term, 
p<0.05 
4 
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Author, Year  Country Condition 
Analysed 
Sample Size 
(Groups T/C)
Treatment 
duration Intervention Control Outcome measures Results 
Jadad 
Score 
Xue 2002 Australia SAR 30 (17/13) 
4 weeks, 
then 
cross 
over 
Acupuncture 
12 sessions 
Sham 
acupuncture 
12 sessions, 
Symptom score, relief 
medication score 
T>C, 
p<0.05 3 
Petti 2002 Italy PAR 90  (30/30/30) 
20 
minutes 
Acupuncture 
1 session 
C1: sham 
acupuncture, 
C2: no 
treatment 
Cytokines IL-2, IL-6, IL-10 
T>C1 and 
C2, 
p<0.05 
2 
Williamson 
1996 UK 
“hay 
fever” 
SAR 
102 
(51/51) 
one 
month per 
year for 3 
years 
Acupuncture  
3 or 4 
sessions 
Sham 
acupuncture 
Daily symptom score; 
Medication usage 
T>C, 
p<0.05 1 
Notes: PAR: perennial allergic rhinitis; SAR: seasonal allergic rhinitis; PER: persistent allergic rhinitis; T: treatment group; C: control group. 
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Using the 6 point (0 to 5) Jadad scale, four studies (Li, Zhuang, Lai, & Jiang, 2007; 
Petti, Liguori, & Ippoliti, 2002; Rao & Han, 2006; Williamson et al., 1996) were 
assessed as low quality (Jadad score 1 or 2) and the other studies (Brinkhaus et al., 
2008; Magnusson, Svensson, Leirvik, & Gunnarsson, 2004; Ng et al., 2004; Xue, 
English, Zhang, Da Costa, & Li, 2002; Xue et al., 2007) were high quality (Jadad 
score 3 and above). 
 
Among the nine studies, comparing real acupuncture with sham acupuncture is the 
most frequently used design (Magnusson, Svensson, Leirvik, & Gunnarsson, 2004; 
Ng et al., 2004; Petti, Liguori, & Ippoliti, 2002; Williamson et al., 1996; Xue, English, 
Zhang, Da Costa, & Li, 2002; Xue et al., 2007). Other studies compared a 
combination of acupuncture treatment and usual care with usual care alone 
(Brinkhaus et al., 2008), or acupuncture treatment versus anti-histamine medication 
(Li, Zhuang, Lai, & Jiang, 2007; Rao & Han, 2006). Electro-acupuncture was 
employed as the intervention in one study (Li, Zhuang, Lai, & Jiang, 2007).  
 
When acupuncture was compared with sham acupuncture, one study (Xue, English, 
Zhang, Da Costa, & Li, 2002) reported that acupuncture was superior for treating 
SAR by reducing the symptom severity score; one study demonstrated the 
effectiveness of acupuncture on mean rhinitis symptoms score during the follow-up 
period for PER patients (Xue et al., 2007); one study showed positive results for 
acupuncture in PER patients by decreasing the symptom scores and increasing the 
symptom-free days (Ng et al., 2004); one study (Williamson et al., 1996) reported 
acupuncture was effective in reducing the weekly symptom score and weekly 
medication usage; while two studies (Ng et al., 2004; Xue, English, Zhang, Da Costa, 
& Li, 2002) found that acupuncture was only effective in reducing symptom scores 
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but not in reducing medication scores. One study (Magnusson 2004) reported that 
acupuncture significantly reduced specific IgE and skin test reactions. When 
acupuncture was compared with oral antihistamine drugs for AR, two RCTs showed 
favourable effects for acupuncture (Li, Zhuang, Lai, & Jiang, 2007; Rao & Han, 2006). 
Li (2007) demonstrated that electroacupuncture was more effective than 
antihistamine (Cetirizine) in terms of the effective rate while Rao (2006) reported that 
acupuncture had a similar short-term effect to that of antihistamine (Cetirizine) but a 
better long-term effect.  
 
The outcome measure of relief medication score was used in four studies (Ng et al., 
2004; Williamson et al., 1996; Xue, English, Zhang, Da Costa, & Li, 2002; Xue et al., 
2007). The results for medication scores from these four studies were not consistent. 
Only one study (Williamson et al., 1996) reported that lower medication usage was 
observed in the real group compared with sham group at the end of treatment period. 
This might be caused by the variety of medications used for AR symptom control and 
the consequent difficulty in determining a single score.  
 
It is important to note that the large sized RCT of acupuncture for AR (Brinkhaus et 
al., 2008) also investigated the cost-effectiveness of acupuncture for AR 
management by assessing the QALYs gained (Witt, Reinhold, Jena, Brinkhaus, & 
Willich, 2009). It was a part of a series of the Acupuncture in Routine Care studies 
funded by the German statutory health insurance companies. This study concluded 
that acupuncture combined with routine care was not only beneficial for AR 
symptomatic control, but also cost effective.   
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Acupuncture does not involve any drug. Therefore, the side effects of drugs and 
pharmacologic interactions can be avoided using this treatment. Some of the studies 
reported mild adverse events such as pain, bruising, dizziness, numbness and 
headache caused by the needling technique (Ng et al., 2004; Xue et al., 2007). No 
serious adverse event was reported, and no withdrawals were attributable to adverse 
events due to acupuncture.  
 
In summary, based on the included studies on acupuncture for AR, acupuncture 
seems to be effective for AR symptomatic relief and quality of life improvement.  
 
3.4.3 Acupuncture combined with CHM for AR 
There is also one study investigating the combination of acupuncture and CHM for 
the management of AR (Brinkhaus et al., 2004). This study was conducted in 
Germany (Brinkhaus et al., 2004). Fifty-four SAR participants were included in this 
study. 
The characteristics are summarised in Table 9. 
 
In this study, acupuncture was combined with CHM as the intervention and 
compared with sham acupuncture plus placebo CHM. A positive result was obtained 
in this study. However, it is not clear if the effectiveness was caused by acupuncture 
or CHM.  
 
This study reported adverse events caused by needling such as severe needle pain, 
haematoma, paraesthesia and bruising from acupuncture; while the adverse events 
caused by CHM were bloating, indigestion, mild stomach ache, nausea and bitter 
taste.  
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Table 9: Characteristics of the three included RCTs (Acupuncture combining with CHM for AR) 
Notes: SAR: seasonal allergic rhinitis; T: treatment group; C: control group. 
 
 
 
Author, Year  Country Condition 
Analysed 
Sample Size 
(Groups T/C)
Treatment 
duration Intervention Control Outcome measures Results 
Jadad 
Score 
Brinkhaus 2004 Germany SAR 54 (28/26) 6 weeks 
Semi-
standardised 
treatment of 
acupuncture, 
6 sessions, 
and CHM for 
6 weeks 
Acupuncture 
on non-
acupuncture 
points, 6 
sessions, 
plus non-
specific CHM 
Global rating of weekly symptom 
severity;  
Symptom score, 
Global assessment of change; 
RQLQ; 
SF-36. 
T>C,  
p<0.05 4 
97 
 
3.4.4 Discussion 
In summary, based on the above review of the clinical research in CHM and 
acupuncture for the management of AR, positive findings from the previous RCTs 
suggested that CHM and acupuncture are effective for treating AR.  
 
However, the exact mechanism of CHM or acupuncture in treating AR still remains 
uncertain. Although some laboratory research has studied the pharmacology and 
immunological action of herbal medicines (Kao, Wang, Wang, Yu, & Lei, 2000; Ko et 
al., 2004; Lenon, Li, Xue, Thien, & Story, 2007; Lenon, Li, Xue, Thien, & Story, 2008; 
Lenon et al., 2007; Makino, Ito, Sasaki, Fujimura, & Kano, 2004), a firm conclusion 
cannot be drawn since the CHM formulas involved in these studies vary greatly from 
study to study.  
 
In recent years, researchers have conducted a number of animal experiments and 
clinical trials to investigate the anti-inflammatory effects of acupuncture. It has been 
reported that electroacupuncture has an impact on the hypothalamus-pituitary-
adrenal (HPA) axis by increasing Adrenocorticotropic hormone (ACTH) levels and 
suppressing oedema (Li et al., 2008), and on nerve pathways such as the 
sympathetic post-ganglionic neurons and the sympatho-adrenal medullary axis (Kim 
et al., 2008), as well as on the opioid neuropeptides (Fu, Wang, & Wu, 2006). A 
recent study suggested that acupuncture is related to the release of adenosine, a 
neuromodulator with anti-nociceptive properties (Goldman et al., 2010).  
 
Electroacupuncture is believed to elicit and enhance innate immunity and modulate 
adaptive immune system (Kim, & Bae, 2010). The effects of acupuncture for allergic 
diseases may rely on the anti-inflammatory effects of acupuncture mediated through 
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neurotrophins, (Nockher & Renz, 2006), cytokines (Joos, Schott, Zou, Daniel, & 
Martin, 2000; Petti, Liguori, & Ippoliti, 2002; Rao & Han, 2006), nitric oxide and 
leukotriene B4 (Carneiro, Xavier, De Castro, Do Nascimento & Silveira, 2010). A 
recent study on asthmatic rats found that acupuncture could specifically and 
effectively regulate the early airway response phase of asthma, and suggested that 
the gene expression of immune response and steroid hormones may play an 
important role in this treatment (Yin et al., 2009). All these mechanisms of 
acupuncture are yet to be confirmed.  
 
Furthermore, the safety issue of CHM for AR management needs to be considered. 
Herbs usually contain active compounds, thus it is not surprising that CHMs have 
some measurable clinical effects. On the other hand, for the same reason, they are 
not completely devoid of side effects and pharmacologic interactions (Passalacqua et 
al., 2006). Some side effects caused by herbal remedies have been reported by 
other studies (Barrett, Kiefer, & Rabago, 1999; Cupp, 1999). Hence, the safety of 
herbal medicines is an issue of public concern.  
 
For acupuncture, the therapeutic effects are obtained by stimulation of the acupoints 
by needling. Being an invasive technique, adverse events such as bruising, pain and 
others can occur. A recent survey of 229,230 patients who had experienced 
acupuncture indicated that bleeding or haematoma were commonly seen adverse 
events related to acupuncture treatment and recommended a consent form prior to 
treatment (Witt, Pach et al., 2009). 
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In addition, CHM or acupuncture treatment can only be delivered by experienced 
practitioners and attending an acupuncture clinic to receive acupuncture treatment is 
considered more time-consuming compared with taking medication. 
 
Therefore, although positive findings from some studies suggest that CHM and 
acupuncture may be effective for AR, for the AR patients who are seeking CAM 
therapies, a non-invasive and safer form of CAM should be considered if it is also 
effective.  
 
Ear-acupressure is a subtype of acupuncture that may be an effective and safe 
method. Firstly, ear-acupressure applies stimulation on acupoints by pressure 
instead of needle penetration, so that the adverse events caused by needling can be 
avoided. Secondly, ear-acupressure is semi-self-administered by patients, thus the 
intensity of pressure can be controlled based on patients’ own feeling. More details 
on ear-acupressure will be introduced in Chapter 4. 
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Chapter 4: Literature review on ear-acupressure for AR 
Ear-acupuncture and ear-acupressure (also called auricular therapy) is a subtype of 
acupuncture. Ear-acupressure is a non-invasive technique of auricular therapy. This 
chapter briefly introduces the background of auricular therapy and furthermore the 
specific ear-acupressure techniques. Two systematic reviews on ear-
acupuncture/ear-acupressure that were conducted prior to the clinical trial are 
presented in this chapter.  
 
4.1 Background 
Auricular therapy is a form of CAM treatment based on the theory that the ear is a 
microsystem in which the entire body is represented. By stimulating certain points on 
the ear, therapeutic effects can be achieved. 
 
4.1.1 The development of auricular therapy 
Auricular therapy has a long history of development and its origin can be dated back 
to ancient China. According to the theory of the meridian system in Chinese medicine, 
all the meridians are connected to the ear directly or indirectly. In traditional 
acupuncture, the points around the ear were used as part of the major meridians or 
channels. The Eber’s papyrus of 1550 BC (now in the British Museum) also 
describes a system of channels and vessels in the body which approximates more 
closely the Chinese system of channels than any known system of blood vessels, 
lymph vessels or nerves. The Egyptologist Alexandre Varille has documented that 
women in ancient Egypt who did not want any more children, had their external ear 
pricked with a needle or cauterized with heat. Hippocrates, the father of Greek 
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medicine, reported that doctors made small openings in the veins situated behind the 
ear to facilitate ejaculation and reduce impotency problems (Gori & Firenzuoli, 2007). 
 
The current system of auricular acupuncture was originally presented by Nogier in 
1956. Nogier is acknowledged as the “Father of Auricular Acupuncture”. He firstly 
observed patients in his practice who had received cauterisations on the ear’s 
antihelix for the treatment of sciatica. Nogier found that this was not only an 
occasional case, there were also some other practitioners delivering this treatment 
even though they were unaware how or why the procedure worked. By further 
investigation of this phenomenon, Nogier developed a mapping of “inverted foetus” 
and located 30 different points with an anatomical correspondence with the whole 
body. This technique was introduced to China and Japan in 1950s. Based on 
Nogier’s findings, the mapping of auricular acupoints was developed based more on 
functional considerations rather than from Nogier’s anatomical viewpoint. Detailed 
maps of the ear acupuncture points and zones were produced and incorporated into 
contemporary acupuncture texts. 
 
The first time an official international organisation studied the subject of auricular 
acupuncture was in 1990, when the World Health Organisation (WHO) held a 
meeting of “the Standardization of the nomenclature of the auricular acupuncture 
points” (Frank & Soliman, 2006).  
 
Today, auricular acupuncture is taught in the majority of Western countries. In France, 
teaching takes place in seven medicine faculties. There is a University diploma of 
auriculotherapy with the Paris faculty of Bobigny. In other European countries, this 
technique is also very popular, especially in Germany, Scandinavia, Spain and Italy 
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(Frank & Soliman, 2006). In Asian countries such as China, Japan, and Korea, this 
simple treatment is also widely applied due to its convenience and clinical 
effectiveness (Frank & Soliman, 2006). 
 
4.1.2 Mechanism of auricular therapy 
Auricular therapy considers the external ear as a microsystem of the whole body. 
Specific zones on the external ear represent certain areas of the body. Stimulating 
specific ear acupoints can produce therapeutic effects in the body for a large variety 
of conditions (Frank & Soliman, 2006).  
 
However, the exact mechanism of auricular therapy remains unknown. One 
explanation of how auricular therapy may work (although not proven) is that the 
stimulation of certain nerves on the ear may send messages to the brain that will in 
turn generate a “response” to the part of the body to be treated. It may also stimulate 
a general relaxation of the body (Frank & Soliman, 2006). 
 
Nowadays, there are two auricular therapy systems existing: the European system 
and Chinese system. In 1950’s, Nogier developed a three dimensional acupuncture 
microsystem. This system stresses that the organs are projected onto the ear as 
specific points within their respective zones. The practitioner should search for the 
active points within the organ’s zone for treatment (Frank & Soliman, 2006). The 
discovery of this system spread to China and led to intensive research by the 
Chinese medical authorities in late 1950s. A study initiated by the Nanjing Army Ear 
Acupuncture Research Team assessed over 2000 clinical patients and recorded the 
ear points that corresponded to the specific disease (Frank & Soliman, 2006). The 
Chinese ear-acupuncture system subsequently is focused on points’ functions and 
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the symptoms treated to build the charts, consequently some of the organs or 
structures differ from Nogier’s three phases chart (Frank & Soliman, 2006).  
 
4.1.3 Application of auricular therapy  
Auricular therapy can be applied through needling, using specifically designed 
machines or acupressure.  
 
4.1.3.1 Needling 
Similar to body acupuncture, needling should be applied to the ear points only after a 
complete sterilisation of the skin. Only needles with short length (13mm) or the press 
needles specifically designed for ear points can be used in ear-acupuncture. The 
insertion of needles should be no more than 2mm. Needles can be retained for 10-30 
minutes (Frank & Soliman, 2006).  
 
4.1.3.2 Auricular electroacupuncture stimulation (AES) 
Once needles are inserted into certain points, electronic stimulation can be applied 
using specifically designed auricular electroacupuncture stimulation equipment. It is 
necessary to select two needles and connect these to the equipment with wires to 
obtain the electronic stimulation as the electricity flows from a positive to a negative 
pole. Both low frequencies of 2 Hz to 10 Hz or a high frequency of 100 Hz can be 
chosen. In theory, the low frequency stimulation will affect enkephalins, endorphins 
and visceral and somatic disorders, while high frequency stimulation will affect 
dynorphins and neurological dysfunction (Frank & Soliman, 2006). 
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4.1.3.3 Acupressure 
Acupressure involves using the fingers, a round tip probe, magnetic or stainless steel 
pellets, or seeds to gently press and massage the points on the external ear to 
achieve therapeutic effects. The most commonly used ear-acupressure technique is 
attaching pellets or seeds to certain ear points using adhesive dressing to produce 
mild, long-term stimulation (Frank & Soliman, 2006). 
 
In addition, other technique such as laser stimulation on ear points, or points’ prick 
blood-letting technique also has been adapted in auricular therapy (Frank & Soliman, 
2006). 
 
The auricular therapy (including ear-acupuncture and ear-acupressure) has been 
popularly used for both acute and chronic pain or anxiety related disorders (Barker et 
al., 2006; Berman, Lundberg, Krook, & Gyllenhammar, 2004; Karst et al., 2007). 
Some other common conditions treated by ear-acupuncture/ear-acupressure are 
weight loss (Li, Wang, Gu & Wang, 2004), drug dependence (Avants, Margolin, 
Holford, & Kosten, 2000), smoking or alcohol dependence (Sapir-Weise, Berglund, 
Frank, & Kristenson, 1999), insomnia (Suen, Wong, Leung, & Ip, 2003), menstrual or 
menopausal syndromes (Zhu & Zhang, 1996; S. M. Wang et al., 2009) and 
psychological disorders such as depression (MacPherson & Schroer, 2007). 
 
4.1.4 Ear-acupressure for AR 
Ear-acupressure method with attaching seeds or pellets has been clinically used for 
AR. As AR is defined as an allergic condition, points related to allergy should be 
selected. In addition, points related to nose may help with nasal symptoms, while 
those related to eyes may relieve eye symptoms.  
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In clinical research, there have been RCTs suggested that ear-acupressure was a 
effective and safe treatment for AR (Gao, Zhang, Zhu, & Zhang, 2008; Huo, 2003; 
Kong, Ren, & Lu, 2006; Qi & Wang, 2008; Rao & Han, 2006; Wang, 2004; Ye, Luo, & 
Xia, 2008). However, there was not any systematic review in this area. Therefore, a 
systematic review on ear-acupuncture/ear-acupressure for AR RCTs was conducted 
to assess the current evidence of ear-acupuncture/ ear-acupressure’s effectiveness 
and safety for the management of AR, and also to specify the methodology of our 
clinical trial design. Furthermore, in order to determine the sham control method, 
another systematic review was conducted to investigate the sham design used in the 
previous ear-acupuncture/ear-acupressure RCTs. 
 
4.2 Ear-acupuncture and ear-acupressure for AR: a systematic 
review 
Although some clinical studies have found that ear-acupuncture or ear-acupressure 
is effective and safe for the management of AR (Gao, Zhang, Zhu, & Zhang, 2008; Qi 
& Wang, 2008; Rao & Han, 2006; Ye, Luo, & Xia, 2008), there lacks a systematic 
review to evaluate the current state of the evidence.  
 
Therefore, a systematic review was conducted in 2008 before the commencement of 
the pilot study. An earlier version of the systematic review based on the literature 
search in 2008 has been published (Zhang et al., 2010). This systematic review was 
updated in January 2011. This chapter introduces the methodology and results of the 
systematic review with the recently updated information. 
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4.2.1 Objectives of the review 
The main objective of this review was to assess the effectiveness and safety of ear-
acupuncture or ear-acupressure for the treatment of AR. Secondary objectives 
included: determining which ear-acupuncture points were used in existing trials; 
gathering data on study design and procedure and effect size to inform the proposed 
randomised controlled trial. 
 
4.2.2 Methods 
The literature search was conducted in April 2008 and updated in January 2011, 
following the methods specified in the Cochrane Handbook for Systematic Reviews 
of Interventions 4.2.6 (Higgins & Green, 2006).  
 
4.2.2.1 Search strategy 
A total of 21 electronic databases were searched from their respective inceptions to 
January 2011, 19 of them were English databases and two were Chinese databases. 
They are listed in Table 10. 
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Table 10: Databases searched for the systematic review on ear-acupuncture 
and ear-acupressure for AR 
English databases Chinese databases 
 Cochrane Central Register of 
Controlled Trials  
 PubMed  
 EMBASE  
 CINAHL  
 Informit  
 Science Direct  
 LILACS (Latin American and 
Caribbean Health Sciences)  
 ProQuest  
 AMED  
 Blackwell Synergy  
 PSYCINFO  
 PANTELEIMON  
 AcuBriefs  
 Koreamed  
 INDMED  
 Ingenta  
 mRCT  
 ISI web of knowledge  
 ERIC 
 VIP Information (www.cqvip.com) 
 China National Knowledge 
Infrastructure (www.cnki.net)  
 
 
Key words used throughout the search process included the combination of ear, 
auricular, acupuncture, acupressure, acupoint, allergic, allergy, rhinitis, hayfever, 
randomised clinical trial and their synonyms. The strategy used for searching 
Pubmed is provided in Table 11 as an example. Similar search strategies were 
applied to other databases. 
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Table 11: Search strategy for the systematic review on ear-acupuncture and 
ear-acupressure for AR used for Pubmed 
#1 ear or auricular 
#2 acupuncture or acupressure or acupoint 
#3 #1 and #2 
#4 allergic or allergy 
#5 rhinitis* 
#6 #4 and #5 
#7 hay fever or hayfever 
#8 #6 or #7 
#9 clinical trial or clinical trials 
#10 clinical study 
#11 #9 or #10 
#12 random* 
#13 #11 and #12 
#14 #3 and #8 and #13 
 
4.2.2.2 Study selection 
Upon the completion of the searches of the electronic databases, two independent 
reviewers initially screened all study titles and abstracts. Based on the selection 
criteria, if the study titles and abstracts did not provide adequate information, the full-
text articles were then obtained for further screening. Any disagreement between two 
reviewers was resolved by a third party researcher. The selection criteria are: 
 
Inclusion criteria: 
 RCTs or quasi-RCTs; 
 Patients with any type of AR and of any age or gender; 
 Intervention: any type of ear-acupuncture or ear-acupressure; 
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 Control: sham/placebo, no intervention, acupuncture, CHM or conventional 
therapies; 
 Co-intervention: co-intervention is allowed as long as all the arms of the trial 
use the same co-intervention;  
 Outcome measures: any type of outcome measure.  
 
Exclusion criteria: 
 Animal experiments; 
 Non-RCTs or non-quasi-RCTs; 
 Non AR; 
 Non ear-acupuncture or ear-acupressure studies; 
 Co-intervention that is not in all the arms of a RCT.  
For all the included studies, full texts were obtained for further evaluation. 
 
4.2.2.3 Methodological quality assessment, data extraction and data analysis 
This review was conducted in 2008 following the Cochrane Handbook for Systematic 
Reviews of Interventions 4.2.6 (Higgins & Green, 2006). Jadad scale was employed 
for the methodological quality assessment rather than the risk of bias tool which was 
introduced by later version of the Cochrane Handbook (Cochrane Handbook for 
Systematic Reviews of Interventions 5.1.0) (Higgins & Green, 2011). For all the 
included studies, two reviewers independently assessed the methodological quality 
of using the 6 point (0-5) Jadad scale (Jadad et al., 1996). Details of this scale have 
been provided in section 3.4. 
 
The two reviewers also extracted data from the included studies independently as 
follows: study setting, sample sizes, the treatment and control interventions, 
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outcomes, and adverse events. Any discrepancy between the two reviewers was 
discussed with the third party to reach agreement. The heterogeneity of the studies 
was interpreted through the characteristics of interventions.  
 
Effect size analysis was performed to explore the differences between interventional 
groups. Dichotomous data were expressed as risk ratio (RR) with 95% confidence 
interval (CI). Continuous data were not reported in all included RCTs. 
 
 
4.2.3 Results 
A total of 103 studies were identified following the search strategy. By screening the 
titles and abstracts, 36 of them were excluded due to not meeting the inclusion 
criteria, 67 full-text manuscripts were retrieved for detailed evaluation. After screening 
the full articles, 60 were excluded and seven studies were included in this review 
(Gao, Zhang, Zhu, & Zhang, 2008; Huo, 2003; Kong, Ren, & Lu, 2006; Qi & Wang, 
2008; Rao & Han, 2006; Wang, 2004; Ye, Luo, & Xia, 2008). 
 
The details of study selection process are shown in Figure 9. 
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Figure 9: Flow chart of the study selection process (SR1) 
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4.2.3.1 Characteristics of included studies 
All seven included studies were conducted in mainland China and published in 
Chinese language. The study sample sizes ranged from 66 to 400. A total of 1,004 
participants with AR, aged from 5 to 66 years, were randomised and 996 participants 
were analysed in these seven original studies. Only one study reported withdrawals 
(Rao & Han, 2006), eight participants discontinued during the treatment period and 
they were not included in the data analysis.  
 
Of the seven included studies, four studies (Gao, Zhang, Zhu, & Zhang, 2008; Qi & 
Wang, 2008; Rao & Han, 2006; Ye, Luo, & Xia, 2008) provided diagnostic criteria as 
the Chinese version “AR diagnostic and effects criteria”. However, none of the 
studies stated detailed inclusion or exclusion criteria. The number of treatment 
sessions and their total treatment duration varied in these studies, ranging from five 
to 30 times and 18 to 84 days respectively, except for one study that did not provide 
details (Gao, Zhang, Zhu, & Zhang, 2008). Two studies (Rao & Han, 2006; Wang, 
2004; Ye, Luo, & Xia, 2008) employed a 6-month follow-up period and one study had 
a one-year follow-up period (Gao, Zhang, Zhu, & Zhang, 2008), the other studies 
(Huo, 2003; Kong, Ren, & Lu, 2006; Qi & Wang, 2008; Wang, 2004) did not have a 
follow-up period. In terms of the intervention, all the seven included studies involved 
ear-acupressure as the active treatment intervention. One study (Ye, Luo, & Xia, 
2008) used magnetic pellets to press the ear points; three studies (Qi & Wang, 2008; 
Wang, 2004; Ye, Luo, & Xia, 2008) used Semen Vaccariae (cow soapwort seed or 
Wang Bu Liu Xing); one study (Gao, Zhang, Zhu, & Zhang, 2008) used “magnetic 
pellets or Semen Vaccariae”; whilst two other studies (Huo, 2003; Kong, Ren, & Lu, 
2006) did not provide details of the instruments used for ear-acupressure. There 
were a total of 14 different ear points used in these seven studies, among them, 
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Internal nose (TG4), External nose (TG1,2i) were used in all studies, Lung (CO14) and 
Spleen (CO13) were used in six studies, Throat, Shenmen (TF4) and Adrenal Gland 
(TG2P) were selected by four studies. Details are summarised in Table 12. 
Table 12: Summary of ear points used in the included RCTs 
Ear point/Trial Frequency Huo 2003 
Wang 
2004 
Kong 
2006 
Rao 
2006 
Ye 
2008 
Gao 
2008 
Qi 
2008 
Internal nose 
(TG4) 
7 √ √ √ √ √ √ √ 
External nose 
(TG1,2i) 
7 √ √ √ √ √ √ √ 
Lung (CO14) 6 √ √ √ √ √ √  
Spleen (CO13) 6 √ √ √ √ √ √  
Throat (TG3) 4  √ √  √ √  
Shenmen(TF4) 4  √ √  √ √  
Adrenal Gland 
(TG2P) 
4 √  √ √   √ 
Liver (CO12) 3 √ √   √   
Kidney (CO10) 3  √ √  √   
Eye (LO5) 3 √ √   √   
Jiaogan (AH6a) 2      √ √ 
Wind stream 
(SF1,2i) 
2    √  √  
Neifenmi 
(CO18) 
1    √    
Heart (CO15) 1  √      
 
Concerning the control methods used for the control group in the seven studies, two 
studies (Kong, Ren, & Lu, 2006; Wang, 2004) compared ear-acupressure with CHM 
tablets; two studies (Huo, 2003; Qi & Wang, 2008) compared ear-acupressure with 
body acupuncture; one study (Ye, Luo, & Xia, 2008) compared ear-acupressure plus 
body acupuncture with body acupuncture alone; one study (Gao, Zhang, Zhu, & 
Zhang, 2008) compared ear-acupressure with an anti-histamine medication 
(Loratadine); while another study (Rao & Han, 2006) was a three-armed trial that 
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compared ear-acupressure with body acupuncture or with an anti-histamine 
medication (Cetirizine).  
 
With regard to outcome measures, five out of the seven studies only used “Total 
effective rate” as their outcome measure (Gao, Zhang, Zhu, & Zhang, 2008; Huo, 
2003; Kong, Ren, & Lu, 2006; Wang, 2004; Ye, Luo, & Xia, 2008). The “Total 
effective rate” was calculated as:  
the number of cases that experienced AR symptom improvement  
after treatment 
X100% the total number of cases in the group 
 
When calculating this “Total effective rate”, all patients who experienced any 
symptom improvement, from minor improvement to significant improvement, were 
considered to be effective cases.  
 
Three studies employed a symptom severity scoring system (Gao, Zhang, Zhu, & 
Zhang, 2008; Qi & Wang, 2008; Rao & Han, 2006). Four symptoms were scored 
using a three point scale (1, 2 and 3) including sneezing, runny nose, blocked nose 
and itchy nose. In these studies, this scoring method was used for “Total effective 
rate” data analysis. All the cases with more than 20% of symptom severity score 
reduction after treatment were considered effective cases. In addition to this scoring 
method, the study (Rao & Han, 2006) also measured total serum IgE, IL-4, and IFN-.  
 
The detailed characteristics of the included studies are summarised in Table 13. 
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Table 13: Characteristics and methodological quality assessment of included studies 
Study Setting Diagnostic criteria 
Sample size Intervention Jadad 
score Treatment 
(n, age) 
Control 
(n, age) Treatment Control 
Huo, 2003 Unclear Unclear 30 (22-65): 
17 in Lung 
and Spleen 
Qi 
deficiency 
subgroup; 
13 in 
Phlegm-
heat with 
blood stasis 
subgroup 
36 (20-62): 
22 in Lung 
and Spleen 
Qi 
deficiency 
subgroup; 
16 in 
Phlegm-
heat with 
blood stasis 
subgroup 
Ear-acupressure: Neibi, Waibi, Eye, 
Shenshangxian, Liver, Spleen, 
Lung; 
Prick blood at Fengxi, Erjian; 
twice a week, 5 times, 2.5 weeks in 
total.  
Body acupuncture:  
twice a week, 5 times, 2.5 weeks in 
total. 
1 
Wang, 
2004 
Hospital 
outpatients 
Unclear 300 (5-59) 100 (5-59) Ear-acupressure (Wangbuliuxing 
seeds): Shenmen, Liver, Kidney, 
Spleen, Lung, Heart, Eye, Nose; 
once every 3 days, 10 times, 30 
days in total. 
Bi Yan Kang (Rhinitis Tablets): 4 
tables, tid,  
30 days in total. 
1 
Kong, 
2006 
Unclear Unclear 54 (14-62) 54 (14-62) Ear-acupressure (seeds): Neibi, 
Waibi, Fei, Shenshangxian (main 
ear points);  
once every 4 days, 21 times, 84 
days in total. 
Fang Zhi Bi Yan Pian (Fang Feng 
and Bai Zhi Rhinitis Tablets): 5 
tablets, tid; and Fu Ma Liquid: 2 
nasal drops, tid;  
21 days in total. 
1 
Rao, 2006 Hospital 
outpatients 
AR diagnostic 
and effects 
criteria 
T1: 50 (20-
66), 3 
dropouts;  
T2: 50 (13-
65), 1 
dropout 
50 (16-65), 
4 dropouts 
T1: Body acupuncture; once a day 
for 28 days in total. 
T2: Ear-acupressure (Wangbuliuxing 
seeds): Fei, Pi, Shen, Neibi, Waibi, 
Fengxi, Neifenmi, Shenshangxian; 
twice a week for 4 weeks, 28 days in 
total. 
Cetirizine: 10mg, Qd,   
28 days in total. 
2 
116 
 
Gao, 2008 Hospital 
outpatients 
AR diagnostic 
and effects 
criteria 
33 (6.5-57) 33 (8-58) Ear acupressure (Wangbuliuxing 
seeds or magnetic pellets): Lung, 
Nose, Jiaogan, Fengxi, Throat, 
Shenmen, Kidney;  
once in every 3-4 days, the total 
duration is unclear. 
Loratadine: 10mg, Qd,   
28 days in total. 
1 
Qi, 2008 Unclear AR diagnostic 
and effects 
criteria 
50 (16-66) 50 (17-67) Ear acupressure (Wangbuliuxing 
seeds): Neibi, Waibi, Jiaogan, 
Shenshangxian; 
once every 2 days, 10 times; 20 
days in total. 
Body acupuncture: 
once daily, 20 times;  
20 days in total. 
1 
Ye, 2008 Hospital 
outpatients 
AR diagnostic 
and effects 
criteria 
40 (10-61) 
 
40 (10-61) 
 
Ear-acupressure (magnetic pellets): 
Shenmen, Gan, Shen, Pi, Fei, Mu, 
Bi, Yan;  
once every 2 days, 30 times; 60 
days in total. 
Body acupuncture: 
once every 2 days,  
30 times; 60 days in total. 
1 
Legend: T: Treatment; C: Control. Tid: three times a day; Qd: once a day. 
Texts in italic indicate that they are terms used in traditional Chinese medicine, acupuncture point names or herbal medicine names. 
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 Table 14: Outcome measures and results of the included studies 
Study Outcome measures 
Results 
Effect size 
RR (95% CI) Treatment group Control group 
Huo, 2003 Total effective rate 
Lung and Spleen Qi deficiency subgroup (subgroup 1) 
Subgroup 1:1.40 (0.97, 2.04); 
Subgroup 2: 0.66 (0.44, 0.98);  
All patients: 1.01 (0.79, 1.28);  
90.9% 64.7% 
Phlegm-heat with blood stasis subgroup (subgroup 2) 
64.3% 100% 
Wang, 2004 Total effective rate 99% 40% 2.48 (1.95, 3.15) 
Kong, 2006 Total effective rate 92.6% 70.4% 1.32 (1.09, 1.59) 
Rao, 2006 Total effective rate  
Treatment group 1 
(T1) 
Treatment group 2  
(T2) Control group  
 
 
Short term (after treatment) T2 vs T1: 0.98 (0.89, 1.08) 
T2 vs C: 0.96 (0.88, 1.04) 95.75% 93.88% 97.83% 
Long term (6 months follow-up) T2 vs T1: 0.85 (0.61, 1.19) 
T2 vs C: 3.02 (1.54, 5.93) 69.05% 58.97% 19.51% 
Gao, 2008 Total effective rate 
Short term (after treatment) 
0.97 (0.82, 1.14) 
87.88% 90.91% 
Long term (12 months follow-up) 
1.36 (0.74, 2.51) 
45.45% 33.33% 
Qi, 2008 Total effective rate 96% 100% 0.96 (0.90, 1.03) 
Ye, 2008 Total effective rate  97.5% 80.0% 1.22 (1.04, 1.43) 
Legends: RR: Risk Ratio; CI: Confidence Interval; T: Treatment; C: Control.  
Note: Texts in italic indicate that they are terms in traditional Chinese medicine.
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4.2.3.2 Methodological quality of included studies 
Randomisation was claimed in all the studies. One study provided the details of using 
the odd/even alternative allocation method for randomisation (Huo, 2003); another 
study used the sequence of clinic attendance for randomisation (Gao, Zhang, Zhu, & 
Zhang, 2008) and the rest did not give details of randomisation methods used. None 
of the seven studies provided information on blinding. In addition, none of them 
applied the sham/placebo control method or intention-to-treat analysis. Only one 
study (Rao & Han, 2006) reported dropouts/withdrawals. Therefore, the Jadad scores 
of the included studies ranged from 0 to 2 (only Rao & Han’s) study was scored with 
2). All these studies were considered to be of low quality. The detailed Jadad scores 
of the included studies are provided in Table 13 (page 115). 
 
4.2.3.3 Clinical effectiveness 
Two studies (Kong, Ren, & Lu, 2006; Wang, 2004) reported that the ear-acupressure 
produced a significantly higher percentage of effectiveness comparing with CHM (RR, 
1.32; 95%CI: 1.09, 1.59 and RR, 2.48; 95%CI: 1.95, 3.15). Rao and Han (2006) 
found that ear-acupressure was not better than body acupuncture (RR, 0.98; 95%CI: 
0.89, 1.08) or anti-histamine (cetirizine) (RR, 0.96; 95%CI: 0.88, 1.04) in the short-
term (four weeks) based on the percentage of cases with symptom severity score 
reduction. However, this study found that ear-acupressure had a significantly better 
long-term (six months) effect than the anti-histamine medication (RR, 3.02; 95%CI: 
1.54, 5.93). Rao and Han (2006) also reported that both acupuncture and ear-
acupressure had similar short-term effects (no data available for long-term follow-up) 
to anti-histamine in reducing the total serum IgE (p<0.01) and IL-4 (p<0.05). Similarly, 
Gao et al. (2008) reported that ear-acupressure was not better than body 
acupuncture (RR, 0.97; 95%CI: 0.82, 1.14) in the short-term but more effective in the 
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long-term (RR, 1.36; 95%CI: 0.74, 2.51). Qi and Wang (2008) found that ear-
acupressure was less effective compared with anti-histamine medication (RR, 0.96; 
95%CI: 0.90, 1.03).  
 
Another study concluded that when ear-acupressure was combined with body 
acupuncture, the combined effect was superior to that of body acupuncture alone 
(RR, 1.22; 95%CI: 1.04, 1.43) (Ye, Luo, & Xia, 2008).  
 
Huo’s study (Huo, 2003) divided patients into subgroups according to Chinese 
medicine principles as follows: Lung and Spleen Qi deficiency and Phlegm-heat with 
blood stasis syndrome. It concluded that ear-acupressure had better effects than 
body acupuncture treatment for participants with Lung and Spleen Qi deficiency 
syndromes. However, there was no difference in the participants with phlegm-heat 
and blood stasis when compared with body acupuncture (RR, 0.66; 95%CI: 0.44, 
0.98). When all participants are combined, the two treatments showed similar clinical 
outcomes (RR, 1.01; 95%CI: 0.79, 1.28).  
 
The outcome measures and results are summarised in Table 14 (page 117). 
 
4.2.3.4 Adverse events reported in the included studies 
Three studies (Kong, Ren, & Lu, 2006; Rao & Han, 2006; Wang, 2004) indicated that 
there were no adverse events observed. The other four studies (Gao, Zhang, Zhu, & 
Zhang, 2008; Huo, 2003; Qi & Wang, 2008; Ye, Luo, & Xia, 2008) did not provide 
information about adverse events.  
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4.2.4 Discussion and conclusion  
This recently updated systematic review shows that only a small number RCTs of 
ear-acupressure for AR are available and all of these studies were conducted in 
China. All the included studies used non-invasive (no skin penetration) mechanical 
stimulation methods on the ear points such as seeds or magnetic pellets. There were 
no studies of ear acupuncture. Commonly used ear points involved in the ear-
acupressure treatments were: Internal nose (TG4), External nose (TG1,2i), Lung (CO14) 
and Spleen (CO13), Throat, Shenmen (TF4) and Adrenal Gland (TG2P). With regard to 
the control interventions, two studies compared ear-acupressure with CHM, three 
studies compared ear-acupressure with body acupuncture, one study compared ear-
acupressure with antihistamine medication (Loratadine) and one study compared 
ear-acupressure with body acupuncture as well as antihistamine medication 
(Cetirizine). Since sham/placebo control was not used in any of the studies, it was 
not possible for the participants to be blinded. Therefore, the results from these 
unblinded RCTs tend to be biased (Wood et al., 2008).  
 
Overall, the included RCTs showed that ear-acupressure appears to have a higher 
percentage of effectiveness than that produced by CHM. When comparing with body 
acupuncture, three studies (Huo, 2003; Qi & Wang, 2008; Rao & Han, 2006) reported 
ear acupressure had similar effectiveness to body acupuncture whereas another 
study (Ye, Luo, & Xia, 2008) concluded that the effect of combining ear-acupressure 
with body acupuncture was better than using body acupuncture alone. On the other 
hand, when comparing ear-acupressure with anti-histamine medication, two studies 
(Gao, Zhang, Zhu, & Zhang, 2008) and (Rao & Han, 2006) showed a better long-
term effect for ear-acupressure. However, due to the fact that all included studies 
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were assessed as low quality, Meta-analysis was not applied to avoid generating 
false results. 
 
Three studies (Kong, Ren, & Lu, 2006, Rao & Han, 2006, Wang, 2004) reported 
there were no adverse events associated with ear-acupressure. This may be due to 
the fact that, unlike standard needle acupuncture for which minor adverse events are 
usually reported (Witt et al., 2009), no skin penetration was involved in these studies.  
 
Consistent with a recent review on CAM for rhinitis and asthma (Passalacqua et al., 
2006), the methodological quality of included studies is low. The results for the 6-
point Jadad scale (0 to 5) assessments of these seven studies were between 0 and 2. 
None of them provided adequate information on appropriate methods used for 
randomisation or concealment of allocation. Neither blinding techniques nor 
sham/placebo ear-acupressure control was applied to any of the included studies. 
Although the studies demonstrated positive results for ear-acupressure when 
compare with CHM (for the short-term) or anti-histamine medications such as 
Cetirizine and Loratadine (for the long-term), firm conclusions cannot be drawn due 
to the inappropriate control method. Selection criteria of participants were not clearly 
described in any of the included studies. Three studies (Gao, Zhang, Zhu, & Zhang, 
2008; Qi & Wang, 2008; Rao & Han, 2006) used a symptom scoring method to 
measure the severity of symptoms, other four studies only employed “Total effective 
rate” as the outcome measures without a detailed scoring system. Quality of life 
improvement or reduction of medication usage, which have been widely used in other 
RCTs of AR in the English literature (Brinkhaus et al., 2008; Xue, English, Zhang, Da 
Costa, & Li, 2002; Xue et al., 2007) were not employed as outcome measures in any 
of the included studies. In addition, only the Rao and Han (2006) study included 
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laboratory serum tests. Due to the significant methodological weaknesses, the 
summarised results from this review must be interpreted with caution.  
 
In conclusion, the existing evidence indicated that ear-acupressure was well tolerated 
by patients with AR. Although ear-acupressure has shown some promising positive 
effects for symptomatic relief of AR, the findings should be carefully interpreted due 
to the lack of blinding, lack of a sham/placebo control and general low 
methodological quality of the included trials. To provide reliable evidence to guide 
clinical practice, a more rigorously designed RCT of ear-acupressure for AR is 
needed. 
 
4.3 Sham control methods used in ear-acupressure RCTs:  a 
systematic review 
The systematic review discussed in section 4.2 showed that the previous RCTs of 
ear-acupuncture/ear-acupressure suffered from methodological flaws including lack 
of appropriate control methods.  
 
In clinical research, RCTs are generally considered as the gold standard experiment 
to provide evidence for the efficacy of the intervention (Devereaux & Yusuf, 2003). In 
drug trials the control used is an inert placebo that is designed to be identical to the 
active intervention and thereby reduce the risk of unblinding the participants to their 
group allocation. However, if the intervention to be tested is a physical procedure, the 
design of the control methods becomes more complex.  
 
“Sham” is the term used to refer to a faked operative intervention which is used in the 
same manner as a placebo to enable blinding and reduce bias. The methodological 
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difficulties in designing proper placebo/sham control interventions in experiments on 
physical interventions such as acupuncture or acupressure has been the topic of 
considerable discussion (White, Filshie, & Cummings, 2001).  
 
A review of sham interventions used in RCTs of acupuncture (Dincer & Linde, 2003) 
has been completed. Forty-seven RCTs comparing real and sham acupuncture 
interventions for pain and a variety of other conditions were identified in this review. 
This review reported that the sham interventions of acupuncture methods could be 
categorised into five types:  
 Superficial needling of “true” acupuncture points (superficial needling of the 
acupoints for the treated condition) 
 Irrelevant acupuncture points (normal needling of acupoints that are not used 
for the treated condition) 
 Non-acupuncture points (needling non-acupoints) 
 Placebo needles (devices that mimic acupuncture without skin penetration) 
 Pseudo-interventions (interventions that are not “true” acupuncture e.g. use of 
switched-off laser acupuncture devices) 
Among these five types of sham intervention, the “non-acupuncture points” method 
was the most commonly used. The findings from this review have assisted 
researchers in designing their acupuncture RCTs (Thomas et al., 2006; Xue et al., 
2007).  
 
Similar to the RCTs on acupuncture or other physical interventions, sham/placebo 
control groups have also been used in ear-acupuncture/ear-acupressure studies. 
Unlike body acupuncture, it is difficult to locate non-acupuncture points on the ear 
due to the small size of the ear and the large number of identified acupoints on the 
124 
 
ear. In the design of an ear-acupuncture/ear-acupressure study, choosing a suitable 
control method to ensure the participant blinding is important. To date, there is no 
published critical review on the control intervention methods used in ear-
acupuncture/ear-acupressure trials.  
 
Therefore, prior to designing the ear-acupressure for AR RCT, a systematic review 
was conducted in April 2008 and updated in January 2011 to investigate all types of 
sham/placebo ear-acupuncture/ear-acupressure methods by reviewing all published 
RCTs that have used sham/placebo ear-acupuncture/ear-acupressure as a control 
intervention. This section details the methods and results of the systematic review 
including the recently updated information. 
 
4.3.1 Methods of the review 
This review was conducted in 2008 following the methods specified in the Cochrane 
Handbook for Systematic Reviews of Interventions 4.2.6 (Higgins & Green, 2006). 
 
4.3.1.1 Search strategy 
Consistently with the systematic review 1, a total of 19 electronic English databases 
and two Chinese databases were searched from their respective inceptions to the 
end of January 2011(details refer to Table 10, page 107). Key words used for the 
search included the combination of ear, auricular, acupuncture, acupressure, 
randomised controlled trial and their synonyms.   
 
4.3.1.2 Study selection 
The study selection procedure was consistent with systematic review 1 (section 
4.2.2.2). The study selection criteria were:  
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Inclusion criteria: 
 RCTs and quasi-RCTs; 
 Patients with any type of clinical condition, any age or gender; 
 Intervention: any type of ear-acupuncture or ear-acupressure (such as 
needles inserting into ear points, electrical stimulation on the ear points, laser 
stimulation on the ear points, seeds, stainless steel pellets or magnetic pellets 
attached on ear points, or prick blood-letting technique on ear points); 
 Control: any type of sham/placebo ear-acupuncture or ear-acupressure control, 
even if the term “sham/placebo” is not mentioned in the article; and 
 Co-intervention is allowed as long as all the arms used the same co-
intervention; 
 Published in English or Chinese; 
 Any type of outcome messures. 
Exclusion criteria: 
 Studies not for a clinical condition;  
 Studies that are not a sham/placebo-controlled trial; and 
 Studies that do not assess the efficacy of ear-acupuncture/ear-acupressure. 
For all the included studies, full texts were obtained for further evaluation.  
 
4.3.1.3. Classification of sham interventions 
Consistent with the sham acupuncture review (Dincer & Linde, 2003), the sham 
interventions used in the included studies were categorised according to the following 
classification:  
 Type I: non-specific ear points for the condition treated;  
 Type II: non-ear points;  
 Type III: placebo needles or adhesive patches; and  
126 
 
 Type IV: pseudo-interventions (eg. switched off laser acupuncture devices, 
electro acupuncture devices with minimum emission, Vaccariae seeds without 
pressing).  
 
4.3.1.4 Data analysis 
The types of interventions were summated. The differences between real and sham 
interventions were then examined, including the number and location of ear points, 
achievement of De Qi sensation (the feelings occur after an acupuncture needle has 
been properly placed in the body, such as numbness, heaviness, and other feelings, 
which is usually considered as an important component of acupuncture treatment), 
number and duration of treatment sessions. Studies were clustered according to the 
main outcome measures used for the type of condition, such as pain intensity for 
pain, State-Trait Anxiety Inventory (STAI) for anxiety and smoking cessation rate for 
smoking cessation.  The results for the main outcome measures were summarised 
as: T>C (real treatment group was significantly superior to sham control group), ND 
(no differences between real and sham groups) and T<C (real treatment group was 
significantly inferior to sham control group). For the RCTs treating the same clinical 
condition, data syntheses were conducted when data was available for the same 
outcome measure in two or more RCTs using the same sham control intervention. 
For trials with a comparable baseline, mean and standard deviation, data were 
entered into Cochrane software Review Manager (RevMan) 5 for meta-analysis. 
Continuous data were presented as mean difference (MD) (if the same scales were 
used for the same outcome measure) or standard mean difference (SMD) (if different 
scales for the same outcome measure were used), and RR was used for 
dichotomous data, both approaches used a 95% CI.  
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4.3.2 Results  
A total of 62 articles were identified and 37 of them were sham-controlled RCTs and 
were included in the current review. The study selection process is shown in Figure 
10.  
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Figure 10: Flow chart of the study selection process (SR2) 
 
4.3.2.1 Description of included studies 
Clinical conditions treated in the included studies consist of:  
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(n=56) 
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- Not a trial to assess the 
efficacy of ear-
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- Protocol (n= 1) 
- Duplicated study (n= 2) 
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 Pain: 11 studies (Alimi et al., 2003; Mazzetto, Carrasco, Bidinelo, de Andrade 
Pizzo, & Mazzetto, 2007; Michalek-Sauberer et al., 2007; Sator-
Katzenschlager et al., 2004; Sator-Katzenschlager et al., 2003; Sator-
Katzenschlager et al., 2006; Simmons & Oleson, 1993; Usichenko et al., 2005; 
Usichenko et al., 2007; Wang, Hsu, Chien, Kao, & Liu, 2009; Wang et al., 
2009) 
 Anxiety: six studies (Karst et al., 2007; Kober et al., 2003; Mora et al., 2007;  
Wang & Kain, 2001; Wang, Maranets, Weinberg, Caldwell-Andrews, & Kain, 
2004, Wang, Peloquin, & Kain, 2001);   
 Drug dependence: nine studies (Avants, Margolin, Holford, & Kosten, 2000; 
Berman, Lundberg, Krook, & Gyllenhammar, 2004; Bullock, Kiresuk, Pheley, 
Culliton, & Lenz, 1999; Bullock et al., 2002; Killeen et al., 2002; Lipton, 
Brewington, & Smith, 1994; Margolin, Avants, & Holford, 2002; Tian & 
Krishnan, 2006; Washburn et al., 1993); 
 Smoking cessation: five studies (Cai, Changxin, Ung, Lei, & Kean, 2000; Otto, 
Quinn, & Sung, 1998; Waite & Clough, 1998; White, Resch, & Ernst, 1998; 
Wu, Chen, Liu, Lin, & Hwang, 2007); 
 Alcohol dependence: two studies (Sapir-Weise, Berglund, Frank, & 
Kristenson, 1999; Trumpler, Oez, Stahli, Brenner, & Juni, 2003);   
 Insomnia: one study (Sjoling, Rolleri, & Englund, 2008); 
 Body weight reduction: two studies (Hsu et al., 2009; Shen, Hsieh, Chang, & 
Lin, 2009);  
 One study was for both anxiety and pain (Barker et al., 2006).  
 
Among these 37 studies, five studies (Barker et al., 2006; Kober et al., 2003; Mora et 
al., 2007; Tian & Krishnan, 2006; Wang, Hsu, Chien, Kao, & Liu, 2009) employed 
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ear-acupressure as the intervention, while other studies used ear-acupuncture. 
Electro-acupuncture was involved in six studies (Michalek-Sauberer et al., 2007; 
Sator-Katzenschlager et al., 2004; Sator-Katzenschlager et al., 2003; Sator-
Katzenschlager et al., 2006; Simmons & Oleson, 1993; White, Resch, & Ernst, 1998). 
One study (Trumpler, Oez, Stahli, Brenner, & Juni, 2003) selected laser stimulation 
as the intervention. 
 
With respect to efficacy, 21 out of 37 trials showed the real ear-acupuncture/ear-
acupressure groups had a significant superiority over the sham control groups (Alimi 
et al., 2003; Avants, Margolin, Holford, & Kosten, 2000; Barker et al., 2006; Kober et 
al., 2003; Mazzetto, Carrasco, Bidinelo, de Andrade Pizzo, & Mazzetto, 2007; Mora 
et al., 2007; Sator-Katzenschlager et al., 2004; Sator-Katzenschlager et al., 2003; 
Sator-Katzenschlager et al., 2006; Shen, Hsieh, Chang, & Lin, 2009; Simmons & 
Oleson, 1993; Tian & Krishnan, 2006; Usichenko et al., 2005; Usichenko et al., 2007; 
Waite & Clough, 1998; Wang & Kain, 2001; Wang, Maranets, Weinberg, Caldwell-
Andrews, & Kain, 2004; Wang, Peloquin, & Kain, 2001;  Wang, Hsu, Chien, Kao, & 
Liu, 2009; Wang et al., 2009; Washburn et al., 1993). The remaining 16 studies found 
that there were no significant differences between the real and sham groups 
(Berman, Lundberg, Krook, & Gyllenhammar, 2004; Bullock, Kiresuk, Pheley, 
Culliton, & Lenz, 1999; Bullock et al., 2002; Cai, Changxin, Ung, Lei, & Kean, 2000; 
Hsu et al., 2009; Karst et al., 2007; Killeen et al., 2002; Lipton, Brewington, & Smith, 
1994; Margolin, Avants, & Holford, 2002; Michalek-Sauberer et al., 2007; Otto, 
Quinn, & Sung, 1998; Sapir-Weise, Berglund, Frank, & Kristenson, 1999; Sjoling, 
Rolleri, & Englund, 2008; Trumpler, Oez, Stahli, Brenner, & Juni, 2003; White, 
Resch, & Ernst, 1998; Wu, Chen, Liu, Lin, & Hwang, 2007). No studies found the 
sham group to be superior.  
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Except for four trials which did not report the data (Michalek-Sauberer et al., 2007; 
Otto, Quinn, & Sung, 1998; Sapir-Weise, Berglund, Frank, & Kristenson, 1999; 
Usichenko et al., 2007), the total number of treatment sessions ranged from one 
session to 40 sessions, and the frequency of treatment ranged from daily to weekly 
treatment. Thirteen studies (Barker et al., 2006; Karst et al., 2007; Killeen et al., 
2002; Kober et al., 2003; Mora et al., 2007; Simmons & Oleson, 1993; Usichenko et 
al., 2005; Usichenko et al., 2007; Waite & Clough, 1998; Wang & Kain, 2001; Wang, 
Maranets, Weinberg, Caldwell-Andrews, & Kain, 2004; Wang, Peloquin, & Kain, 
2001; Wang et al., 2009) only provided one real or sham treatment for the clinical 
condition. Seven studies treated either the real or sham ear points once a week 
(Shen, Hsieh, Chang, & Lin, 2009; Sator-Katzenschlager et al., 2004; Sator-
Katzenschlager et al., 2003; Sator-Katzenschlager et al., 2006; Tian & Krishnan, 
2006; Washburn et al., 1993; Wu, Chen, Liu, Lin, & Hwang, 2007); two trials treated 
twice a week (Hsu et al., 2009; Mazzetto, Carrasco, Bidinelo, de Andrade Pizzo, & 
Mazzetto, 2007); one study treated three times a week (Cai, Changxin, Ung, Lei, & 
Kean, 2000); and four trials used daily treatment (Bullock et al., 2002; Lipton, 
Brewington, & Smith, 1994; Margolin, Avants, & Holford, 2002; Trumpler, Oez, Stahli, 
Brenner, & Juni, 2003). The duration of treatment sessions varied greatly, lasting 
from 4 minutes to two weeks. Seven trials did not report the duration of treatment 
sessions (Barker et al., 2006; Bullock, Kiresuk, Pheley, Culliton, & Lenz, 1999; Kober 
et al., 2003; Mazzetto, Carrasco, Bidinelo, de Andrade Pizzo, & Mazzetto, 2007; 
Mora et al., 2007; Michalek-Sauberer et al., 2007; Usichenko et al., 2007).  
 
None of studies indicated whether a De Qi sensation was achieved during the real 
ear-acupuncture/ear-acupressure treatment. Needle insertion depth on the ear points 
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and manipulation on needles or seeds were not described in the majority trials. The 
characteristics of the included studies are summarised in Table 15. 
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Table 15: Characteristics of 37 studies included in this review 
Sham 
control 
method 
Condition Condition subgroup Author, Year 
Analysed 
Sample Size 
(Groups T/C) 
Ear-
acupuncture 
or Ear-
acupressure 
No of Ear 
Points 
(T/C) 
Unilateral 
or Bilateral 
Treatment 
Treatment 
Sessions 
and total 
duration 
Duration 
of Each 
Session 
Result Jadad score 
Type I 
(Non-
specific 
points) 
Pain and 
Anxiety 
Pain and 
anxiety Barker, 2006 18/20 
Ear-
acupressure 3/1 Bilateral 1 session NS 
T>C, 
p=0.000
1, 0.018 
5 
Anxiety 
Karst, 2007 19/19 Ear-acupuncture 3/2 NS 1 session 25 min 
ND, 
p>0.05 3 
Kober, 2003 17/19 Ear-acupressure 1/1 Bilateral 1 session NS 
T>C, 
p=0.002 4 
Mora, 2007 24/24 Ear-acupressure 1/1 Bilateral 1 session NS 
T>C, 
p=0.001 4 
Wang, 2001a 22/15/18 (T1/T2/C) 
Ear-
acupuncture 1/1/1 Bilateral 1 session 48 hours 
T2>T1, 
C, p= 1 
Wang, 2001b 31/32/27 (T1/T2/C) 
Ear-
acupuncture 3/3/3 Unilateral 1 session 30 min 
T2>T1, 
C. 
p=0.001 
1 
Wang, 2004 34/33 Ear-acupuncture 3/3 Unilateral 1 session Various 
T>C, 
p=0.04 4 
Pain 
Simmons, 
1993 10/10 
Ear-
acupuncture 5/5 Unilateral 1 session  15 min 
T>C, 
p<0.000
1 
3 
Wang, 2009b 58/54 Ear-acupuncture 3/3 Unilateral 1 session 1 week 
T>C, 
p=0.01 4 
Substance 
abuse 
(Alcohol, 
drug, 
smoking) 
 
Drug 
dependence 
Avants 2000 28/27 Ear-acupuncture 4/4 Bilateral 
40 
sessions 
within 8 
weeks 
40 min T>C, p=0.01 3 
Berman, 
2004 32/44 
Ear-
acupuncture 5/5 Bilateral 
14 
session 40 min 
ND, 
p>0.05 2 
Bullock, 1999 236(NS) Ear-acupuncture 5/5 Bilateral 
28 
sessions 
within 8 
weeks 
NS ND, p=0.89 3 
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Bullock, 2002 133/132 Ear-acupuncture 4/4 NS 
18 
sessions 
within 3 
weeks 
40 min ND, p>0.05 3 
Killeen, 2002 15/15 Ear-acupuncture 5/5 NS 1 session 45 min 
ND, 
p=0.68 1 
Lipton, 1994 73/77 Ear-acupuncture 4/4 NS 
 10 
sessions 45 min 
ND, 
p>0.05 3 
Margolin, 
2002 222/203 
Ear-
acupuncture 4/3 Bilateral 
40 
sessions 
daily 
40 min ND, p>0.05 5 
Washburn, 
1993 55/45 
Ear-
acupuncture 4/4 Bilateral 5 sessions
20-45 
min 
T>C, 
p<0.05 2 
Smoking 
cessation 
Otto, 1998 25/11 Ear-acupuncture 5/5 Bilateral NS 
30-40 
min 
ND, 
p>0.05 4 
Wu, 2007 59/59 Ear-acupuncture 4/4 NS 
8 sessions 
within 8 
weeks 
1 week ND, p>0.05 2 
Alcohol 
dependence 
Sapir-Weise, 
1999 36/36 
Ear-
acupuncture 3/3 Bilateral NS 45 min 
ND, 
p>0.05 5 
Obesity  Shen, 2009 6/7 Ear-acupuncture 4/4 Unilateral 
8 sessions 
within 8 
weeks 
1 week T>C, p=0.03 2 
Insomnia  Sjoling, 2008 14/14 Ear-acupuncture 5/5 Bilateral 
15 
sessions 
within 6 
weeks 
45 min ND, p>0.05 2 
Type II  
(non ear-
points) 
Pain and 
Anxiety Pain 
Alimi 2003 29/30 Ear-acupuncture NS NS 60 days 43 min 
T>C, 
p<0.001 3 
Usichenko, 
2005 31/30 
Ear-
acupuncture 4/4 NS 1 session 3 days 
T>C, 
p=0.004 5 
Usichenko, 
2007 59/61 
Ear-
acupuncture 3/3 NS NS NS 
T>C, 
p=0.012 5 
Substance 
abuse 
(Alcohol, 
drug, 
smoking) 
Drug 
dependence Tian, 2006 5/4 
Ear-
acupressure 5/2 Bilateral 
6 sessions 
within 6 
weeks 
1 week T>C, p=0.009 3 
Smoking 
cessation Waite, 1998 40/38 
Ear-
acupuncture 1/1 Bilateral 1 session 2 weeks 
T>C, 
p<0.05 2 
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White, 1998 38/19 Ear-acupuncture 1/1 Bilateral 
3 sessions 
within 7 
days 
20 min ND, p>0.05 3 
Type III 
(placebo 
needles) 
Pain and 
Anxiety Pain Wang, 2009a 36/35 
Ear-
acupressure 3/3 NS NS 20 days 
T>C, 
p<0.05 3 
Obesity  Hsu, 2009 30/30 Ear-acupuncture 4/4 Unilateral 
12 
sessions 
within 6 
weeks 
3 days  ND, p>0.05 3 
Type IV  
(pseudo-
intervent
ion) 
Pain and 
Anxiety Pain 
Mazzetto, 
2007 24/24 
Ear-
acupuncture 1/1 Bilateral 
8 sessions 
within 4 
weeks 
NS T>C, p>0.05 3 
Michalek-
Sauberer, 
2007 
76/37 Ear-acupuncture 3/3 Unilateral NS NS 
ND, 
p>0.05 3 
Sator-
Katzenschlag
er, 2004 
31/30 Ear-acupuncture 3/3 Unilateral 
6 sessions 
within 6 
weeks 
48 hours T>C, p=0.021 4 
Sator-
Katzenschlag
er, 2003 
10/11 Ear-acupuncture 4/4 Unilateral 
6 sessions 
within 6 
weeks 
48 hours T>C,  p=N/A 5 
Sator-
Katzenschlag
er, 2006 
32/32 Ear-acupuncture 3/3 Unilateral 
6 sessions 
within 6 
weeks 
48 hours T>C, p<0.001 5 
Substance 
abuse 
(Alcohol, 
drug, 
smoking) 
Alcohol 
dependence 
Trumpler, 
2003 17/16 
Ear-
acupuncture NS NS 
> 1 
session 
30-45 
min 
ND, 
p>0.05 5 
Smoking 
cessation Cai, 2000 128/140 
Ear-
acupuncture 4/4 Unilateral 
12 
sessions 
within 4 
weeks 
4 min ND, p>0.05 2 
Legends: T: treatment group; T1: treatment group 1; T2: treatment group 2; C: control group; ND: no differences between real and sham groups; NS: 
not stated; Sham control method type: type I: Non-specific ear points; type II: Non ear point; type III: Placebo needles or adhesive patch, type IV: 
Pseudo-interventions.  
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4.3.2.2 Sham Interventions 
Different sham control methods were used in these RCTs. Twenty-two trials selected 
non-specific ear points for the condition treated (Type I) (Avants, Margolin, Holford, & 
Kosten, 2000; Barker et al., 2006; Berman, Lundberg, Krook, & Gyllenhammar, 2004; 
Bullock, Kiresuk, Pheley, Culliton, & Lenz, 1999; Bullock et al., 2002; Karst et al., 
2007; Killeen et al., 2002; Kober et al., 2003; Lipton, Brewington, & Smith, 1994; 
Margolin, Avants, & Holford, 2002; Mora et al., 2007; Otto, Quinn, & Sung, 1998; 
Sapir-Weise, Berglund, Frank, & Kristenson, 1999; Shen, Hsieh, Chang, & Lin, 2009; 
Simmons & Oleson, 1993; Sjoling, Rolleri, & Englund, 2008; Wang & Kain, 2001; 
Wang, Maranets, Weinberg, Caldwell-Andrews, & Kain, 2004; Wang, Peloquin, & 
Kain, 2001; Wang et al., 2009; Washburn et al., 1993; Wu, Chen, Liu, Lin, & Hwang, 
2007). Among them, five studies selected points located on the helix (Avants, 
Margolin, Holford, & Kosten, 2000; Berman, Lundberg, Krook, & Gyllenhammar, 
2004; Killeen et al., 2002; Margolin, Avants, & Holford, 2002; Sjoling, Rolleri, & 
Englund, 2008); three trials chose points at the tip of the concha (Kober et al., 2003; 
Mora et al., 2007; Wang & Kain, 2001); another five studies located non-specific ear 
points within 5mm from the specific points (Bullock, Kiresuk, Pheley, Culliton, & Lenz, 
1999; Bullock et al., 2002; Lipton, Brewington, & Smith, 1994; Sapir-Weise, Berglund, 
Frank, & Kristenson, 1999; Washburn et al., 1993). The other nine trials did not 
provide the principles for selecting the non-specific ear points (Barker et al., 2006; 
Karst et al., 2007; Otto, Quinn, & Sung, 1998; Shen, Hsieh, Chang, & Lin, 2009; 
Simmons & Oleson, 1993; Wang, Maranets, Weinberg, Caldwell-Andrews, & Kain, 
2004; Wang, Peloquin, & Kain, 2001; Wang et al., 2009; Wu, Chen, Liu, Lin, & 
Hwang, 2007). 
 
Six trials used non-ear points as the sham control points (Type II) (Alimi et al., 2003; 
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Tian & Krishnan, 2006; Usichenko et al., 2005; Usichenko et al., 2007; Waite & 
Clough, 1998; White, Resch, & Ernst, 1998). Three chose non-ear points on the helix 
(Tian & Krishnan, 2006; Usichenko et al., 2005; Usichenko et al., 2007). Two trials 
used an electro acupuncture device to apply minimum stimulation on the non-ear 
points (Waite & Clough, 1998; White, Resch, & Ernst, 1998). One study chose points 
that did not show any electrical response when a probe was used (Alimi et al., 2003).  
 
Two studies (Hsu et al., 2009; Wang, Hsu, Chien, Kao, & Liu, 2009) applied placebo 
needles (needles with blunt tips) or taped adhesive patches (without pellets or seeds) 
to the same ear points used in the real groups (Type III).  
 
Six trials (Mazzetto, Carrasco, Bidinelo, de Andrade Pizzo, & Mazzetto, 2007; 
Michalek-Sauberer et al., 2007; Sator-Katzenschlager et al., 2003; Sator-
Katzenschlager et al., 2006; Trumpler, Oez, Stahli, Brenner, & Juni, 2003; Cai, 
Changxin, Ung, Lei, & Kean, 2000) which employed laser acupuncture, electro 
acupuncture or magnetic pellets in the treatment intervention chose no or minimal 
stimulation on the same points in the sham control group (Type IV). The four types of 
control methods are summarised in Table 16.  
 
Table 16: Types of sham interventions used in the 37 included studies 
Type of sham control No. of RCTs 
I Non-specific ear points for the condition treated  22 
II Non-ear points 6 
III Placebo needles or adhesive patches 2 
IV 
Pseudo-interventions (e.g. switched off laser acupuncture devices, 
electro acupuncture devices with minimum emission, Vaccariae seeds 
without pressing) 
7 
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Three trials (Barker et al., 2006; Karst et al., 2007; Tian & Krishnan, 2006) used a 
lower number of ear points in the sham ear-acupuncture/ear-acupressure group than 
in the real treatment group. The rest of 34 trials applied the same number of ear 
points in both real and sham groups. All trials except one (Karst et al., 2007) applied 
the same real ear-acupuncture/ear-acupressure technique to both real and sham 
groups. Karst and his colleague’s study used placebo needles to treat non-specific 
ear points (Karst et al., 2007). 
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Meta-analysis 
Data syntheses were attempted for 13 of the 37 RCTs as the remaining 24 trials did 
not provide adequate data for the major outcome measures. Due to heterogeneity 
and insufficient data reported for the included studies, data analysis could not be 
performed for alcohol dependence, body weight reduction, drug dependence and 
insomnia. Results from the data analyses for anxiety, pain and smoking cessation 
are reported as follows.  
 
Anxiety 
All the seven studies for anxiety provided one session of treatment to the 
participants. Four of them adopted the State-Trait Anxiety Inventory (STAI) form 
(Karst et al., 2007; Wang & Kain, 2001; Wang, Maranets, Weinberg, Caldwell-
Andrews, & Kain, 2004; Wang, Peloquin, & Kain, 2001) and used an anxiety VAS as 
one of the outcome measures (Karst et al., 2007; Kober et al., 2003; Mora et al., 
2007). The meta-analysis outcomes are presented in Figure 11. The synthesised 
results demonstrated that the real ear-acupuncture/ear-acupressure reduced more 
STAI scores (MD: -4.21, 95%CI: -7.14, -1.29) and anxiety VAS scores (SMD: -1.12, 
95%CI: -2.13, -0.11) than the sham ear-acupuncture/ear-acupressure. However, the 
evidence of ear-acupuncture/ear-acupressure reducing anxiety VAS scores needs to 
be interpreted with cautious due to the high level of heterogeneity (I2= 88%). All 
seven studies used non-specific ear points in the sham control group (Type I). Only 
Karst (2007) applied fewer ear points in the sham group than in the real ear-
acupuncture group.  
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a. Post-treatment STAI scores: real EAP versus sham EAP groups (Type I sham intervention) 
 
 
b. Post-treatment anxiety VAS scores: real EAP versus sham EAP groups (Type I sham intervention) 
 
Figure 11: Comparison of real and sham ear-acupuncture/ear-acupressure 
groups for anxiety 
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Pain 
Among the trials on Pain using Type II sham control interventions (Alimi et al., 2003; 
Usichenko et al., 2005; Usichenko et al., 2007), two trials (Alimi et al., 2003; 
Usichenko et al., 2005) used pain intensity or modified pain intensity and two trials 
chose the use of analgesic medication as the outcome measures (Usichenko et al., 
2005; Usichenko et al., 2007). The comparisons indicate that there were no 
significant differences between real and sham ear-acupuncture/ear-acupressure 
interventions in reducing pain intensity (MD: -4.56, 95%CI: -14.32, 5.20) or the use of 
analgesic medication (SMD: -0.42, 95%CI: -1.36, 0.51) when only trials using Type II 
sham control interventions were included, although a high level of heterogeneity was 
detected (I2= 87%) when comparing real and sham ear-acupuncture/ear-acupressure 
for reducing the analgesic medication usage. However, when combined with the trial 
that used a Type III sham intervention (Wang, Hsu, Chien, Kao, & Liu, 2009), the real 
ear-acupuncture/ear-acupressure group became more effective in reducing pain 
intensity than the sham ear-acupuncture/ear-acupressure group (MD: -8.22, 95%CI: -
15.05, 1.40) (see Figure 12a, b, c).  
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a. Post-treatment Pain Intensity: real EAP versus sham EAP groups (Type II sham intervention) 
 
 
b. Post-treatment Pain Intensity: real EAP versus sham EAP groups (Type II & III sham interventions) 
 
 
c. Post-treatment Use of Medication: real EAP versus sham EAP groups (Type II sham intervention) 
 
Figure 12: Comparison of real and sham ear-acupuncture/ear-acupressure 
groups for pain 
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Smoking 
Three trials (Waite & Clough, 1998; White, Resch, & Ernst, 1998; Wu, Chen, Liu, Lin, 
& Hwang, 2007) investigated the effects of ear-acupuncture/ear-acupressure for 
smoking cessation using smoking cessation rate as the outcome measure. The 
synthesised results indicate that there are no differences between real and sham ear-
acupuncture/ear-acupressure groups either for trials employing Type II sham 
intervention only (RR: 1.31, 95%CI: 0.62, 2.81) or when the Type I and Type II sham 
intervention studies are combined (RR: 1.27, 95%CI: 0.83, 1.96) (See Figure 13). 
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a, Post-treatment Smoking Cessation: real EAP versus sham EAP groups (Type II sham intervention) 
 
 
b, Post-treatment Smoking Cessation: real EAP versus sham EAP groups (Type I & II sham 
interventions) 
 
Figure 13: Comparison of real and sham ear-acupuncture/ear-acupressure 
groups for smoking cessation  
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4.3.3 Discussion 
The findings of this recently updated systematic review show that four types of sham 
interventions have been used in RCTs of ear-acupuncture/ear-acupressure and the 
majority of studies used non-specific ear points or non-ear points in the sham control 
group.  
 
The application of ear-acupuncture/ear-acupressure for different clinical conditions is 
increasing. Ear-acupuncture/ear-acupressure involves self-administration which 
differentiates itself from other types of therapies, such as acupuncture. Thus, the 
factors should be considered when designing a randomised, single-blinded, sham-
controlled trial on ear-acupuncture/ear-acupressure, including point selection, 
manipulation and De Qi sensation. The treatment sessions should be also specified 
in the trial so that the outcomes from a trial can be implemented in the daily clinical 
practice.  
 
As there are 93 acupoints on each ear (General Administration of Quality Supervision, 
& Inspection and Quarantine of the People's Republic of China, 2008), it is difficult to 
locate any non-ear points due to the small size of the ear. Particularly, the use of less 
number of ear points in the control group may tend to lead to positive results of the 
experimental intervention. It is preferred to have the equal number of ear points used 
in both groups which may make the single blinding possible.  
 
Ear-acupuncture/ear-acupressure is a kind of microsystem acupuncture. Like 
acupuncture, De Qi sensation is critical for achieving the therapeutic effects (Frank & 
Soliman, 2006). In ear-acupuncture/ear-acupressure treatment, small press-stud 
acupuncture needles or ear pellets can be taped to the ear points and thus they can 
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remain on the ear points between the two visits to the clinicians. Consequently 
regular self-administered manipulation on the points becomes feasible. Continuous 
stimulation on the ear points may increase the therapeutic effects. Therefore, 
participants should be educated in the self-administration methods after the needles 
or pellets are placed on their ears. To achieve blinding, the same manipulation 
method should be taught to and applied by the participants from both experimental 
and control groups. 
 
A different design is to answer a different research question. For example, to 
investigate which ear points should be chosen for treating a clinical condition, it may 
apply a same ear-acupuncture/ear-acupressure technique to specific and non-
specific ear points. To examine the efficacy of an ear-acupuncture/ear-acupressure 
technique, the trial may use real and placebo ear-acupuncture/ear-acupressure 
techniques on the same ear points. To answer a question whether point localisation 
and skin penetration make a difference, the trial may use placebo needles on non-
specific ear points in the sham control group. It is inappropriate to compare magnetic 
pellets with Semen Vaccariae seeds on the same points as the effects of Semen 
Vaccariae seeds have not been determined. 
 
In conclusion, there are a number of different designs for sham interventions used in 
ear-acupuncture/ear-acupressure trials. Meta-analyses do not demonstrate a 
correlation between the sham intervention method and the results of the trial. When 
designing an RCT on ear-acupuncture/ear-acupressure, the control method should 
be designed carefully. To fulfil patients’ blinding, equal number of points, same 
needling or pressing pellets with same stimulation should be employed. In 
consideration of the fact that it is difficult to locate any non-ear points due to the small 
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size of the ear, the “equal number of non-specific points method (type I) control 
method” seems to be the most common and credible method. In addition, it would 
make the result more reliable if the credibility of blinding is properly assessed during 
the RCT. 
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Chapter 5: General methodology of the ear-acupressure for 
allergic rhinitis clinical trial 
Based on the findings from the two systematic reviews described in Chapter 4, the 
protocol of a randomised, single blinded, sham controlled clinical trial following a 
rigorous methodology was designed. The trial aimed to provide evidence for the 
efficacy and safety of ear-acupressure for the management of AR. The trial was 
conducted at two centres, and data were collected for different geographical 
locations and different ethnic groups. The two trial centres were: the Australian 
centre at RMIT University and the Chinese centre at Guangdong Provincial Academy 
of Chinese Medical Sciences, Guangdong Province, China.  
 
The whole trial consists of three phases:  
Phase I: Pilot study I for testing the feasibility; 
Phase II: Pilot study II for testing the efficacy and sample size estimation; 
Phase III: The main trial. 
 
Pilot study I (feasibility study) and Pilot study II (efficacy study) were conducted at the 
Australian trial centre while the main trial was conducted at both centres.  
 
5.1 Trial aims and objectives 
The aim of this clinical trial was to investigate whether ear-acupressure was effective 
in relieving AR symptom severity, improving AR sufferer’s quality of life, and reducing 
the usage of Western medicine in the management of AR. It also evaluated whether 
ear-acupressure was safe in the management of AR. 
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5.2 Trial design 
This trial was designed as a randomised, single blinded, sham controlled, multi-
centre trial using ear-acupressure to treat AR.  
 
5.2.1 Randomisation 
Randomisation numbers were generated by an independent statistician using Excel 
program. The numbers were randomly assigned to the real ear-acupressure or sham 
ear-acupressure group and sealed in individual opaque envelopes in blocks of 8, 
which were allocated by a central officer who was unaware of participants’ 
characteristics. To ensure the severity of the AR in the two groups was comparable, 
the randomisation was stratified based on the total nasal symptom score (TNSS). 
TNSS was calculated as the sum of the scores of four nasal symptoms (sneezing, 
blocked nose, runny nose, and itchy nose). The randomisation numbers generated 
for the TNSS 0-6 group and TNSS 7-12 group were kept in separate folders. 
 
When participants came in for the first treatment visit, prior to the treatment the 
acupuncturist calculated the participants’ TNSS score according to four nasal 
symptom scores reported in the baseline case report forms (CRFs). Then each 
participant was asked to pick one sealed envelope which contained the 
randomisation number either from the TNSS 0-6 folder or from the TNSS 7-12 folder. 
The envelope was opened by the acupuncturist before the treatment. The 
randomisation number in the sealed envelope was used as participant’s code in the 
trial. The acupuncturist checked the participant’s code in the randomisation allocation 
table generated by independent statistician then delivered real or sham treatment 
accordingly.    
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5.2.2 Blinding 
This study was designed as a single-blinded trial. In this study, only the acupuncturist 
knew which group the participants were assigned into as the acupuncturist was the 
person who performed the real and sham treatments. All other people involved in the 
study, including the participants, the personnel involved in recruitment, assessment, 
data entry and data analysis, were blinded. 
 
5.2.3 Data management 
5.2.3.1 Data collection 
All data were collected using CRFs. Throughout the whole study, participants were 
required to record their AR symptom severity and other relevant information in their 
CRFs, during the run-in, treatment and follow-up periods. In all reports, participants 
were identified only by the code and initials rather than their names to protect their 
identity. Participants completing the CRFs, were required to always use a black ball-
pen when writing, clearly state their participation code and initials on each page of 
the form and sign and date any changes that needed to be made. 
 
5.2.3.2 Data handling  
All data filled in the CRFs were the source data. Data entry was conducted by 
authorised independent research assistants involved in this project. Personnel who 
conducted data entry had received a training session on how to enter data prior to 
the commencement of the study. Data entry personnel did not know the group 
allocation of participants. A computer program (Excel) was used as the database to 
store all data. Data entry into the database was performed continuously throughout 
the study. Any corrections or changes of data were recorded. Double-checking was 
performed after entering data into databases to ensure accuracy of the data. The 
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data were stored in a password-protected computer and the database was secured 
by password to access.  
 
All the record forms were filed in a locked cabinet during the trial and will be stored in 
the Chinese medicine clinical trial storage room at RMIT University for 15 years after 
publication. The records will then be shredded and disposed as required by the 
Therapeutic Goods Administration (TGA) (The Therapeutic Goods Administration, 
2000). 
 
5.2.4 Sample size  
Pilot study I (feasibility study) included a small number of participants in order to test 
the trial design. Pilot study II (efficacy study) also included a small number of 
participants since it aimed to collect data to estimate the effect size for sample size 
calculation for the main trial. Upon the completion of the second pilot study, the 
sample size of the main trial was determined (Chapter 7, section 7.3.3).  
 
5.3 Participant selection criteria 
5.3.1 Inclusion criteria 
According to the protocol, participants who met the following criteria were included in 
the study: 
 Aged between 18 and 70 years (inclusive); 
 A history of at least two years of typical symptoms of AR;  
 Have a positive skin prick test to one or more of the following allergens: seven-
grass mix, perennial rye, ragweed, dust mite, animal’s dander or mould;  
 Currently not involved in other clinical trials for the treatment of AR;  
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 Agree to make themselves available for the period of the study; and  
 Provide written consent for participation. 
 
As discussed in Chapter 2, grass pollen, especially that of ryegrass, has been proven 
to be the major source of airborne allergens in Melbourne causing AR in the spring 
pollen season (Schappi et al., 1999). Therefore, for a trial scheduled in a pollen 
season (SAR trial), participants must have a typical seasonal pollen-induced AR 
history and a positive skin prick test result to any of the allergens of “seven-grass 
mix”, “ragweed” or “perennial ryegrass”. For the trial scheduled in non-pollen seasons 
(PAR trial), participants must have a typical PAR history and a positive skin prick test 
result to any of the allergens of “dust mite”, “animal’s dander” or “mould”, with or 
without a positive skin prick test to “seven-grass mix”, “ragweed” or “perennial 
ryegrass”.  
 
5.3.2 Exclusion criteria 
Participants with one or more of the following conditions were excluded from the 
study: 
 Current systemic corticosteroid therapy;  
 Other current active respiratory disease such as asthma;  
 Nasal polyposis;  
 Other structural defects of the upper respiratory tract;  
 Wearing a hearing aid; 
 History of being allergic to adhesive tape; 
 History of HIV, Hepatitis B or C; 
 Pregnancy; 
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 Have used ear-acupressure for respiratory diseases within the last six months; 
or 
 Do not read or understand English. 
 
The exclusion criterion of wearing a hearing aid was included because wearing the 
hearing aid may interfere with the pellets attached to ear and change their location. 
People who are allergic to adhesive tape may not tolerate the pellets being attached 
to ear points using adhesive dressing, therefore, they were also excluded.  
 
5.4 Recruitment and withdrawal of participants 
5.4.1 Recruitment strategy 
Trial participants were recruited through the media. Before recruiting, brief 
information about this trial was released to newspapers in the areas around the two 
trial sites, such as MX newspaper in the Melbourne CBD, Leader newspapers in the 
cities of Whittlesea, Manningham, Heidelberg, Diamond Valley, and Preston. 
Meanwhile, information on the trial was posted in University campuses and local 
clinics around Bundoora and Melbourne CBD areas. RMIT University media release 
promoted this trial on RMIT news via the RMIT update, RMIT student bulletin and 
RMIT alumni email. In addition, the information was put on the Google AdWords for 
one month. An example of the advertising poster is shown in Appendix A1.1. 
 
During the recruitment, when volunteers made an enquiry and expressed their 
interest in this study through telephone or email, a brief introduction of this trial was 
provided and a short interview about the major selection criteria was conducted 
through telephone conversation. Once the volunteer’s condition was potentially 
eligible and she/he was willing to proceed with the study, a Plain Language 
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Statement (Appendix A1.2) was sent to this potential participant via email or mail to 
provide more detailed information about the trial. When the potential participants 
agreed to participate by signing informed consent forms (Appendix A1.3) after 
reading the Plain Language Statement, a recruiting questionnaire (Appendix A1.4 
and A1.5) was sent to him/her to collect general information and other relevant 
information. Once the completed questionnaire had been returned, a preliminary 
screening was carried out according to the information provided in the questionnaire. 
All potentially eligible participants were invited to attend an initial assessment at the 
trial clinic, including a skin prick test (SPT), to enable a final decision regarding 
recruitment.  
 
5.4.2 Initial assessment 
The steps involved in the initial assessment are as follows: 
a. Greeting and introduction by the investigators to the potential participants. 
b. A detailed verbal explanation about the study was given and any questions 
from the participants were answered before seeking informed consent. 
c. All participants were asked to provide informed consent in writing prior to 
other examinations. The informed consent forms consisted of two forms 
(Appendix A1.3): 
 Prescribed Consent Form for Persons Participating in Research 
Projects Involving Tests and/or Medical Procedures. 
 Prescribed Consent Form for Persons Participating in Research 
Projects Involving Interviews, Questionnaires or Disclosure of Personal 
Information. 
Once signed off, a copy of the informed consent forms was given to the 
participants for their own record. 
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d. The allergen sensitivity skin prick test was carried out by a trained research 
assistant under close supervision by the same medical doctor. Allergens used 
in the skin prick tests were (Appendix A1.6): 
 7 grass mix (Kentucky bluegrass, Orchard grass, Redtop, Timothy, 
Sweet vernal grass, Meadow fescue and Perennial ryegrass), 
 Perennial ryegrass, 
 Ragweed,  
 Dust mite,  
 10 mould mix [Alternaria tenuis, Hormodendrum cladosporioides, 
Phoma herbarum, Helminthosporium interseminatum, Aspergillus Mix 
(Aspergillus fumigatus, Aspergillus nidulans, Aspergillus niger, 
Aspergillus terreus), Penicillium Mix (Penicillium digitatum, Penicillium 
expansum, Penicillium glaucum, Penicillium notatum, Penicillium 
roseum), Fusarium vasinfectum, Rhizopus nigricans, Mucor racemosus, 
Pullularia pullulans], 
 Cat hair, 
 Dog hair. 
All these test allergens were produced by Hollister-Stier Laboratories, Spokane, 
Washington, USA. For comparison, positive (histamine) and negative (saline) 
controls were also applied. The test was considered positive when the diameter of 
the wheal produced by an allergen was at least 3 mm larger than that of the negative 
control.  
 
e. A physical examination was performed by a medical practitioner including the 
previous medical and allergy history, with special attention being paid to the 
examination of the nose (Appendix A1.7).  
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f. A registered Chinese medicine practitioner with more than 10 years’ clinical 
experience preformed the Chinese medicine differential diagnosis based on 
the principles described by the State Administration of Traditional Chinese 
Medicine (State Administration of Traditional Chinese Medicine, 1995). The 
Chinese medicine differential diagnosis of AR is classified as four types: 1: 
Lung Deficiency; 2: Lung + Spleen Deficiency; 3: Lung + Kidney Deficiency; 4: 
Lung + Spleen + Kidney Deficiency (Appendix A1.8).  
 
At the end of the initial assessment, decisions regarding inclusion or exclusion were 
made based on the results of the assessment according to the inclusion and 
exclusion criteria (Appendix A1.9). Then, baseline CRFs were provided to the 
included participants.  
 
5.4.3 Withdrawal of participants 
During the whole trial period, participants were free to withdraw at any stage of the 
trial without having to provide a reason to the investigators. The data of drop-outs 
were treated as missing data and the worst-case-scenario method was applied to the 
missing data when intention-to-treat analysis was conducted.  
 
5.5 Process of the trial 
5.5.1 Pilot study I (feasibility study) and the main trial 
Pilot study I (feasibility study) and the main trial were conducted in non-peak pollen 
season. According to the protocol, pilot study I and the main trial lasted 22 weeks: a 
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two-week run-in period, an eight-week treatment period and a 12-week follow-up 
period.  
 
5.5.1.1 Run-in period 
Between the initial assessment and the eight-week treatment period, there was a 
two-week run-in period. During these two weeks, all included participants were asked 
to complete baseline CRFs to record their AR symptom severity, quality of life related 
to AR and their medication usage. They were also asked to record their opinion 
about ear-acupressure treatment in a validated credibility scale. 
 
5.5.1.2 Treatment period 
In the first visit to trial clinic, participants were randomised into either the real or sham 
ear-acupressure group. Subsequently, participants received either real or sham ear-
acupressure treatments once a week for eight weeks. In each treatment, once the 
ear pellets were attached to the ear-points, participants were instructed on how to 
press the pellets to achieve therapeutic effects. In addition, participants were given 
guidance on how to ensure the pellets remain in place throughout the week. During 
the eight-week treatment period, participants were asked to complete the CRFs 
fortnightly (Pilot study I) or weekly (Pilot study II & main trial). Besides AR symptom 
severity, quality of life related to AR, their medication usage and opinion about ear-
acupressure treatment, participants recorded the number of pellets remaining on 
their ear every day as a measure of dosage. In addition, participants were required to 
record unexpected adverse events, if any. In the CRFs for the first treatment week, 
there was one additional question about which group participants thought they were 
in to test the adequacy of blinding.  
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5.5.1.3 Follow-up period 
All the participants with PAR were followed up for 12 weeks. After the ear-
acupressure treatment ceased, participants were required to complete the CRFs 
once every four weeks. In the follow-up CRFs, all the information related to AR and 
ear-acupressure treatment was still recorded, except for the treatment dosage data. 
All the follow-up CRFs were sent back to the trial investigator by post.  
 
The detailed procedure for clinic visits and CRF return during the 22- week trial 
period is summarised in Table 17. 
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Table 17: Summary of trial timing (Pilot study I and main trial) 
 Trial timing 
Pilot study I (feasibility 
study) Main trial 
Visit clinic CRF return Visit 
CRF 
return 
22
 w
ee
ks
 
Week 1 Baseline week 1 √ Initial assessment  
√ Initial 
assessment  
Week 2 Baseline week 2     
Week 3 Treatment week 1 √ √ √ √ 
Week 4 Treatment week 2 √  √ √ 
Week 5 Treatment week 3 √ √ √ √ 
Week 6 Treatment week 4 √  √ √ 
Week 7 Treatment week 5 √ √ √ √ 
Week 8 Treatment week 6 √  √ √ 
Week 9 Treatment week 7 √ √ √ √ 
Week 10 Treatment week 8 √  √ √ 
Week 11 Follow-up week 1  
√CRF 
return by 
post 
 
√CRF 
return by 
post 
Week 12 Follow-up week 2     
Week 13 Follow-up week 3     
Week 14 Follow-up week 4     
Week 15 Follow-up week 5  
√CRF 
return by 
post 
 
√CRF 
return by 
post 
Week 16 Follow-up week 6     
Week 17 Follow-up week 7     
Week 18 Follow-up week 8     
Week 19 Follow-up week 9  
√CRF 
return by 
post 
 
√CRF 
return by 
post 
Week 20 Follow-up week 10     
Week 21 Follow-up week 11     
Week 22 Follow-up week 12     
End of week 22 End of trial  
√CRF 
return by 
post 
 
√CRF 
return by 
post 
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5.5.2 Pilot study II (efficacy study) 
This pilot study was conducted in Melbourne’s peak pollen season. The participants 
included in this study suffered AR symptoms induced by pollens. Consequently, once 
the pollen season ends, these symptoms would be relieved as the pollen count falls 
off. There was no need to follow up after the pollen season ended. Therefore, this 
study lasted for ten weeks, including a two-week run-in period and an eight-week 
treatment period.  
 
The detailed procedure of clinic visits and CRF return during the 10 week trial period 
is summarised in Table 18. 
Table 18: Summary of trial timing (Pilot study II) 
 Trial timing 
Pilot study II (efficacy study) 
Visit clinic CRF return 
10
 w
ee
ks
 
Week 1 Baseline week 1 √ Initial assessment   
Week 2 Baseline week 2   
Week 3 Treatment week 1 √ √ 
Week 4 Treatment week 2 √ √ 
Week 5 Treatment week 3 √ √ 
Week 6 Treatment week 4 √ √ 
Week 7 Treatment week 5 √ √ 
Week 8 Treatment week 6 √ √ 
Week 9 Treatment week 7 √ √ 
Week 10 Treatment week 8 √ √ 
End of Week 
10 End of trial  
√ CRF return by 
post 
 
To monitor the pollen count, daily pollen count data were collected from September 
to December 2008 from the website provided by the School of Botany, Faculty of 
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Science, University of Melbourne. The detailed flow of the trial procedure is shown in 
Figure 14. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Detailed trial procedures  
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5.6 Real and sham ear-acupressure treatments 
5.6.1 Treatment sessions 
Based on our literature review, this trial was designed to provide ear-acupressure 
treatment once a week for eight weeks. In the eight-week treatment period, 
participants were invited to attend the trial clinic once a week to receive an ear-
acupressure treatment. All treatments during the eight weeks were delivered by the 
same registered acupuncturist who had a five-year degree level training and over 10 
years’ clinical experience in acupuncture. Each treatment session took 10 to 15 
minutes. In the first treatment session, the acupuncturist explained the ear-
acupressure technique to participants in detail before attaching the pellets to the ear 
points on one of the ears, and instructed participants about the proper method of 
maintaining adhesion of the pellets and stimulating the points during the treatment 
week. In the following treatment session, the acupuncturist removed the previous 
treatment pellets and attached new pellets on the other ear; participants returned the 
completed fortnightly CRF (Pilot study I) or weekly CRF (Pilot study II and main trial) 
and received a new CRF for the following two weeks (Pilot study I) or one week (Pilot 
study II and main trial).  
 
5.6.2 Treatment process 
In each treatment session, the participant was seated comfortably in an arm chair. 
The acupuncturist sterilised the skin surface of the ear with a commercial 70% 
isopropyl alcoholic skin cleansing swab, located the points with a detecting probe 
which had a round head that measured 1.2 mm in diameter then attached five pellets 
to the real or sham ear points of one of the participant’s ears. All the eight-week 
treatments started with using the left side ear. Once pellets were attached, the 
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acupuncturist gently pressed each pellet for about 10 seconds or until the ear 
became red or slightly sore. There was no skin penetration in the treatment. In the 
following treatment session, the other ear was selected for attaching pellets. Thus, 
the two ears were used alternately on a weekly basis. All participants were instructed 
by the acupuncturist to follow the same pressing technique and they were asked to 
press the five pellets three times a day regardless of real or sham group. The 
pressing technique was to promote the desired stimulation on the points in order to 
achieve the therapeutic effects.  
 
5.6.3 Ear-acupressure pellets 
The ear-acupressure treatment used commercial stainless steel press-pellet tapes 
(Migraine Pellets: Cat. No. PELSST S/Steel Tan, Acuneeds Co., Australia). The 
pellet measures 1.2 mm in diameter and is attached to a round adhesive tape 7 mm 
in diameter in a tan colour which is close to skin colour. 
 
5.6.4 Ear-acupressure points selection  
The real ear-acupressure points used in the RCT were selected according to the 
knowledge from the traditional literature, existing ear-acupressure for AR RCTs and 
experts’ opinions. Based on the review of the sham methods of ear-acupuncture/ear-
acupressure treatment used in controlled trials (See Chapter 4, section 4.3), the 
method of sham ear-acupressure employed in this trial was to use non-specific 
points. The main reason for selecting this approach is the difficulty and lack of 
reliability of locating five non-therapeutic points near the real ear points. Considering 
that there are 93 points on the ear, the density of real points is high. Also the system 
of auricular therapy focuses more on zones of the ear rather than precisely located 
points. Consequently, for the sham control five non-allergy-specific ear points on the 
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helix were selected. Each of these is a real point so the sham control can be 
accurately replicated.  
 
The ear points selected for this trial are as below: 
 
5.6.4.1 Real ear-acupressure points 
For the real treatment group, five specific ear points for AR were selected: Shenmen 
(TF4), Internal Nose (TG4), Lung (CO14), Wind Stream (SF1,2i) and Adrenal Gland 
(TG2p). These five points were frequently used in other AR clinical trials (Zhang et al., 
2010). Theoretically, Shenmen (TF4) is considered to relieve stress and calm the 
mind; Internal Nose (TG4) and Lung (CO14) are used to relieve nasal symptoms; 
Wind Stream (SF1,2i) and Adrenal Gland (TG2p) target allergy relief (General 
Administration of Quality Supervision, & Inspection and Quarantine of the People's 
Republic of China, 2008). 
 
5.6.4.2 Sham ear-acupressure points 
For the sham control group, another five non-AR-specific ear points on the helix were 
chosen: Helix 2 (HX10), Shoulder (SF4,5), Clavicle (SF6), Occiput (AT3), and Tooth 
(LO1). These five points are not functionally related to the treatment of allergy or nose 
problems (General Administration of Quality Supervision, & Inspection and 
Quarantine of the People's Republic of China, 2008). 
 
The locations of the points are shown in Figure 15. 
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5.7.1.2 Skin prick test  
The skin prick test was performed during the initial assessment of the trial (Appendix 
A1.6). It was conducted by a trained research assistant under close supervision by a 
medical doctor. Results were recorded on the skin prick test form and reviewed by 
the medical doctor for recruitment decision making (refer to 5.4.2 point d).  
 
5.7.1.3 Clinical history and physical examination  
This instrument was administered during the initial assessment by the Western 
medical doctor (Appendix A1.7). The purpose of this instrument was to collect 
general medical history with a focus on allergy history. The information obtained was 
utilised to confirm the diagnosis of AR in Western medicine and assist in the 
selection process by excluding participants with indications listed in the exclusion 
criteria (refer to 5.4.2 point e).  
 
5.7.1.4 Chinese medicine questionnaire  
The Chinese medicine questionnaire was administered during the initial assessment. 
This questionnaire was to determine the Chinese medicine differential diagnosis 
(Appendix A1.8). Diagnostic details of the tongue and pulse were collected by a 
registered Chinese medicine practitioner (refer to 5.4.2 point f). 
 
5.7.2 Outcome measure instruments 
According to the protocol, the outcome measures of this trial were:  
 Nasal symptoms and non-nasal symptoms severity 
 Quality of life questionnaire  
 Medication usage  
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 Participants’ opinion about ear-acupressure  
 Adverse event record 
Data from outcome measures were collected through participant self-administered 
questionnaires. The instruments used for collecting primary and secondary outcome 
measures data are listed below:  
 
5.7.2.1 Symptom severity and quality of life assessment  
The AR symptom severity was the primary outcome measure. Two scales were 
employed to investigate the symptom severity, which were Juniper 4 point scale 
(Juniper et al., 2005) and Spector 7 point VAS (Spector et al., 2003). A symptom 
recording diary of the Juniper 4 point scale was applied to assist participants in 
making an accurate weekly assessment. In addition, a question about quality of life 
was included in the Spector 7 point VAS questionnaire.  
 
Furthermore, participants’ quality of life related to AR was assessed by the 
Rhinoconjunctivitis Quality of Life Questionnaire (in Pilot study I) or the 
Rhinoconjunctivitis Quality of Life Questionnaire with Standardised Activities 
(RQLQ(S)) (in Pilot study II and main trial). 
 
a. Juniper 4 point scale (Appendix A2.2 and Appendix A2.3) 
The 4 point scale for symptom severity assessment used in this trial was adapted 
from the Clinical Outcomes and Adverse Effect Monitoring in AR reported by Juniper 
et al (Juniper et al., 2005). In this article, a 4 point scale (0, 1, 2, and 3) system was 
suggested to assess the four major nasal symptoms of AR, i.e., sneezing, stuffy/ 
blocked nose, runny nose and itchy nose. In our clinical trial, we included another 4 
non-nasal symptoms in this assessment: itchy eyes, watery eyes, redness of eyes, 
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itchiness of ears and/or palate. TNSS was calculated as the sum of the scores of the 
four nasal symptoms (sneezing, blocked nose, runny nose, itchy nose). As each 
symptom can have values from 0 to 3, the lowest possible TNSS score is 0 while the 
highest TNSS is 12.  
 
However, evaluating AR severity using these eight questions alone does not provide 
sufficient insight into the overall effects of the disease. Therefore, other 
questionnaires were also employed in this study. 
 
b. 7 point VAS (Spector et al., 2003) (Appendix A2.4) 
Details of this VAS instrument have been introduced in Chapter 2, section 2.10.1.2.  
This 7-point instrument contains VAS for assessing nasal symptom severity 
(individually for sneezing, running nose, congestion, itchy nose, and postnasal drip), 
non-nasal symptoms (individually for eye symptoms, throat symptoms, chronic cough, 
ear symptoms, headache and mental function), global assessment of overall nasal 
and non-nasal symptoms severity as well as global quality of life related to rhinitis 
severity (Spector et al., 2003). The scales used for assessment of the severity of 
each of the individual symptoms are: 1= none; 2= between 1 and 3; 3= mild; 4= 
between 3 and 5; 5= moderately bothersome; 6= between 5 and 7; 7= unbearably 
severe. The scales for assessing the global assessment of overall nasal and non-
nasal symptoms severity as well as global quality of life related to rhinitis severity are 
with opposite scoring, which means, 1= unbearably severe and 7= none.  
 
c. Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) (Appendix A2.5) and 
Rhinoconjunctivitis Quality of Life Questionnaire with Standardised Activities 
(RQLQ(S)) (Appendix A2.6) 
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The RQLQ (Juniper & Guyatt, 1991) including 28 questions was employed to assess 
participants’ rhinitis-related quality of life. Participants were required to score those 
questions using a 7 point scale (0= not troubled; 1= hardly troubled at all; 2= 
somewhat troubled; 3= moderately troubled; 4= quite a bit troubled; 5= very troubled; 
6= extremely troubled). The RQLQ(S) (Juniper, Thompson, Ferrie, & Roberts, 1999) 
is an updated and validated version of RQLQ. Instead of letting participants select 
their own activities, in RQLQ(S), three questions about activities are defined as 
“regular activities at home and at work”, “social activities” and “outdoor activities” 
(more details refer to Chapter 2, section 2.10.2.2, Appendix A2.6).  
 
In both the RQLQ and RQLQ(S) questionnaires, the 28 questions are clustered into 
seven domains: Activity domain, Sleep domain, Non nasal symptoms domain, 
Practical domain, Nasal symptoms domain, Eye symptoms domain and Emotional 
domain. The total score of symptoms in each domain was calculated for the 7 
domains data analysis. As the number of questions included in each domain is 
different, the total score for each domain varies as listed in Table 19. 
The total score of these seven domains were used for assessing the treatment 
effects. 
Table 19: RQLQ seven domains’ total score 
Seven 
domains Activity Sleep 
Non nasal 
symptoms Practical 
Nasal 
symptoms
Eye 
symptoms Emotional
Number of 
questions 
in each 
domain 
3 3 7 3 4 4 4 
Total 
score of 
each 
domain 
0 - 18 0 - 18 0 - 42 0 - 18 0 - 24 0 - 24 0 - 24 
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5.7.2.2 Relief medication scores  
Participants were permitted to use symptomatic relief medications and they were 
required to keep a record of their usage of relief medication during the trial using a 
standard form (Appendix A2.7). The use of anti-allergy relief medication is calculated 
as one point for each basic dose of tablet, eye drop or nasal spray. For example, a 
tablet of “Telfast 120mg” is calculated as 1 point, while a tablet of “Telfast 180mg” is 
1.5 point. The total medication usage scores were calculated for data analysis as a 
secondary outcome measure.  
 
5.7.2.3 Ear-acupressure dosage 
Participants were required to record how many pellets were attached to ear points 
each day during the treatment period in a diary (Appendix A2.8). The total number of 
pellets each week was calculated to be the weekly dosage data for data analysis. 
  
5.7.2.4 Participants’ opinion about ear-acupressure  
Many therapy outcome investigations now employ some form of credibility and/or 
expectancy assessment to ensure initial equivalence among compared therapy 
conditions (Deviliya & Borkovecb, 2000). A validated questionnaire about 
participants’ opinion on the intervention was also employed in the CRFs in the 
present study (baseline, end of treatment and end of follow-up periods) (Appendix 
A2.10). This questionnaire consists of six questions related to expectancy and 
credibility, with a rating scale from 1 to 9 (Deviliya & Borkovecb, 2000).  
 
5.7.2.5 Adverse event record  
Participants were asked to record any unexpected feelings, signs and symptoms 
throughout the whole study period (treatment period and follow-up period) (Appendix 
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A2.9). When completing the adverse event form, participants were required to record 
when the event started; when the event stopped; the intensity of the unexpected 
feelings using the scale 1, 2 and 3 (1= mild, 2= moderate, 3= severe); the 
relationship between these feelings and the ear-acupressure was assessed as: 1= 
unrelated, 2= possibly, 3= probably, 4= definitely. 
 
5.7.2.6 Credibility of blinding  
To ensure the credibility of the blinding procedure for the real and sham ear-
acupressure used in this study, a question about which group the participants 
thought they had been assigned into was employed in the first and last treatment 
weeks in the main trial (Appendix A2.10). 
 
5.8 Data analysis 
All data were processed and analysed by an independent statistician at RMIT 
University. The Statistical Package for the Social Sciences software version 18.0 for 
Windows (SPSS Inc., Chicago, USA) was used for data analysis. Baseline 
demographic characteristics such as gender and age were analysed by chi square 
test or t test to determine equivalence between the two groups. Variables showing 
baseline imbalance were taken into consideration when conducting data analysis 
(using the variables as covariates or performing sensitivity analysis to reveal the 
relationship between the variables and the outcome measures).  
 
Intention-to-treat analysis was applied to outcome data to minimise bias due to 
withdrawals. Due to the fact that AR symptoms may reduce spontaneously along with 
the change of amount of airborne allergen, the worst-case-scenario method was 
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used in intention-to-treat data analysis, that is, all missing data were replaced by the 
highest score to represent the worst situation. 
 
Data were presented as means, standard deviation (SD), standard error (SE), or 
95% confidence interval (CI). Demographic information, pellets dosage, medication 
score and patients’ opinion data were reported as mean ± SD while symptom severity 
and quality of life outcome measures data were reported as mean ± SE. The mean 
differences between real and sham treatment groups were compared using Non-
parametric Mann-Whitney Test. P value ≤ 0.05 was considered as statistically 
significant. 
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Chapter 6: Pilot study I (feasibility study) 
This chapter presents the results of Pilot study I (feasibility study) conducted in 2008.  
 
Upon approval of the trial protocol and the Ethics application by the RMIT Human 
Research Ethics Committee in November 2007 and registration with the Therapeutic 
Goods Administration (TGA) and the Australian New Zealand Clinical Trial Registry 
(ANZCTR) in March 2008, the pilot study was conducted at the Chinese Medicine 
Research Group, RMIT University, Bundoora West Campus following the trial 
protocol. The major purpose for conducting this pilot study was to test the 
methodology of this trial. 
 
6.1 Methods 
This pilot study was designed as a randomised, single blinded, sham-controlled trial. 
It was conducted in the non-pollen season in Melbourne (between May and 
November 2008). The whole study lasted 22 weeks including a two-week baseline, 
eight-week treatment and 12-week follow-up period. The details of the methods used 
in this pilot study have been discussed in Chapter 5. As mentioned, in this study, 
fortnightly CRFs were employed for data collection during the baseline and treatment 
periods. RQLQ which allowed participants to choose their three activities was used in 
all CRFs.  
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6.2 Results 
6.2.1 Participants 
Following advertising in the local newspaper in the Bundoora area, 81 volunteers 
showed interest in this study. Among them 28 volunteers were excluded due to not 
meeting the selection criteria; 35 volunteers could not participate because of time 
restrictions. Eventually 18 participants were included in the study and randomised 
into real (n= 10) and sham (n= 8) groups. One participant from the intervention group 
did not complete the treatment due to family reasons; three participants (one from the 
intervention group and two from the control group) failed to send back follow-up 
CRFs (Figure 16). 
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Figure 16: Procedure of Pilot study I 
 
6.2.2 Demographic data and baseline characteristics of Pilot study I 
Among all the included participants, the age ranged from 21 to 67 years old. The 
duration of PAR morbidity was between 2 and 36 years. The demographics in terms 
of age and gender of the two groups showed no statistically significant difference. 
There was no significant difference between the two groups in: the number of current, 
previous and non smokers; the duration of participants’ PAR morbidity; and whether 
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they had family history of AR.  For the Chinese medicine differential diagnosis, only 
two participants were diagnosed as Lung Deficiency, the others were diagnosed as 
Lung + Spleen, Lung + Kidney or Lung + Spleen + Kidney Deficiency. Details are 
reported in Table 20. 
 
Table 20: Demographics and baseline characteristics of included participants 
for Pilot study I 
 Intervention 
(n= 10) 
Control 
(n= 8) Significance 
Mean±SD 
Age  36.30±11.42 47.38±16.20 t= -1.927 p= 0.072 
Duration of AR in years  21.30±7.19 20.50±12.75 t= 0.168 p= 0.868 
 Number of participants Significance 
Gender 
Male  8 4 
X2= 1.8 p= 0.312 
Female  2 4 
Smoking 
status 
Current  0 1 
X2= 1.8 p= 0.407 Former  4 4 
Never  6 3 
Has family history of AR  3 4 X2= 0.748 p= 0.63 
Chinese 
Medicine 
Differenti
ation 
Lung Deficiency  1 1 
X 2= 0.99 p= 0.804 
Lung + Spleen 
Deficiency  2 3 
Lung + Kidney 
Deficiency  1 1 
Lung + Spleen + 
Kidney 
Deficiency  
6 3 
 
The results of the allergy skin prick tests show that most participants were allergic to 
more than one allergen and that the number of participants who were allergic to each 
allergen was not significantly different between the two groups (p > 0.05). Details are 
shown in Table 21. 
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Table 21: Skin prick test results of Pilot study I 
 
Number of participants who were 
positive to each allergen 
Significance Intervention 
group 
(n= 10) 
Control group 
(n= 8) 
Grass Mix 5 5 X2= 0.281 p= 0.664 
Perennial Rye Grass 7 4 X2= 0.748 p= 0.63 
Ragweed 5 4 X2= 0 p= 1.00 
Mould Mix 4 5 X2= 0.9 p= 0.637 
Cat Hair 6 4 X2= 0.18 p= 1.00 
Dog Hair 2 3 X2= 0.678 p= 0.608 
Dust Mite 7 6 X2= 0.055 p= 1.00 
 
Not all outcome measures between the two groups at baseline were comparable. 
There were significant differences between the two groups in some of the symptom 
severity scales: Juniper 4 point Watery eyes (p= 0.034), Juniper 4 point redness of 
eyes (p= 0.024), Spector VAS congestion (p= 0.018), Spector VAS mental function 
(p= 0.008)) (Table 22). However, these differences may be caused by the very small 
sample size. 
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Table 22: Baseline and treatment effects for Pilot study I  
a. Juniper 4 point symptom score  
Symptom 
severity 
Baseline End of treatment period End of follow-up period 
Intervention 
group 
(n= 10) 
Mean±SE 
Control 
group 
(n= 8) 
Mean±SE 
Significance 
Intervention 
group 
(n= 10) 
Mean±SE 
Control group 
(n= 8) 
Mean±SE 
Significance 
Intervention 
group 
(n= 10) 
Mean±SE 
Control 
group 
(n= 8) 
Mean±SE 
Significance 
Total nasal 
symptom 
score 
8.9±0.888 6.88±0.693 U=26.0 p= 0.209 4.6±1.422 4.88±1.175 
U=36.0 
p= 0.72 6.5±1.55 6.75±1.264 
U=34.5 
p= 0.618 
Blocked nose 2±0.365 1.5±0.189 U=28.0 p= 0.261 1.15±0.38 1.31±0.377 
U=36.0 
p= 0.716 1.7±0.396 1.75±0.313 
U=39.0 
p= 0.925 
Sneezing 2.3±0.26 2±0.267 U=31.0 p= 0.392 1.25±0.352 1.25±0.401 
U=40.0 
p= 1.0 1.7±0.367 1.88±0.295 
U=35.0 
p= 0.669 
Runny nose 2.6±0.221 1.88±0.398 U=24.5 p= 0.127 1.2±0.351 1.56±0.346 
U=32.0 
p= 0.472 1.6±0.4 1.63±0.375 
U=39.0 
p= 0.925 
Itchy nose 2±0.298 1.5±0.267 U=28.0 p= 0.246 1±0.387 0.75±0.327 
U=36.0 
p= 0.709 1.5±0.428 1.5±0.378 
U=38.5 
p= 0.888 
Itchy eyes 2±0.365 1.13±0.227 U=19.0 p= 0.053 0.8±0.359 1.13±0.279 
U=28.0 
p= 0.266 1.3±0.423 1.25±0.453 
U=39.5 
p= 0.963 
Watery eyes 2.1±0.348 1±0.267 U=17.0 p= 0.034* 0.85±0.35 0.69±0.282 
U=38.0 
p= 0.849 1.4±0.476 1.25±0.453 
U=39.0 
p= 0.924 
Redness of 
eyes 2±0.298 0.88±0.35 
U=16.0 
p= 0.024* 0.8±0.416 0.63±0.227 
U=34.5 
p= 0.591 1.2±0.49 1.38±0.498 
U=35.0 
p= 0.623 
Itchiness of 
ears and 
palate 
1.2±0.327 1.13±0.35 U=38.0 p= 0.852 0.8±0.389 0.81±0.34 
U=37.0 
p= 0.769 1.3±0.423 1.38±0.42 
U=37.5 
p= 0.817 
Note: U: Mann-Whitney U test; *: p<0.05  
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b. Spector 7 point VAS 
 
Baseline End of treatment period End of follow-up period 
Intervention 
(n= 10) 
Mean±SE 
Control 
(n= 8) 
Mean±SE
Significance 
Intervention 
(n= 10) 
Mean±SE
Control 
(n= 8) 
Mean±SE 
Significance 
Intervention 
(n= 10) 
Mean±SE
Control 
(n= 8) 
Mean±SE
Significance 
Sneezing 4.5±0.703 2.88±0.581 U=22.5 p= 0.116 3.1±0.71 2.88±0.451 
U=39.0 
p= 0.927 4±0.789 3.88±0.811 
U=39.5 
p= 0.964 
Runny nose 4.7±0.539 4.25±0.648 U=35.0 p= 0.649 3.2±0.668 3.06±0.593 
U=40.0 
p= 1 4.1±0.752 4±0.824 
U=38.0 
p= 0.856 
Congestion 5.5±0.522 3.38±0.42 U=14.0 p= 0.018* 3.05±0.736 2.56±0.538 
U=36.0 
p= 0.717 4.1±0.767 3.75±0.861 
U=36.5 
p= 0.751 
Itchy nose 3.5±0.562 3.125±0.693 U=34.5 p= 0.619 2.7±0.688 2.13±0.375 
U=38.5 
p= 0.89 3.3±0.831 3.25±0.861 
U=36.0 
p= 0.714 
Post nasal 
drip 4.5±0.582 2.88±0.639 
U=20.0 
p= 0.072 2.8±0.668 2.63±0.541 
U=37.5 
p= 0.821 3.8±0.841 3.75±0.861 
U=39.5 
p= 0.964 
Total nasal 
symptoms 5.1±0.504 4.25±0.559 
U=27.5 
p= 0.247 3.15±0.679 3.25±0.62 
U=37.0 
p= 0.788 4±0.789 4±0.779 
U=38.5 
p= 0.891 
Eye 
symptoms 4.2±0.593 2.5±0.378 
U=17.5 
p= 0.042 2.5±0.687 2.31±0.4 
U=38.0 
p= 0.849 3.3±0.803 3.63±0.865 
U=35.5 
p= 0.681 
Throat 
symptoms 3.2±0.442 2±0.5 
U=19.5 
p= 0.060 2.55±0.66 2.19±0.526 
U=39.5 
p= 0.963 3.2±0.814 3.25±0.861 
U=36.0 
p= 0.714 
Chronic 
Cough 2.3±0.396 2.13±0.581 
U=33.0 
p= 0.51 1.9±0.586 2±0.509 
U=38.0 
p= 0.839 2.6±0.791 3±0.945 
U=36.0 
p= 0.694 
Ear 
symptoms 1.9±0.233 2.25±0.62 
U=39.5 
p= 0.963 2.05±0.634 2.06±0.563 
U=34.5 
p= 0.578 2.9±0.795 3.13±0.915 
U=36.5 
p= 0.743 
Headache 2.4±0.476 1.88±0.639 U=28.5 p= 0.261 2.3±0.638 1.19±0.132 
U=27.0 
p= 0.188 2.9±0.836 2.88±0.972 
U=37.5 
p= 0.806 
Mental 
function 3.8±0.533 1.75±0.526 
U=11.0 
p= 0.008* 2.2±0.616 2.25±0.62 
U=39.0 
p= 0.924 2.9±0.836 3±0.906 
U=35.5 
p= 0.672 
Global nasal 
and non-
nasal 
symptoms 
2.85±0.38 4.13±0.398 U=19.0 p= 0.054 4.95±0.594 4.31±0.559 
U=29.0 
p= 0.325 3.9±0.752 3.88±0.718 
U=38.0 
p= 0.855 
Global 
quality of life 2.3±0.3 3.5±0.327 
U=15.0 
p= 0.021 4.7±0.63 3.94±0.608 
U=28.5 
p= 0.303 3.9±0.752 3.88±0.693 
U=36.5 
p= 0.75 
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c. RQLQ 7 domains 
Note: U: Mann-Whitney U test 
 
 
 
 
Baseline End of treatment period End of follow-up period 
Intervention 
group 
(n= 10) 
Mean±SE 
Control 
group 
(n= 8) 
Mean±SE 
Significance 
Intervention 
group 
(n= 10) 
Mean±SE 
Control group 
(n= 8) 
Mean±SE 
Significance 
Intervention 
group 
(n= 10) 
Mean±SE 
Control 
group 
(n= 8) 
Mean±SE 
Significance 
Activities 10.5±1.855 6.65±2.058 U=36.5 p= 0.349 8.9±2.268 10.25±0.901 
U=38.5 
p= 0.894 7.06±2.159 8.63±2.195 
U=38.0 
p= 0.857 
Sleep 11.7±0.159 7.05±2.11 U=17.5 p= 0.099 9.1±2.228 6.5±1.018 
U=32.0 
p= 0.476 5.19±1.96 7.25±2.358 
U=35.5 
p= 0.684 
Non nose/eye 
symptoms 22.4±3.37 11.85±4.74 
U=19.5 
p= 0.304 19.9±5.154 11±2.605 
U=39.0 
p= 0.929 11.06±4.342 15.63±5.803 
U=32.0 
p= 0.474 
Practical 13.3±1.461 6.25±2.132 U=24.0 p= 0.533 9.3±2.124 11.13±1.302 
U=32.0 
p= 0.477 7.63±1.894 8.34±2.5 
U=35.5 
p= 0.686 
Nasal 
symptoms 15.4±2.396 8.45±2.82 
U=29.5 
p= 0.053 13.1±3.096 13.13±1.329 
U=35.0 
p= 0.656 8.16±2.119 10.75±3 
U=36.0 
p= 0.716 
Eye 
symptoms 12.8±2.615 5.5±2.647 
U=21.5 
p= 0.154 11.4±3.413 7.25±1.386 
U=38.5 
p= 0.892 5.69±2.144 7.75±3.609 
U=32.5 
p= 0.498 
Emotional 13.3±2.098 6.75±2.594 U=28.5 p= 0.211 12.5±3.277 9.88±1.38 
U=39.5 
p= 0.964 6.56±2.65 8.25±3.5 
U=28.5 
p= 0.296 
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6.2.3 Pellet dosage 
In treatment week 2 and week 4, the pellet dosage in the real ear-acupressure group 
was lower than in the sham ear-acupressure group, while in week 6 and week 8, the 
difference between two groups reduced. There is no significant difference between 
the two groups in the total pellets dosage data for the eight weeks of the treatment 
period. There was no difference between real and sham intervention in terms of 
dosage (p>0.05). The results of pellet dosage are shown in Table 23.  
Table 23: Pellet dosage for Pilot study I 
 
Intervention 
(n= 10) 
Mean±SD 
Control 
(n= 8) 
Mean±SD 
Significance 
Fortnightly total pellet 
dosage - week 1, 2 57.6±9.442 64.3±9.019 t= -1.514 p= 0.150 
Fortnightly total pellet 
dosage - week 3, 4  59.7±6.961 64.5±7.616 t= -1.395 p= 0.182 
Fortnightly total pellet 
dosage - week 5, 6  61.6±8.566 63.0±8.928 t= -0.338 p= 0.740 
Fortnightly total pellet 
dosage - week 7, 8  60.2±9.355 61.3±11.997 t= -0.209 p= 0.837 
 
 
6.2.4 Treatment effects for Pilot study I 
Overall, the treatment effects for all outcome measures showed a trend of decrease 
in symptom severity and an increase in patients’ quality of life over the eight-week 
treatment period. The real ear-acupressure group achieved a greater trend compared 
with the sham ear-acupressure group in terms of most of the outcome measures. 
However, there was no significant difference between the two groups at the end of 
the eight-week treatment period or the twelve-week follow-up period (p>0.05) (Table 
22, page 178). Examples are shown in Figure 17 and Figure 18. 
  
182 
 
 
 
Figure 17: Juniper TNSS for Pilot study I 
 
 
 
Figure 18: Spector VAS Global quality of life score for Pilot study I 
 
 
6.2.5 Participants’ opinion about ear-acupressure for Pilot study I   
In the two-week run-in period, the eight-week treatment and the 12-week follow-up 
period, the participants’ opinion about the ear-acupressure method for the two groups 
showed no significant difference (p>0.05) (Table 24).
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Table 24: Participants’ opinion about ear-acupressure for Pilot study I 
Note: SD: Standard deviation. 
Question 1: At this point, how logical does the treatment offered you seem?  
Question 2: At this point, how useful do you think the treatment will be in reducing your hay fever symptoms?  
Question 3: How confident would you be in recommending this treatment to a friend who experiences similar problems? 
Question 4: By the end of the therapy period, how much improvement in your hay fever symptoms do you think will occur? 
Question 5: At this point, how much do you really feel that therapy will help you to reduce your hay fever symptoms? 
Question 6: By the end of the therapy period, how much improvement in your hay fever symptoms do you really feel will occur? 
 
Baseline End of treatment period End of follow-up period 
Intervention 
group 
(n= 10) 
Mean±SD 
Control group
(n= 8) 
Mean±SD 
Significance 
Intervention 
group 
(n= 10) 
Mean±SD 
Control group 
(n= 8) 
Mean±SD 
Significance 
Intervention 
group 
(n= 10) 
Mean±SD 
Control group
(n= 8) 
Mean±SD 
Significance 
Question 1 6±1.943 6.34±1.06 p= 0.632 6.6±2.503 5.31±2.251 p= 0.274 5.2±3.155 4±2.878 p= 0.417 
Question 2 6.1±2.283 6.5±1.195 p= 0.661 6.5±2.494 4.81±2.725 p= 0.19 5.2±3.047 3.75±2.866 p= 0.319 
Question 3 5.4±1.937 6.34±0.754 p= 0.313 6.35±2.625 5.25±2.493 p= 0.38 5.2±3.155 4±3.162 p= 0.435 
Question 4 5.8±0.874 6.75±0.886 p= 0.207 6.05±2.455 4.94±2.859 p= 0.387 5.1±3.035 3.63±2.925 p= 0.313 
Question 5 5.7±2.213 6.88±1.246 p= 0.2 6.4±2.355 4.88±2.167 p= 0.177 5.3±3.164 3.5±2.828 p= 0.227 
Question 6 5.8±2.098 7.13±1.246 p= 0.135 6.05±2.409 4.63±2.722 p= 0.256 5.3±3.129 3.5±3.024 p= 0.236 
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6.2.6 Medication score 
Medication usage data in the two-week run-in period, at the end of eight-week 
treatment and the end of the twelve-week follow-up period showed no significant 
differences between the two groups (p= 0.748, 0.273 and 0.105 respectively).  
 
6.2.7 Adverse events 
During the eight-week treatment period and the twelve-week follow-up period, all 
participants tolerated the ear-acupressure well and no adverse event related to the 
real or sham treatment was reported. 
 
6.3 Discussion  
In this pilot study, only one participant dropped out during the treatment period due to 
family reasons. The participants’ compliance with this trial was reliable. With regard 
to the pellet dosage, the real acupressure group’s dosage was lower than the sham 
group at the beginning of the trial and then became similar to that of the sham group. 
This was possibly caused by the different locations of the ear points in two groups. 
Once the real group participants became familiar with the pellets being attached to 
the ear points the pellets were less liable to fall off.  
 
A trend of decreasing of symptom severity and increasing patient global quality of life 
was observed over the eight-week treatment period, however, it was not evident in 
the follow-up period (Figures 17 and 18, page 182). This suggested that ear-
acupressure may have some short-term effects on the symptomatic relief of AR. Due 
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to the very small sample size of this pilot study, the conclusion of efficacy cannot be 
drawn reliable.  
 
The major aim of conducting this pilot study was to test the methods used in this trial. 
Upon the completion of this pilot study, a few shortcomings of the study design were 
identified: 
 Collecting data on participants’ symptom severity once every two weeks was 
not very reliable. When participants were filling in the fortnightly CRFs, their 
assessments of symptom severities usually were based on their memory of 
recent days. 
 In the RQLQ questionnaire, three questions about activities let participants 
choose three most frequently affected activities in each CRF. However, these 
three activities were not consistent throughout the whole study as participants’ 
activities varied from day to day. 
 Blinding credibility was not tested in this study. 
Otherwise, the trial procedure regarding participant recruitment, conduct of the initial 
assessment, delivery of the treatment and data collection was feasible.  
 
6.4 Conclusion 
This pilot study showed that the trial protocol was feasible and that the ear-
acupressure treatment might be effective and safe for the treatment of AR. The ear-
acupressure methods were also well tolerated by patients. However, the sample size 
of this trial was too small to draw any conclusion. A larger size clinical trial was 
needed.  
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To ensure the accuracy of data collection in a further trial, a symptom severity diary 
was considered important and data collection should be more frequent than once 
every two weeks. Based on a suggestion from the author of the RQLQ 
questionnaires, RQLQ(S) should be employed in further studies to avoid the 
inconsistency in the activity assessment. In the RQLQ(S), the three questions about 
activities have been defined as:  
1. Regular activities at home and at work (your occupation or tasks that you have 
to do regularly around your home); 
2. Social activities (e.g. activities with your family and friends, playing with 
children and pets, sex, hobbies); 
3. Outdoor activities (e.g. gardening, mowing the lawn, sitting outdoors, sports, 
going for a walk). 
Finally, a credibility of blinding question is also necessary as effective blinding of 
participants to the treatment allocation reduces the risk of performance bias.   
 
6.5 Minor changes to the protocol 
Based on the findings from this pilot study, some minor changes were made to the 
original protocol: 
I. A symptom diary was added to the CRFs. Participants were required to 
assess their overall symptom severity based on the symptom diary. 
II. The fortnightly CRFs were changed to a weekly form in the run-in period and 
treatment period. 
III. RQLQ questionnaire was replaced by the RQLQ(S) questionnaire. 
IV. One question was added to ask participants about the credibility of blinding in 
a new form titled “Credibility of Blinding Questionnaire”. This question was 
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applied at the end of the first week and at the end of the eighth-week 
treatment period of the main trial. 
The amended trial protocol was submitted to and approved by the RMIT Human 
Research Ethics Committee in August 2008. 
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Chapter 7: Ear-acupressure for allergic rhinitis Pilot study II 
(efficacy study) 
Upon the completion of Pilot study I, the amendments for the trial protocol specified 
in Chapter 6 were submitted to and approved by the RMIT Human Research Ethics 
Committee in August 2008. Pilot study II (efficacy study) was conducted between 
September and December 2008 to investigate the efficacy of ear-acupressure for AR 
to provide data for sample size estimation for the main trial. This pilot study included 
63 participants and was conducted at two sites: one site was located in the 
Melbourne CBD (RMIT University City campus) and another was in a suburb which 
was approximately 20 kilometres from the Melbourne CBD (RMIT University 
Bundoora West campus). As the period between September and December is 
Melbourne’s peak pollen season, participants with typical pollen induced AR were 
included in this pilot study. 
 
7.1 Methods 
This pilot study was conducted following the amended protocol. Details have been 
provided in Chapter 5. As discussed in Chapters 5 and 6, the outcome measures 
employed in this trial are: 4 point symptom score, 7 point VAS, RQLQ(S), medication 
usage related to AR and participants’ opinion about ear-acupressure treatment 
(Appendices A2.2, A2.3, A2.4, A2.6, A2.7, and A2.8). All the outcome measures data 
were collected from the participants’ self-assessments in the CRFs. 
 
In addition, this pilot study was conducted during September and December 2008 (in 
the peak pollen season of Melbourne). In this season, patients may have severe AR 
symptoms during this short period, and afterwards their severe symptoms may 
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disappear spontaneously (Ong, Singh, & Knox, 1995). Therefore, due to the time 
restriction imposed by the duration of the pollen season, this trial lasted 10 weeks 
including two-week run-in period and eight-week treatment period. The twelve weeks 
follow-up period specified in the general protocol was not applied in this pilot study 
since this would extend the trial beyond the pollen season and into the time when 
seasonal rhinitis sufferers would be expected to recover spontaneously.  
 
In the spring pollen season in Melbourne, from 1st September each year to 31st 
January the following year (considered as the peak pollen season), the School of 
Botany at the University of Melbourne and Asthma Victoria offer a service that 
forecasts the level of pollen in the air on a daily basis. The count is given as a 
quantitative assessment, on a scale from low to extremely high, and as actual values 
of the number of grass pollen grains per cubic meter of air/total number of all pollen 
types. For example, 30/105 means there were 30 grass pollen grains and 105 pollen 
grains of all types per cubic meter of air in the preceding 24-hour period.  
   
7.2 Results 
7.2.1 Participants 
With media release and other recruiting strategies, 113 volunteers made enquiries 
and expressed their interest in this study. Thirty of them were excluded after the 
telephone interview or initial assessment due to not meeting the inclusion criteria, 
and 20 of them were not able to participate due to time restrictions. As a result, 63 
volunteers were included in the trial and randomised into either real or sham ear-
acupressure groups at a ratio of 1:1. Three in the real ear-acupressure group and 
three in the sham ear-acupressure group discontinued treatment, therefore, 28 in the 
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treatment group and 29 in the control completed the study. The details are presented 
in Figure 19. 
  
Figure 19: Procedure of Pilot study II 
 
7.2.2 Demographic data and baseline characteristics 
Among all the included participants, the age ranged from 23 to 66 years old. The real 
ear-acupressure group had an average age of 39.97 years while the sham ear-
acupressure group was 43.44 years. The demographics in terms of age and gender 
showed no significant differences (p> 0.05) between the two groups. There were no 
significant differences between the two groups in: number of participants who were 
current, previous or non smokers, the duration of participants’ AR morbidity, and 
whether they had a family history of AR.  For the Chinese medicine differential 
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diagnosis, participants were diagnosed as belonging to all four syndrome categories: 
Lung Deficiency, Lung + Spleen Deficiency, Lung + Kidney Deficiency or Lung + 
Spleen + Kidney Deficiency with no statistical difference between the two groups (p> 
0.05). The demographics of the included participants were comparable (see Table 
25). 
Table 25: Demographics and baseline characteristics of included participants 
of Pilot study II  
 Intervention 
(n= 31) 
Control 
(n= 32) Significance 
Mean±SD 
Age  39.97±11.51 43.44±10.74 t= -1.237 p= 0.221 
Duration of AR in years  20.06±13.17 19.84±12.48 t = 0.068 p= 0.946 
 Number of participants Significance 
Gender 
Male 17 14 
X2= 0.775 p= 0.454 
Female 14 18 
Smoking 
status 
Current 4 1 
X2= 2.417 p = 0.299  Former 7 6 
Never 20 25 
Has family history of AR (n) 14 17 X2= 0.4 p= 0.617 
Chinese 
Medicine 
Differential 
Diagnosis   
Lung 
Deficiency 11 8 
X2= 1.921 p= 0.589 
Lung + 
Spleen 
Deficiency 
7 6 
Lung + 
Kidney 
Deficiency 
4 8 
Lung + 
Spleen + 
Kidney 
Deficiency 
9 10 
 
The skin prick test results for allergy status in the two groups were comparable at 
baseline (p>0.05) (see Table 26). 
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Table 26: Skin prick test results for Pilot study II 
 
Number of participants who were 
positive to each allergen Significance Intervention 
(n= 31) 
Control 
(n= 32) 
Grass Mix 26 23 X2= 1.311 p= 0.365 
Perennial Rye Grass 26 26 X2= 0.075 p= 1.00 
Ragweed 21 25 X2= 0.862 p= 0.405 
Mould Mix 12 14 X2= 0.165 p= 0.799 
Cat Hair 17 19 X2= 0.132 p= 0.801 
Dog Hair 12 14 X2= 0.165 p= 0.799 
Dust Mite 27 24 X2= 1.494 p= 0.337 
 
The baseline data for the main outcome measures, Juniper 4 point symptom 
questionnaire, Spector 7 point VAS and RQLQ(S) were all comparable between the 
two groups (p>0.05) (see Table 27). The results for the end of the 8 week treatment 
phase are discussed in 7.2.5. 
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Table 27: Baseline and treatment effects for Pilot study II 
a. Juniper 4 point symptom scores for Pilot study II 
Symptom 
severity 
Baseline End of treatment period 
Intervention 
group 
(n= 31) 
Mean±SE 
Control group 
(n= 32) 
Mean±SE 
Significance 
Intervention 
group 
(n= 10) 
Mean±SE 
Control group 
(n= 8) 
Mean±SE 
Significance 
Total nasal 
symptom score 5.18±0.425 5.45±0.484 U= 537.00, p= 0.572 3.52±0.652 4.81±0.686 U= 606.50, p= 0.126 
Sneezing 1.34±0.176 1.29±0.155 U= 538.00, p= 0.956 0.87±0.178 1.25±0.18 U= 622.50, p= 0.102 
Blocked nose 1.42±0.145 1.45±0.134 U= 492.00, p= 0.554 0.94±0.191 1.38±0.178 U= 608.50, p= 0.07 
Runny nose 1.31±0.146 1.49±0.142 U= 561.00, p= 0.361 0.90±0.188 1.13±0.19 U= 558.50, p= 0.364 
Itchy nose 1.11±0.122 1.22±0.174 U= 516.50, p= 0.774 0.82±0.17 1.06±0.195 U= 553.50, p= 0.4 
Itchy eyes 0.94±0.135 1.25±0.151 U= 608.50, p= 0.116 0.74±0.193 1.06±0.185 U= 589.50, p= 0.168 
Watery eyes 0.71±0.144 0.81±0.128 U= 549.50, p= 0.445 0.42±0.166 0.81±0.193 U= 613.50, p= 0.056 
Redness of eyes 0.53±0.127 0.63±0.119 U= 546.00, p= 0.464 0.39±0.165 0.72±0.197 U= 584.50, p= 0.126 
Itchiness of ears 
and palate 0.82±0.132 0.79±0.144 U= 471.00, p= 0.724 3.52±0.652 4.81±0.686 U= 581.50, p= 0.126 
Note: U: Mann-Whitney U test; SE: Standard error. 
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b. Spector 7 point VAS for Pilot study II 
 
Baseline End of treatment period 
Intervention group 
(n= 31) 
Mean±SE 
Control group 
(n= 32) 
Mean±SE
Significance 
Intervention group 
(n= 10) 
Mean±SE 
Control group 
(n= 8) 
Mean±SE
Significance 
Sneezing 2.71±0.244 3±0.266 U= 557.00, p= 0.398 2.19±0.336 3.281±0.376 U= 670.00, p= 0.013* 
Runny nose 2.76±0.241 2.938±0.204 U= 560.50, p= 0.371 2.23±0.337 2.75±0.386 U= 567.00, p= 0.3 
Congestion 3.11±0.3 2.672±0.241 U= 432.50, p= 0.379 2.29±0.325 2.97±0.361 U= 612.50, p= 0.097 
Itchy nose 2.31±0.191 2.703±0.278 U= 543.50, p= 0.508 2.10±0.336 2.69±0.377 U= 591.50, p= 0.159 
Post nasal drip 2.21±0.246 2.344±0.245 U= 515.50, p= 0.784 1.97±0.352 2.66±0.4 U= 608.00, p= 0.077 
Total nasal 
symptoms 3.10±0.245 3.141±0.218 U= 523.50, p= 0.703 2.16±0.344 3.10±0.369 U= 657.00, p= 0.02* 
Eye symptoms 2.19±0.212 2.703±0.216 U= 618.00, p= 0.09 2.13±0.324 2.78±0.37 U= 604.00, p= 0.118 
Throat symptoms 2.03±0.226 2.125±0.192 U= 544.50, p= 0.492 2.10±0.369 2.56±0.391 U= 567.50, p= 0.253 
Chronic Cough 1.68±0.218 1.969±0.248 U= 540.00, p= 0.488 2±0.385 2.56±0.4 U= 597.50, p= 0.09 
Ear symptoms 1.71±0.165 1.75±0.225 U= 467.50, p= 0.676 1.77±0.324 2.45±0.394 U= 603.50, p= 0.085 
Headache 2.34±0.296 2.094±0.239 U= 482.50, p= 0.842 1.81±0.339 2.34±0.39 U= 584.50, p= 0.14 
Mental function 2.16±0.259 1.984±0.18 U= 498.00, p= 0.977 1.81±0.329 2.38±0.401 U= 549.00, p= 0.368 
Global nasal and 
non-nasal 
symptoms 
4.37±0.241 4.313±0.243 U= 464.50, p= 0.663 5.39±0.33 4.41±0.364 U= 351.00, p= 0.042* 
Global quality of 
life 4.26±0.191 4.406±0.208 U= 518.50, p= 0.755 5.39±0.337 4.56±0.351 U= 360.00, p= 0.056 
Note: U: Mann-Whitney U test; SE: Standard error; *: p<0.05.  
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c. RQLQ 7 domains for Pilot study II 
Note: U: Mann-Whitney U test; SE: Standard error. 
 
 
 
Baseline End of treatment period 
Intervention 
group 
(n= 31) 
Mean±SE 
Control group 
(n= 32) 
Mean±SE 
Significance 
Intervention 
group 
(n= 31) 
Mean±SE 
Control group 
(n= 32) 
Mean±SE 
Significance 
Activities 7.79±0.662 7.58±0.71 U= 498.50, p= 0.973 4.26±1.01 7.41±1.078 U= 629.50, p= 0.062 
Sleep 4.47±0.806 4.61±0.693 U= 525.50, p= 0.684 3.74±0.998 5.34±1.154 U= 560.00, p= 0.36 
Non nose/eye 
symptoms 12.05±1.616 12.34±1.497 U= 516.50, p= 0.778 8.13±2.304 12.38±2.614 U= 577.00, p= 0.255 
Practical 7.02±0.801 7.80±0.731 U= 523.00, p= 0.71  4.52±0.996 7.25±1.066 U= 598.00, p= 0.157 
Nasal symptoms 8.90±0.922 8.30±0.87 U= 494.50, p= 0.984  5.68±1.315 8.16±1.386 U= 624.50, p= 0.076 
Eye symptoms 5.07±0.887 5.63±0.839 U= 546.00, p= 0.491  4.48±1.284 7.47±1.448 U= 595.00, p= 0.167 
Emotional 7.29±1.022 4.17±0.801 U= 454.50, p= 0.568 5.23±1.327 7.78±1.482 U= 548.50, p= 0.46 
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7.2.3 Pellet dosage 
In treatment weeks 1 and 2, the weekly total pellet dosage in the real group was 
significantly lower than the weekly total dosage in the sham group (p= 0.008 and 
0.017). From treatment weeks 3 to 8, the weekly total pellet dosage data of the real 
group and sham group were not significantly different (p>0.05). Details are listed in 
Table 28: 
Table 28: Pellet dosage for Pilot study II 
 Intervention 
(n= 31) 
Mean±SD 
Control 
(n= 32) 
Mean±SD 
Significance 
Weekly total pellet 
dosage- week 1  30.16±4.228 32.81±3.345 p= 0.008* 
Weekly total pellet 
dosage- week 2  29.45±5.137 32.28±3.937 p= 0.017* 
Weekly total pellet 
dosage- week 3  32.87±2.986 32.41±3.5 p= 0.573 
Weekly total pellet 
dosage- week 4  32.10±3.477 32.84±3.184 p= 0.377 
Weekly total pellet 
dosage- week 5  33.32±3.166 33.47±3.016 p= 0.852 
Weekly total pellet 
dosage- week 6  33.32±2.386 33.56±3.141 p= 0.735 
Weekly total pellet 
dosage- week 7  33.58±2.321 33.41±3.151 p= 0.804 
Weekly total pellet 
dosage- week 8  33.16±2.806 32.94±3.809 p= 0.792 
Note: *: p<0.05  
 
7.2.4 Pollen count data for Pilot study II 
Pollen count data were obtained from the website of the School of Botany, University 
of Melbourne: 
http://www.botany.unimelb.edu.au/botany/pollencount/counts_pollen.html 
The daily pollen count was reported as grass/all kinds of pollen (grains per cubic 
metre of air) caught in the trap in the previous 24 hours. The average pollen count 
was calculated based on the daily pollen count report and is presented in Figure 20. 
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However, no significant difference was found at the end of week 8 in terms of all the 
Juniper 4 point symptom scores, or TNSS (p>0.05) (Table 27a). 
 
7.2.5.2 Spector 7 point VAS questionnaire at the end of treatment week 8 
For the Spector 7 point VAS questionnaire, when comparing the scores between the 
real and sham ear-acupressure groups, significant differences at the end of week 8 
were found in three of the scores (Table 27b, Appendix A3.2). 
a. Spector VAS Sneezing score  
The two groups’ sneezing scores for Spector VAS were comparable at baseline (p= 
0.398). At the end of the eight week treatment, the sneezing score in the real group 
was significantly lower than that in the sham group (p= 0.013) Figure 21. 
 
 Note: *: p< 0.05 
Figure 21: Spector VAS sneezing score for Pilot study II 
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b. Spector VAS Total nasal symptoms score 
The scores for total nasal symptoms for Spector VAS for the two groups were 
comparable at baseline (p= 0.703). A significant difference was obtained at the end 
of the treatment period (p= 0.02) in favour of the real group (Figure 22). 
 
Note: *: p< 0.05 
Figure 22: Spector VAS total nasal symptoms score for Pilot study II 
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c. Spector VAS global nasal and non-nasal symptom score 
The global nasal and non-nasal symptom score for the Spector VAS is a reverse 
score. The lower the score is, the more severe symptom is. This scores for two 
groups were comparable at baseline (p= 0.663). At the end of treatment, the real 
group’s global nasal and non-nasal symptoms score was significantly higher than 
that in the sham group (p= 0.042) (Figure 23). 
 
 Note: *: p< 0.05 
Figure 23: Spector VAS global nasal and non-nasal symptom severity score for 
Pilot study II 
 
In the above figures, data are presented as Mean±SE of the symptoms assessed at 
baseline and at the end of each treatment week. The real ear-acupressure group 
achieved significantly less symptom severity compared with the sham ear-
acupressure group at the end of the eight-week treatment period in terms of sneezing 
(p= 0.013), total nasal symptoms (p= 0.02) and global nasal and non-nasal symptom 
scores (p= 0.042). No significant differences were obtained for the other symptoms 
(p>0.05) (Tables 27b).  
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Trends were evident in favour of the real group for other Spector VAS items (see 
Appendix A3.b). In particular there was a clear trend for a greater increase in global 
quality of life in the real group compared with the sham group (U= 360.00, p= 0.056) 
(Table 27b). 
 
7.2.5.3 RQLQ(S) questionnaire 7 domains at the end of treatment week 8 
Consistent with the Juniper 4 point and Spector 7 point VAS instruments, the results 
of RQLQ(S) questionnaire showed similar trends in favour of the real ear-
acupressure group (Appendix A3.3). However, no significant differences between the 
two groups were found at the end of the treatment period for all seven domains 
(p>0.05) (Table 27c).  
 
Further analysis of the individual questions showed a significant difference for 
Regular activities at home and work (real ear-acupressure group 1.323±1.939 vs 
sham ear-acupressure group 2.031±1.992, p= 0.04) in the Activities domain.  
 
7.2.6 Patients’ opinion about ear-acupressure  
The six questions in the Patients’ opinion about ear-acupressure questionnaire asked 
how confident participants were regarding the possible treatment effects (Appendix 
2.10). In the two-week run-in period, the participants’ opinion about ear-acupressure 
treatment between the two groups was not significantly different in terms of all six 
questions (p>0.05). By the end of the eight weeks treatment period, there were 
significant differences between the two groups for five of the six questions: 
 Question 2: “At this point, how useful do you think the treatment will be in 
reducing your hay fever symptoms?” 
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 Question 3: “How confident would you be in recommending this treatment to a 
friend who experiences similar problems?”  
 Question 4: “By the end of the therapy period, how much improvement in your 
hay fever symptoms do you think will occur?” 
 Question 5: “At this point, how useful do you really feel the treatment will be in 
reducing your hay fever symptoms?” 
 Question 6: “By the end of the therapy period, how much improvement in your 
hay fever symptoms do you really feel will occur?” 
 
These significant differences indicate that at the end of the eight-week treatment 
period, the participants in the sham ear-acupressure group were less confident of a 
treatment effect from this technique compared with those in the real group. Details 
are listed in Table 29. 
Table 29: Participants’ opinion about ear-acupressure for Pilot study II   
Note: *: p<0.05  
 
7.2.7 AR related medication usage score 
The sum of all AR related medications used in each week was calculated as the 
weekly medication usage score. Comparison of the medication usage scores 
 
Baseline End of treatment period 
Intervention 
group 
(n= 31) 
Mean±SD 
Control
group 
(n= 32) 
Mean±SD 
Significance 
Intervention
group 
(n= 31) 
Mean±SD 
Control group 
(n= 32) 
Mean±SD 
Significance 
Question 1 5.52±1.651 5.45±1.907 p= 0.889 5.39±2.704 4.625±2.791 p= 0.276 
Question 2 5.39±1.308 5.41±1.634 p= 0.959 5.55±2.767 3.969±2.857 p= 0.03* 
Question 3 4.97±1.426 5.19±1.731 p= 0.585 5.55±2.694 4.188±2.669 p= 0.048* 
Question 4 5.37±1.418 5.66±1.757 p= 0.488 5.48±2.755 3.781±2.636 p= 0.015* 
Question 5 5.26±1.384 5.5±1.818 p= 0.555 5.42±2.693 3.969±2.788 p= 0.04* 
Question 6 5.13±1.565 5.52±1.725 p= 0.356 5.61±2.825 3.844±2.653 p= 0.013* 
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between the two groups, found no significant difference in the baseline period and at 
the end of the treatment period. Furthermore, the weekly antihistamine medication 
score between two groups also was not significantly different at baseline and at the 
end of treatment (p>0.05). Details are summarised in Table 30. 
Table 30:  Medication score of Pilot study II 
Medication Endpoint 
Intervention 
(n= 31) 
Mean±SD 
Control 
(n= 32) 
Mean±SD 
Significance 
All AR 
medication 
score 
Baseline 3.06±4.308 3.00±5.828 p= 0.965 
At the end of 
treatment 
period 
0.86±2.206 1.02±3.300 p= 0.831 
Antihistamine 
medication 
score 
Baseline 1.27±1.875 1.35±2.785 p= 0.857 
At the end of 
treatment 
period 
0.5±1.527 0.46±2.022 p= 0.878 
 
 
7.2.8 Adverse events 
Some adverse events related to the ear-acupressure treatment were reported during 
the eight-week treatment period as shown in Table 31. 
Table 31: Summary of adverse events of Pilot study II 
Events/Group Intervention (n= 31) 
Control 
(n= 32) 
Sore on the ear with pellets 
attached  3 mild, 3 moderate 3 mild 
Itchiness on the ear with pellets 
attached 3 mild, 2 moderate  7 mild, 1 moderate 
Feels annoying to have pellets 
attached to the ear 2 moderate 1 mild  
Feel embarrassed to have pellets 
attached to the ear 1 mild 0 
Feel uncomfortable at wrist when 
pressing pellets 4 moderate 0 
All adverse events reported in 
treatment period 7 mild, 11 moderate 11 mild, 1 moderate 
Number of participants reported 
adverse events (n= ) 9 7 
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The proportion of participants who reported mild or moderate adverse events was not 
significantly different between the treatment and sham groups (29.0% vs. 21.9%, p= 
0.51). The most frequent events reported were soreness on the ear due to pressure 
(6 real and 3 sham treatment participants) and itchiness on the ear (4 and 3 
participants respectively). Over the eight weeks treatment period, participants in the 
real group reported 18 adverse events (seven mild and 11 moderate) with 12 
adverse events reported by the sham group (11 mild and one moderate). Most of 
these mild or moderate discomforts were reported early in the treatment stage and 
were short-term or effectively managed by refinement of the pressing techniques by 
participants, without any medical assistance being required. No severe adverse 
event was reported in either group.   
  
7.2.9 Credibility of blinding 
The credibility of blinding question which let participants guess which group they 
were assigned into was employed in treatment week 1’s CRF. There was no 
significant difference between the two groups in the credibility of blinding. Details are 
provided in Table 32. 
Table 32: Credibility of blinding for Pilot study II 
 Number of participants guessing 
group assignment  Significance Intervention 
(n= 31) 
Control 
(n= 32) 
Credibility of 
blinding 
Real  9 8 
X2= 0.376 p= 0.828 
Sham 5 7 
Not sure 17 17 
Total  31 32 
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7.3 Discussion and conclusion 
This trial is a pilot study for evaluating the efficacy of ear-acupressure for SAR. The 
results of this trial demonstrated the usefulness of ear-acupressure treatment for the 
short-term symptomatic management of AR. The efficacy results of this trial were 
used for sample size estimation for the main trial. 
 
7.3.1 Amended protocol 
Pilot study I proved that the trial protocol was feasible. Pilot study II, the amended 
questionnaires were employed. Firstly, the symptom diary required participants to 
record their symptoms every day, then all the weekly symptom assessment 
questionnaires were completed based on the diary. This ensured the data recorded 
in the weekly CRFs were accurate. Secondly, the CRFs required participants to 
assess their symptoms on a weekly basis (rather than fortnightly as in Pilot study I), 
this also helped ensure all the data were recorded in the CRFs accurately. Thirdly, 
according to the suggestion from questionnaires’ developer (Juniper, personal 
communication, August, 2008), RQLQ was replaced by RQLQ(S). Therefore, the 
three questions about participants’ activity could be kept consistent throughout the 
whole study. Finally, the question on credibility of blinding asked participants to 
guess which group they were assigned into when they received the first treatment. 
Participants were required to make this judgement based on their own understanding 
about this treatment. The results of this test indicated that more than half of the 
participants were not sure which group they were in. Statistically, there was no 
difference between two groups in terms of this question so the blinding procedure 
was considered successful. This successful blinding proved that the sham ear-
acupressure method employed in this trial was appropriate.  
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The completion of this pilot study verified that the amended protocol was better-
established and could be applied to the main trial. 
 
7.3.2 Interpretation of results 
7.3.2.1 Efficacy 
This study was conducted during the peak pollen season. In the pollen season, 
participants’ allergy symptoms are influenced by the pollen count. Therefore, to 
simply compare patient’s symptom severity before and after treatment does not 
reflect the treatment effectiveness. When comparing symptom severity between the 
groups, there were some findings that indicated that the effects of the real ear-
acupressure treatment were greater than those of the sham treatment in this trial. 
 Juniper 4 point symptom score 
Comparison of the two groups’ individual symptom scores and TNSS did not achieve 
significant results, though there was a trend towards greater reduction in the real ear-
acupressure group than in the sham group. This might be caused by the small 
sample size. Moreover, the 4 point scale (0, 1, 2, 3 system) might not be able to 
detect minor changes in symptom severity precisely. 
 Spector 7 point VAS 
Significant differences between the two groups at the end of the treatment period 
were obtained for three questions: sneezing, total nasal symptoms and global nasal 
and non nasal symptoms. This questionnaire employed a seven point VAS instead of 
the four point system (none, mild, moderate, severe), which gave participants more 
options to select from. Perhaps this allowed participants to assess their symptom 
severity more precisely.  
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 RQLQ(S) 7 domains 
Consistently, the scores for all seven domains showed a greater reduction in the real 
ear-acupressure group than that in the sham ear-acupressure group during the 
treatment period, although significant difference was not found at the end of the 
treatment.  
 
7.3.2.2 Safety 
There were some adverse events related to the ear-acupressure treatment reported 
during the eight week treatment period. However, all the reported adverse events 
were discomfort feelings caused by the ear-acupressure technique or social 
discomforts. Once participants got used to having the ear-acupressure pellets or 
became familiar with this treatment, these discomforts could be managed.  
 
This study demonstrated that ear-acupressure treatment was well tolerated by 
participants and was a safe method for the management of AR.  
 
This pilot study was scheduled in Melbourne’s peak pollen season. Participants 
involved in this study were suffering from acute pollen-induced AR symptoms. Since 
a follow-up period was impractical, no conclusion can be drawn regarding the long-
term effect of ear-acupressure on SAR. 
 
7.3.3 Semi-self-administration of ear-acupressure  
To administrate the ear-acupressure treatment, participants themselves were 
involved in providing the pressure by pressing the pellets regularly during the whole 
treatment week after clinic attendance. Ten minutes each time, once a week 
attendance did not cause much inconvenience, nor was it time consuming. When 
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pressing the pellets, participants controlled the pressure and time, and they were 
allowed to take off the pellets if any of them caused unbearable pain. This semi-self-
administered method was expected to reduce the possibility of adverse events.  
The loss or removal of ear pellets has been reported in other trials (White, Moody, & 
Campbell, 2007) and may have been a factor in the lack of a clinical outcome but it 
was not known whether the loss of one or more of the five pellets would have an 
impact on the outcome in this trial. The weekly pellet dosage in real group was 
significantly lower in the real group in treatment week 1 and week 2. This difference 
possibly was caused by the locations of different ear points used for real and sham 
treatment resulting in a greater likelihood of certain points becoming detached. 
However, there was no difference between the two groups for the rest of the 
treatment weeks. This result suggests that once the participants became used to the 
treatment, maintenance of the ear pellets and the administration of pressure on the 
pellets compliance by participants was equivalent in both groups.  
 
With regard to efficacy, an increasing divergence between the two groups is evident 
from week 3 onwards, so it is plausible that the reduced pellet dosage in the real 
groups during weeks 1 and 2 had an effect on efficacy.  
 
7.3.4 Sample size calculation for the main trial 
Using G. Power 3.0.5 Software, based on data gathered using the Spector 7 point 
VAS (Spector et al., 2003), after the eight-week treatment the effect size estimate for 
total nasal symptoms (the primary end-point of the pilot study) was 0.466 (post-
treatment mean scores 2.161±1.917 and 3.094±2.085 for the real and sham ear-
acupressure groups respectively, p= 0.02). Aiming for 90% statistical power with a 
significance level of 5% (2-tailed), the required sample size was 98 participants per 
 
209 
 
group. Based on the literature, most studies have an expected drop-out rate of 15% 
to 20% (Magnusson, Svensson, Leirvik, & Gunnarsson, 2004). Therefore, we 
expected a dropout rate of up to 18%, thus, the sample size required would be 116 
participants in each group with 232 in total (see Table 33).  
Table 33 Sample size calculation according to various effect size 
Effect size estimate Required sample size per group for 90% power and 5% level of significance 
0.30 n = 235  
0.40 n = 133  
0.47 n = 116  
0.50 n = 86  
0.55 n = 71  
0.60 n = 60  
 
Subsequently, the main trial was conducted in Australia and China. The results of the 
main trial at the Australian site are reported in Chapter 8. 
 
7.3.5 Conclusion and recommendations 
In conclusion, ear-acupressure seemed to be an effective treatment for pollen 
induced AR with regard to relieving the severity of sneezing, total nasal symptoms 
and global nasal and non-nasal symptoms. Being a pilot study, however, the sample 
size of this study was small so a solid conclusion could not be drawn. A larger size 
trial with a follow-up period was needed to further investigate both the short-term and 
long-term efficacy and safety of ear-acupressure treatment for AR.  
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Chapter 8: Ear-acupressure for allergic rhinitis: main trial 
Upon completion of two pilot studies (Chapters 6 and 7), the main trial of ear-
acupressure for AR was conducted. This main trial was an adequately powered, 
international, multi-centre, single-blinded, randomised controlled trial. Two trial 
centres were located in Melbourne, Australia and Guangzhou, China. This chapter 
reports the results from the Australia trial centre. The main trial at the Australia centre 
was conducted in the years of 2009 and 2010. The trial recruiting and treatment 
period was scheduled in non-pollen season (between April and September); the 
follow-up period was ended at spring season (November). This part of trial recruited 
a total of 117 participants. Same as Pilot study II, the Australia centre main trial was 
conducted in two sites: Melbourne CBD (RMIT University City Campus) and 
Bundoora, a suburb approximately 20 kilometres from the Melbourne CBD (RMIT 
University Bundoora West Campus).  
 
8.1 Methods 
This trial was conducted according to the amended protocol (Chapter 6, section 6.5). 
As the timing of this trial avoided peak pollen season, participants who have typical 
perennial AR history and a positive skin prick test to dust mite, animal’s dander or 
mould were included in this trial. The trial lasted 22 weeks including a two-week run-
in period, an eight-week treatment period and a 12-week follow-up period. 
 
8.2 Results 
8.2.1 Participants 
Following the recruitment strategy provided in Chapter 5 (section 5.4.1), 231 
volunteers were screened from enquiries. The telephone interview and initial 
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assessment excluded 56 volunteers due to not meeting inclusion criteria. Fifty-eight 
volunteers were not able to participate due to time constrain and hence 117 were 
included in the trial. They were randomised into either real (n= 58) or sham ear-
acupressure group (n= 59) in the first week of treatment after the 2 weeks run-in 
period. During the eight-week treatment period, 8 participants in real ear-acupressure 
group and 9 in sham ear-acupressure group discontinued due to time restriction; 
during the follow-up period, 4 participants in real ear-acupressure group and 8 in 
sham ear-acupressure group lost contact and failed to send back the follow-up 
CRFs. As a result, 100 participants completed the treatment and 88 participants 
completed follow-up assessment. Details of the trial procedure are shown in Figure 
24. 
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Figure 24: Procedure of the main trial 
 
Assessed for eligibility 
(n= 231)  
Excluded (n= 114): 
- Not meeting selection 
criteria (n= 56) 
- Time restriction (n= 58) 
Included (n= 117) 
2 weeks baseline 
1st Visit 
Randomised (n= 117) 
Real EAP group (n= 58) 
8 weeks treatment, once a week 
Sham EAP group (n= 59) 
12 weeks follow-up 
3 CRFs, weeks 4, 8, 12 
Real EAP group (n= 58) 
12 weeks follow-up 
3 CRFs, weeks 4, 8, 12 
Analysed (n= 58) 
 
Analysed (n= 59) 
Sham EAP group (n= 59) 
8 weeks treatment, once a week 
8 drop-outs 
Due to time restrictions 
4 drop-outs 
Due to loss of contact 
8 drop-outs 
Due to loss of contact 
9 drop-outs 
Due to time restrictions 
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8.2.2 Demographic data and baseline characteristics for the main trial 
The age range of the 117 participants included in this trial was from 21 to 70 years 
old. The average age of the real ear-acupressure group was 42.91±11.09 years while 
that of the sham ear-acupressure group was 43.47±12.51 years. There was no 
significant difference between the two groups with regard to age and gender (p>0.05). 
Nor was there any significant difference between the two groups in terms of the 
number of current, previous and non-smokers in the two groups, the duration of 
participants’ AR morbidity and whether they had a family history of AR. For the four 
types of Chinese medicine differential diagnoses, no difference was found between 
the two groups. The demographics of the included participants were all comparable 
(p>0.05). Details are shown in Table 34. 
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Table 34: Demographics and baseline characteristics of included participants 
of the main trial  
 Intervention 
(n= 58) 
Control 
(n= 59) Significance 
Mean±SD 
Age  42.91±11.09 43.47±12.51 t= -0.256 p= 0.798 
Duration of AR in years  21.84±13.59 19.14±4.07 t= 1.059 p= 0.292 
 Number of participants Significance 
Gender 
Male 26 28 
X2= 0.775 p= 0.854 
Female 32 31 
Smoking 
status 
Current 6 3 
X2= 1.202 p= 0.548  Former 16 16 
Never 36 40 
Has family history of AR (n) 26 19 X2= 1.969 p= 0.186 
Chinese 
Medicine 
Differenti
ation 
Lung Deficiency 13 17 
X2= 1.731 p= 0.63 
Lung + Spleen 
Deficiency 10 8 
Lung + Kidney 
Deficiency 12 8 
Lung + Spleen + 
Kidney Deficiency 23 26 
 
The skin prick test results in the two groups were also comparable (p>0.05), see 
Table 35. 
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Table 35: Skin prick test results for the main trial 
 
Number of participants who were 
positive to each allergen Significance Intervention 
(n= 58) 
Control 
(n= 59) 
Grass Mix 43 40 X2 = 0.571 p= 0.542 
Perennial Rye 
Grass 48 14 X
2= 1.165 p= 0.368 
Ragweed 38 33 X2= 1.126 p= 0.345 
Mould Mix 27 22 X2= 1.031 p= 0.352 
Cat Hair 38 30 X2= 2.586 p= 0.135 
Dog Hair 27 28 X2= 1.010 p= 1.000 
Dust Mite 50 52 X2= 0.097 p= 0.789 
 
 
Using the nonparametric Mann-Whitney test, the baseline outcome measure data 
were comparable except for three variables (watery eyes in the Juniper 4 point 
symptom score, total nasal symptoms and global nasal and non-nasal symptoms 
from the Spector 7 point VAS). Detailed baseline data are listed in Table 36 (page 
217): 
 Juniper 4 point symptom score 
In the Juniper 4 point symptom score questionnaire, the real ear-acupressure group’s 
“watery eyes” symptom score was more severe than that in the sham ear-
acupressure group (0.74±0.098 and 0.49±0.091, U= 1334.50, p= 0.029). Other 
symptoms and TNSS were all comparable (p>0.05). 
 Spector 7 point VAS  
In this questionnaire, the scores for “total nasal symptom” were significantly different 
between the two groups (U= 1313.00, p= 0.029). The real ear-acupressure group’s 
score was more severe than that of the sham ear-acupressure group (3.25±0.151 
and 2.77±0.159). The score for “global nasal and non-nasal symptoms” also was not 
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comparable (U= 1419.00, p= 0.042). The real ear-acupressure group had a more 
severe score of 4.03±0.14 while sham ear-acupressure group’s score was 
4.69±0.118. Other scores showed no significant difference at baseline (p>0.05).  
 RQLQ(S) 7 domains baseline data 
In this trial, all the RQLQ(S) 7 domains baseline data were comparable (p>0.05). 
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Table 36: Baseline and treatment effects for the main trial 
a. Juniper 4 point symptom severity scores for the main trial 
Symptom 
severity 
Baseline End of treatment period End of follow-up period 
Intervention 
(n= 58) 
Mean±SE 
Control 
(n= 59) 
Mean±SE
Significance 
Intervention 
(n= 58) 
Mean±SE 
Control 
(n= 59) 
Mean±SE
Significance 
Intervention 
(n= 58) 
Mean±SE 
Control 
(n= 59) 
Mean±SE
Significance 
Total nasal 
symptom 
score 
4.90±0.248 4.46±0.32 U= 1468.00 p= 0.184 4.37±0.449 5.56±0.456 
U= 1280.00 
p= 0.018* 5.12±0.53 6.09±0.542 
U= 1437.00 
p= 0.131 
Sneezing 1.39±0.077 1.28±0.105 U= 1562.50 p= 0.404 1.21±0.12 1.54±0.122 
U= 1351.00 
p= 0.036* 1.36±0.136 1.63±0.135 
U= 1441.50 
p= 0.157 
Blocked nose 1.39±0.103 1.36±0.108 U= 1651.00 p= 0.738 1.16±0.124 1.57±0.141 
U= 1331.00 
p= 0.031* 1.40±0.137 1.79±0.147 
U= 1339.50 
p= 0.05*  
Runny nose 1.34±0.101 1.08±0.100 U= 1389.50 p= 0.074 1.17±0.126 1.38±0.138 
U= 1517.00 
p= 0.268 1.35±0.147 1.5±0.156 
U= 1567.50 
p= 0.508 
Itchy nose 0.81±0.09 0.79±0.098 U= 1658.00 p= 0.766 0.83±0.133 1.07±0.145 
U= 1516.00 
p= 0.256 1.02±0.153 1.27±0.158 
U= 1461.00 
p= 0.196 
Itchy eyes 0.83±0.101 0.65±0.095 U= 1479.00 p= 0.189 0.75±0.138 1.03±0.139 
U= 1415.00 
p= 0.083 1.01±0.151 1.35±0.159 
U= 1419.50  
p= 0.128 
Watery eyes 0.74±0.098 0.49±0.091 U= 1334.50 p= 0.029* 0.66±0.138 0.90±0.146 
U= 1500.00 
p= 0.196 0.95±0.154 1.16±0.167 
U= 1544.50 
p= 0.415 
Redness of 
eyes 0.50±0.102 0.5±0.091 
U= 1643.50 
p= 0.677 0.59±0.143 0.83±0.143 
U= 1435.50 
p= 0.08 0.85±0.157 1.24±0.167 
U= 1393.50 
p= 0.084 
Itchiness of 
ears and 
palate 
0.62±0.109 0.44±0.086 U= 1546.00 p= 0.324 0.69±0.146 0.81±0.14 
U= 1533.00 
p= 0.272 0.86±0.158 1.08±0.166 
U= 1493.50 
p= 0.252 
Note: U: Mann-Whitney U test; *: p<0.05; SE: standard error 
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b. Spector 7 point VAS for the main trial 
Symptom 
severity 
Baseline End of treatment period End of follow-up period 
Intervention 
(n= 58) 
Mean±SE 
Control 
(n= 59) 
Mean±SE
Significance 
Intervention 
(n= 58) 
Mean±SE 
Control 
(n= 59) 
Mean±SE
Significance 
Intervention 
(n= 58) 
Mean±SE 
Control 
(n= 59) 
Mean±SE
Significance 
Sneezing 2.76±0.156 2.44±0.137 U= 1491.50 p= 0.226 2.65±0.254 3.32±0.253 
U= 1273.50  
p= 0.014* 3.10±0.307 3.67±0.306 
U= 1384.00 
p= 0.092 
Runny nose 2.87±0.172 2.41±0.142 U= 1367.00 p= 0.058 2.79±0.26 3.17±0.262 
U= 1482.00 
p= 0.197 3.19±0.309 3.55±0.317 
U= 1526.50 
p= 0.377 
Congestion 2.77±0.16 2.70±0.179 U= 1617.50 p= 0.607 2.73±0.255 3.25±0.261 
U= 1404.50 
p= 0.087 3.17±0.296 3.72±0.308 
U= 1450.00 
p= 0.19 
Itchy nose 2.04±0.132 2.02±0.151 U= 1602.50 p= 0.543 2.19±0.267 2.76±0.268 
U= 1307.00 
p= 0.019* 2.66±0.313 3.28±0.325 
U= 1367.50 
p= 0.066 
Post nasal 
drip 2.49±0.182 2.03±0.154 
U= 1382.00 
p= 0.067 2.21±0.265 2.78±0.29 
U= 1463.00  
p= 0.147 2.83±0.311 3.4±0.336 
U= 1485.50 
p= 0.25 
Total nasal 
symptoms 3.25±0.151 2.77±0.159 
U= 1313.00 
p= 0.029* 2.71±0.252 3.44±0.244 
U= 1216.00 
p= 0.005* 3.10±0.300 3.81±0.296 
U= 1326.00 
p= 0.044* 
Eye 
symptoms 2.14±0.139 1.98±0.144 
U= 1495.00 
p= 0.227 2.24±0.266 2.75±0.276 
U= 1421.00 
p= 0.09 2.7±0.307 3.35±0.323 
U= 1397.00 
p= 0.099 
Throat 
symptoms 2.09±0.168 1.78±0.131 
U= 1554.50 
p= 0.371 2.28±0.267 2.49±0.286 
U= 1648.00 
p= 0.709 2.66±0.313 3.14±0.339 
U= 1498.00 
p= 0.273 
Chronic 
Cough 1.73±0.16 1.68±0.132 
U= 1687.00 
p= 0.882 2.26±0.273 2.29±0.291 
U= 1645.50 
p= 0.682 2.5±0.316 3±0.343 
U= 1498.50 
p= 0.252 
Ear symptoms 1.67±0.125 1.45±0.1 U= 1504.00 p= 0.202 2.08±0.268 2.22±0.278 
U= 1666.00 
p= 0.778 2.56±0.321 2.97±0.34 
U= 1483.50 
p= 0.223 
Headache 1.75±0.146 1.85±0.14 U= 1522.50 p= 0.275 2.12±0.277 2.39±0.282 
U= 1495.50 
p= 0.178 2.54±0.315 3.14±0.343 
U= 1477.00 
p= 0.214 
Mental 
function 1.86±0.138 1.84±0.157 
U= 1613.00 
p= 0.566 2.17±0.271 2.46±0.288 
U= 1622.50 
p= 0.587 2.60±0.311 3.24±0.337 
U= 1474.50 
p= 0.216 
Global nasal 
and non-
nasal 
symptoms 
4.03±0.14 4.69±0.118 U= 1419.00 p= 0.042*   4.97±0.246 4.05±0.223 
U= 1092.50 
p= 0.001* 4.41±0.266 3.85±0.279 
U= 1425.00 
p= 0.148  
Global quality 
of life 4.33±0.11 4.65±0.125 
U= 1345.00 
p= 0.102 5.05±0.242 4.27±0.234 
U= 1170.00 
p= 0.002* 4.47±0.267 3.93±0.279 
U= 1420.00 
p= 0.139 
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c. RQLQ(S) 7 domains for the main trial 
Symptom 
severity 
Baseline End of treatment period End of follow-up period 
Intervention 
(n= 58) 
Mean±SE 
Control 
(n= 59) 
Mean±SE
Significance 
Intervention 
(n= 58) 
Mean±SE 
Control 
(n= 59) 
Mean±SE
Significance 
Intervention 
(n= 58) 
Mean±SE 
Control 
(n= 59) 
Mean±SE
Significance 
Activities 5.75±0.391 4.97±0.448 U= 1423.50 p= 0.116 4.89±0.776 6.92±0.745 
U= 1202.00 
p= 0.005* 6.27±0.895 8.19±0.914 
U= 1409.00 
p= 0.094 
Sleep 4.02±0.482 4.31±0.424 U= 1544.00 p= 0.36 4.09±0.788 6.02±0.825 
U= 1306.00 
p= 0.024* 5.36±0.91 7.75±0.964 
U= 1360.00 
p= 0.05* 
Non nose/eye 
symptoms 11.13±1.164 10.36±1.141 
U= 1595.00 
p= 0.527 9.22±1.857 12.54±1.943 
U= 1402.50 
p= 0.087 12.60±2.111 17.72±2.214 
U= 1369.50 
p= 0.059 
Practical 6.83±0.502 5.76±0.593 U= 1372.00 p= 0.064 5.40±0.772 6.53±0.803 
U= 1502.00 
p= 0.25 6.61±0.888 8.10±0.928 
U= 1465.00 
p= 0.175 
Nasal 
symptoms 8.44±0.557 7.64±0.635 
U= 1537.50 
p= 0.344 7.15±0.952 9.53±0.96 
U= 1242.50 
p= 0.01* 9.06±1.116 11.36±1.194 
U= 1456.50 
p= 0.161 
Eye 
symptoms 4.60±0.563 3.96±0.542 
U= 1527.50 
p= 0.315 4.86±1.04 6.40±1.103 
U= 1520.50 
p= 0.289 6.41±1.214 9.15±1.31 
U= 1414.50 
p= 0.1 
Emotional 6.74±0.663 6.62±0.694 U= 1697.50 p= 0.941 6.04±1.051 8±1.092 
U= 1421.00 
p= 0.11 7.60±1.208 10.60±1.278 
U= 1391.00 
p= 0.076 
Note: U: Mann-Whitney U test; *: p<0.05; SE: standard error 
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8.2.3 Pellet dosage  
During the eight-week treatment period, participants were required to record the daily 
number of pellets remaining on their ears to provide dosage data. The sum of weekly 
total pellet dosage was calculated for dosage data analysis. In the early weeks of the 
treatment period, the weekly total pellet dosage in the real group was lower than the 
weekly total dosage in the sham group and there was a significant difference in week 
2 (week 2, real group 31.741±4.918, sham group 33.398±2.449, p= 0.023). From 
treatment week 3 to week 8, there were no significant differences in terms of weekly 
total pellet dosage between the real and sham groups. Details are listed in Table 37: 
Table 37: Pellet dosage for the main trial 
 Intervention 
(n= 58) 
Mean±SD 
Control 
(n= 59) 
Mean±SD 
Significance 
Weekly total pellets 
dosage - week 1  32.24±3.724 33±4.03 p= 0.292 
Weekly total pellets 
dosage - week 2  31.74±4.918 33.4±2.449 p= 0.023 
Weekly total pellets 
dosage - week 3  32.91±3.757 33.61±3.227 p= 0.284 
Weekly total pellets 
dosage - week 4  33.07±4.068 32.80±3.362 p= 0.694 
Weekly total pellets 
dosage - week 5  33.45±3.174 33.63±2.228 p= 0.725 
Weekly total pellets 
dosage - week 6  33.02±3.601 33.39±2.659 p= 0.525 
Weekly total pellets 
dosage - week 7  33.60±2.759 33.53±3.093 p= 0.886 
Weekly total pellets 
dosage - week 8  33.55±2.747 33.70±2.298 p= 0.76 
 
 
8.2.4 Treatment effects 
By the end of the eight-week treatment period and at the end of the follow-up period, 
the symptom severity in the real ear-acupressure group was generally lower 
compared with the sham ear-acupressure group (Table 36, page 217). Furthermore, 
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all the significant treatment effect results at the end of treatment period and follow-up 
period are summarised in Table 38. Details are discussed below.
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Table 38: Summary of significant results for the main trial 
Questionnaire Symptom severity 
End of treatment period End of follow-up period 
Intervention 
(n= 58) 
Mean±SE 
Control 
(n= 59) 
Mean±SE 
Significance* Effect size 
Intervention 
(n= 58) 
Mean±SE 
Control 
(n= 59) 
Mean±SE 
Significance* Effect size 
Juniper 4 
points 
symptom 
severity 
score 
Total nasal 
symptom 
score 
4.37±0.449 5.56±0.456 p= 0.018* -0.97 5.12±0.53 6.09±0.542 p= 0.131 -1.19 
Sneezing 1.21±0.12 1.54±0.122 p= 0.036* -0.27 1.36±0.136 1.63±0.135 p= 0.157 -0.33 
Blocked 
nose 1.16±0.124 1.57±0.141 p= 0.031* -0.39 1.4±0.137 1.79±0.147 p= 0.05* -0.41 
Spector 7 
points VAS 
Sneezing 2.65±0.254 3.32±0.253 p= 0.014* -0.57 3.10±0.307 3.67±0.306 p= 0.092 -0.67 
Itchy nose 2.19±0.267 2.76±0.268 p= 0.019* -0.62 2.66±0.313 3.28±0.325 p= 0.066 -0.57 
Total nasal 
symptoms 2.71±0.252 3.44±0.244 p= 0.005* -0.71 3.1±0.3 3.81±0.296 p= 0.044* -0.73 
Global nasal 
and non-
nasal 
symptoms 
4.97±0.246 4.05±0.223 p= 0.001* 0.56 4.41±0.266 3.85±0.279 p= 0.148 0.92 
RQLQ(S) 
Activities 
domain 4.89±0.776 6.92±0.745 p= 0.005* -1.92 6.27±0.895 8.19±0.914 p= 0.094 -2.03 
Sleep 
domain 4.09±0.788 6.02±0.825 p= 0.024* -2.39 5.36±0.91 7.75±0.964 p= 0.05* -1.93 
Nasal 
symptoms 
domain 
7.15±0.952 9.53±0.96 p= 0.01* -2.30 9.06±1.116 11.36±1.194 p= 0.161 -2.38 
Note: U: *: p<0.05 by Mann-Whitney U test.
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8.2.4.1 Juniper 4 point symptom score at the end of treatment period and 
follow-up period 
By applying the nonparametric Mann-Whitney test to compare the real/sham ear-
acupressure groups, significant differences were found for: Sneezing (U= 1351.00, 
p= 0.036) and blocked nose (U= 1331.00, p= 0.031) between the two groups, as well 
as for TNSS (U= 1280.00, p= 0.018) at the end of the eight- week treatment period.  
At the end of the follow-up period, a significant difference between the two groups 
was observed for blocked nose (U= 1339.50, p= 0.05). 
 
Figures 25 to 33 show the scores of TNSS and all individual symptoms at the 
baseline, for each week of the 8 week treatment period and at three points during the 
follow-up period: Follow up 1 (4 weeks), Follow up 2 (8 weeks), Follow up 3 (12 
weeks). 
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a. Total nasal symptom score (TNSS) 
The TNSS was calculated as the sum score of four nasal symptoms (sneezing, 
blocked nose, runny nose, itchy nose). The weekly TNSS was comparable between 
the real and sham groups at baseline (U= 1468.00, p= 0.184). At the end of the eight-
week treatment period, the TNSS of the real group was significantly lower than that 
of the sham group (U= 1280.00, p= 0.018). At the end of follow-up period, the TNSS 
from two groups showed no significant difference (U= 1437.00, p= 0.131) (Figure 25). 
 
Note: *: p< 0.05 
Figure 25: Juniper TNSS for the main trial 
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b. Sneezing score 
Similar to the TNSS, the sneezing score did not show a significant difference 
between real and sham groups at baseline (U= 1468.00, p= 0.404). A significant 
difference between the two groups in favour of the real group was evident at the end 
of the treatment period (U= 1351.00, p= 0.036) but not at the end of the follow-up 
period (U= 1441.50, p= 0.157) (Figure 26). 
 
 
Note: *: p< 0.05 
Figure 26: Juniper sneezing score for the main trial 
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c. Blocked nose score 
In terms of the blocked nose scores, there was no significant difference between the 
two groups at baseline (U= 1651.00, p= 0.738). A significant difference in favour of 
the treatment group was obtained at the end of the treatment period (U= 1331.00, p= 
0.031) and at the end of the follow-up period (U= 1339.50, p= 0.05) (Figure 27). 
 
Note: *: p< 0.05 
Figure 27: Juniper blocked nose score for the main trial 
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d. Runny nose score 
The symptom scores for runny nose were comparable between the real and sham 
treatment groups at baseline (U= 1389.50, p= 0.074), at the end of the treatment 
period (U= 1517.00, p= 0.268) and at the end of the follow-up period (U= 1567.50, p= 
0.508) (Figure 28). 
 
Figure 28: Juniper runny nose score for the main trial 
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e. Itchy nose score 
The itchy nose scores for the two groups were comparable at baseline (U= 1658.00, 
p= 0.766), at the end of the treatment period (U= 1516.00, p= 0.256) and at the end 
of the follow-up period (U= 1461.00, p= 0.196) (Figure 29). 
 
Figure 29: Juniper itchy nose score for the main trial 
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f. Itchy eyes score 
There were no statistically significant differences between the two groups in terms of 
itchy eyes scores before and after treatment and at the end of the follow-up period 
(U= 1479.00, 1415.00 and 1419.50, p= 0.189, 0.083 and 0.196) (Figure 30). 
 
Figure 30: Juniper itchy eyes score for the main trial 
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g. Watery eyes score 
When comparing the scores for watery eyes between the two groups at baseline, the 
score for the real group was significantly higher than that of the sham group (U= 
1334.50, p= 0.029). However, at the end of the treatment period and at the end of 
follow-up, there were no differences between the two groups (U= 1500.00 and 
1544.50, p= 0.196 and 0.415) (Figure 31). 
 
Note: *: p< 0.05 
Figure 31: Juniper watery eyes score for the main trial 
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h. Redness of eyes score 
The scores for redness of eyes for the two groups were comparable at baseline, and 
were not significantly different at the end of treatment and the end of follow-up period 
(U= 1643.50, p= 0.677; U= 1435.50, p= 0.08; and U= 1393.50, p= 0.084) (Figure 32). 
 
Figure 32: Juniper redness of eyes score for the main trial 
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i. Itchiness of ears and palate score 
The scores for itchiness of ears and palate were comparable at baseline, the end of 
treatment and the end of the follow-up period (U= 1546.00, p= 0.324; U= 1533.00 p= 
0.272, and U= 1493.50, p= 0.252) (Figure 33). 
 
Figure 33: Juniper itchiness of ears and palate score for the main trial 
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8.2.4.2 Spector 7 point VAS at the end of treatment period and follow-up period 
When comparing the Spector 7 point VAS scales between the real and sham ear-
acupressure groups by applying the nonparametric Mann-Whitney test, at the end of 
the treatment period significant differences between the two groups were obtained for: 
sneezing (U= 1273.50, p= 0.014), itchy nose (U= 1307.00, p= 0.019), total nasal 
symptoms (U= 1216.00, p= 0.005), global nasal and non-nasal symptoms (U= 
1092.50, p= 0.001), global quality of life (U= 1170.00, p= 0.002). At the end of the 
follow-up period, significant differences between two groups were found for total 
nasal symptoms (U= 1326.00, p= 0.044). 
 
The detailed scores for the Spector 7 point VAS from baseline to the end of the 
follow-up period are shown in Figures 34 to 47. 
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a. Spector VAS Sneezing score 
The sneezing scores from Spector 7 point VAS for the two groups were comparable 
at baseline (U= 1491.50, p= 0.226) and at the end of follow-up period (U= 1384.00, 
p= 0.092). However, there was significant difference at the end of the treatment 
period (U= 1273.50, p= 0.014) (Figure 34). 
 
Note: *: p< 0.05 
Figure 34: Spector VAS sneezing score for the main trial 
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b. Spector VAS Runny nose score 
When the runny nose scores were compared between the two groups, no significant 
difference was observed at baseline (U= 1367.00, p= 0.058), the end of treatment 
(U= 1482.00, p= 0.197) or the end of the follow-up period (U= 1526.50, p= 0.377) 
(Figure 35). 
 
Figure 35: Spector VAS runny nose score for the main trial 
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c. Spector VAS Congestion score 
The congestion scores were not significantly different between the two groups at 
baseline (U= 1617.50, p= 0.607), the end of treatment (U= 1404.50, p= 0.087) or the 
end of the follow-up period (U= 1450.00, p= 0.19) (Figure 36). 
 
Figure 36: Spector VAS congestion score for the main trial 
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d. Spector VAS Itchy nose score 
Itchy nose scores were comparable at baseline (U= 1602.50, p= 0.543). At the end of 
the eight-week treatment, the itchy nose score of the real group was significantly 
lower than that of the sham group (U= 1307.00, p= 0.019). However, at the end of 
the follow-up period, no significant difference was obtained (U= 1367.50, p= 0.066) 
(Figure 37). 
 
Note: *: p< 0.05 
Figure 37: Spector VAS itchy nose score for the main trial 
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e. Spector VAS Post nasal drip score 
The post nasal drip score was comparable at baseline (U= 1382.00, p= 0.067), the 
end of the treatment period (U= 1463.00, p= 0.147) and the end of the follow-up 
period (U= 1485.50, p= 0.25) (Figure 38). 
 
Figure 38: Spector VAS post nasal drip score for the main trial 
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f. Spector VAS Total nasal symptoms score 
At baseline, the Spector VAS total nasal symptoms score of the real group was 
significantly higher than that of the sham group (U= 1313.00, p= 0.029). At the end of 
the treatment period, the score of the real group was significantly lower than that of 
the sham group (U= 1216.00, p= 0.005). At the end of the follow-up period, the score 
of the real group was significantly lower than that of the sham group (U= 1326.00, p= 
0.044) as well (Figure 39). 
 
Note: *: p< 0.05 
Figure 39: Spector VAS total nasal symptoms score for the main trial 
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g. Spector VAS Eye symptoms score 
The Spector VAS eye symptoms scores showed no significant difference between 
the two groups at baseline (U= 1495.00, p= 0.227), the end of treatment period (U= 
1421.00, p= 0.09) or the end of the follow-up period (U= 1397.00, p= 0.099) (Figure 
40). 
 
Figure 40: Spector VAS eye symptoms score for the main trial 
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h. Spector VAS Throat symptoms score 
The Spector VAS throat symptoms scores of the two groups were comparable at 
baseline (U= 1554.50, p= 0.371), the end of the treatment period (U= 1648.00, p= 
0.709) and the end of the follow-up period (U= 1498.00, p= 0.273) (Figure 41). 
 
Figure 41: Spector VAS throat symptoms score for the main trial 
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i. Spector VAS Chronic cough score 
The Spector VAS chronic cough scores also showed no significant difference 
between the two groups at baseline (U= 1687.00, p= 0.882), the end of treatment 
period (U= 1645.00, p= 0.682) and the end of follow-up period (U= 1498.50, p= 0.252) 
(Figure 42). 
 
Figure 42: Spector VAS chronic cough score for the main trial 
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j. Spector VAS Ear symptoms score 
Similarly, the Spector VAS ear symptom scores showed no significant difference 
between the two groups at baseline (U= 1504.00, p= 0.202), the end of treatment 
period (U= 1666.00, p= 0.778) or the end of the follow-up period (U= 1483.50, p= 
0.223) (Figure 43). 
 
Figure 43: Spector VAS ear symptoms score for the main trial 
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k. Spector VAS Headache score 
No significant difference was found between the two groups in terms of Spector VAS 
headache scores at the baseline (U= 1522.50, p= 0.275), the end of treatment period 
(U= 1495.50, p= 0.178) and the end of follow-up period (U= 1477.00, p= 0.214) 
(Figure 44). 
 
Figure 44: Spector VAS headache score for the main trial 
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l. Spector VAS Mental function score 
The Spector VAS Mental function scores were comparable at the baseline (U= 
1613.00, p= 0.566), the end of the treatment period (U= 1622.50, p= 0.587) and the 
end of the follow-up period (U= 1477.00, p= 0.216) (Figure 45). 
 
Figure 45: Spector VAS mental function score for the main trial 
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m. Spector VAS Global nasal and non-nasal symptom score 
The Spector VAS Global nasal and non-nasal symptoms scores is a reverse score.  
The real group’s score was significantly lower than that in sham group at the baseline 
(U= 1419.00, p= 0.042). At the end of the treatment period, the real group’s score 
was significant higher than that in the sham group (U= 1092.50, p= 0.001). However, 
no significant difference was observed at the end of the follow-up period (U= 1425.00, 
p= 0.148) (Figure 46). 
 
Note: *: p< 0.05 
Figure 46: Spector VAS global nasal and non-nasal symptoms score for the 
main trial 
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n. Spector VAS Global quality of life score 
The Spector VAS Global quality of life score is a reverse score as well. The two 
groups’ Spector VAS Global quality of life scores were comparable at the baseline 
(U= 1345.00, p= 0.102). A significant difference was evident at the end of the 
treatment period (U= 1170.00, p= 0.002); however, there was no significant 
difference at the end of the follow-up period (U= 1420.00, p= 0.139) (Figure 47). 
 
Note: *: p< 0.05 
Figure 47: Spector VAS global quality of life score for the main trial 
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8.2.4.3 RQLQ(S) 7 domains at the end of treatment period and follow-up period 
When comparing the scores for the 7 domains of the RQLQ(S) questionnaire 
between the real and sham ear-acupressure groups at the end the treatment period 
by applying the nonparametric Mann-Whitney test, significant differences between 
the two groups in favour of the treatment group were obtained in: Activities domain 
(U= 1202.00, p= 0.005), Sleep domain (U= 1306.00, p= 0.024), and Nasal symptoms 
domain (U= 1242.50, p= 0.01). At the end of the follow-up period, a significant 
difference was observed in the Sleep domain (U= 1360.00, p= 0.05). 
 
The detailed total scores for the RQLQ(S) 7 domains for the baseline, the treatment 
period and the follow up period are illustrated in Figures 48 to 54: 
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a. RQLQ(S) Activities domain score 
When comparing the activities domain scores between the two groups, the baseline 
data were comparable (U= 1423.50, p= 0.115). A significant difference was observed 
at the end of treatment (U= 1202.00, p= 0.005) but not at the end of the follow-up 
period (U= 1409.00, p= 0.094) (Figure 48). 
 
Note: *: p< 0.05 
Figure 48: RQLQ(S) activities domain score for the main trial 
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b. RQLQ(S) Sleep domain score 
When comparing the sleep domain scores, the baseline data were comparable 
between the two groups (U= 1544.00, p= 0.36). At the end of the treatment period 
and at the end of the follow-up period, the sleep domain scores of the real group 
were significantly lower than those of the sham group (U= 1306.00 and 1360.00, p= 
0.024 and 0.05) (Figure 49). 
 
Note: *: p< 0.05 
Figure 49: RQLQ(S) sleep domain score for the main trial 
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c. RQLQ(S) Non nose/eye symptoms domain score 
Non nose/eye symptoms domain scores showed no difference between the two 
groups at the baseline (U= 1595.00, p= 0.527), the end of treatment period (U= 
1402.50, p= 0.087) or the end of the follow-up period (U= 1369.50, p= 0.059) (Figure 
50). 
 
Figure 50: RQLQ(S) non nose/eye symptoms domain score for the main trial 
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d. RQLQ(S) Practical domain score 
The practical domain scores showed no difference between the two groups at the 
baseline (U= 1372.00, p= 0.064), the end of treatment period (U= 1502.00, p= 0.25) 
and the end of the follow-up period (U= 1465.00, p= 0.157) (Figure 51). 
 
Figure 51: RQLQ(S) practical domain score for the main trial 
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e. RQLQ(S) Nasal symptoms domain score 
The baseline data of the nasal symptoms domain scores were comparable (U= 
1537.50, p= 0.344). At the end of treatment, the score for real treatment group was 
significantly lower than that of the sham group (U= 1242.50, p= 0.01). However, no 
significant difference was found at the end of the follow-up period (U= 1456.50, p= 
0.161) (Figure 52). 
 
Note: *: p< 0.05 
Figure 52: RQLQ(S) nasal symptoms domain score for the main trial 
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f. RQLQ(S) Eye symptoms domain score 
The eye symptoms domain scores showed no significant difference between the two 
groups at the baseline (U= 1527.50, p= 0.315), at the end of treatment (U= 1520.50, 
p= 0.289) and at the end of the follow-up period (U= 1414.50, p= 0.1) (Figure 53). 
 
Figure 53: RQLQ(S) eye symptoms domain score for the main trial 
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g. RQLQ(S) Emotional domain score 
When comparing the emotional scores for the two groups, no significant difference 
was obtained at the baseline (U= 1697.50, p= 0.941), the end of the treatment period 
(U= 1421.00, p= 0.11) or the end of the follow-up period (U= 1391.00, p= 0.076) 
(Figure 54). 
 
Figure 54: RQLQ(S) emotional domain score for the main trial 
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8.2.5 Participants’ opinion about ear-acupressure 
There was a significant difference between the two groups for questions 6 and 3 
using T-test: 
  Question 6: “By the end of the therapy period, how much improvement in your 
hay fever symptoms do you really feel will occur?” 
Participants’ mean response to this question from the sham group (5.35±1.737) was 
significantly higher than that from the real group (6.04±1.693), (p= 0.03). It shows 
that at baseline, the participants in the sham group had a higher expectation of a 
treatment effect. However, at the end of eight weeks treatment period, there was no 
differences between the two groups (p>0.05).  
 
At the end of the follow-up period, a significant difference between the two groups 
was found for question 3: 
 Question 3: “How confident would you be in recommending this treatment to a 
friend who experiences similar problems?” 
The mean response to this question from the real group participants (4.64±2.667) 
was significantly higher than that from the sham group (3.63±2.525), (p= 0.037), 
indicating that at the end of the follow-up period, the participants in the real group 
had more confidence in this treatment than those in the sham group. See Table 39.
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Table 39: Participants’ opinion about ear-acupressure for the main trial  
Note: Note: *: p<0.05; SD: Standard deviation 
Question 1: At this point, how logical does the treatment offered you seem?  
Question 2: At this point, how useful do you think the treatment will be in reducing your hay fever symptoms?  
Question 3: How confident would you be in recommending this treatment to a friend who experiences similar problems? 
Question 4: By the end of the therapy period, how much improvement in your hay fever symptoms do you think will occur? 
Question 5: At this point, how much do you really feel that therapy will help you to reduce your hay fever symptoms? 
Question 6: By the end of the therapy period, how much improvement in your hay fever symptoms do you really feel will occur? 
 
 
 
Baseline End of treatment period End of follow-up period 
Intervention 
group 
(n= 58) 
Mean±SD 
Control 
group 
(n= 59) 
Mean±SD 
Significance 
Intervention 
group 
(n= 58) 
Mean±SD 
Control group
(n= 59) 
Mean±SD 
Significance 
Intervention 
group 
(n= 58) 
Mean±SD 
Control group
(n= 59) 
Mean±SD 
Significance 
Question 1 5.33±1.81 5.78±1.529 p= 0.188 4.92±2.481 4.71±2.539 p= 0.651 4.38±2.553 3.81±2.642 p= 0.241 
Question 2 5.35±1.896 5.69±1.435 p= 0.286 4.68±2.471 4.44±2.654 p= 0.665 4.36±2.627 3.56±2.547 p= 0.098 
Question 3 5.30±2.154 5.81±1.972 p= 0.19 4.94±2.548 4.48±2.542 p= 0.325 4.64±2.667 3.63±2.525 p= 0.037* 
Question 4 5.45±1.954 5.92±1.524 p= 0.152 4.69±2.429 4.48±2.615 p= 0.646 4.04±2.519 3.34±2.577 p= 0.143 
Question 5 5.35±1.78 5.90±1.659 p= 0.082 4.64±2.483 4.34±2.604 p= 0.526 4.12±2.616 3.63±2.658 p= 0.314 
Question 6 5.35±1.737 6.04±1.693 p= 0.03* 4.64±2.497 4.39±2.566 p= 0.597 3.88±2.499 3.49±2.622 p= 0.415 
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8.2.6 Medication score for medicines related to AR 
The weekly scores for all AR related medications and for antihistamine medications 
were compared between the two groups at the baseline, at the end of the treatment 
period and at the end of the follow-up period. No significant differences were 
observed. Details are shown in Table 40. 
Table 40: Medication scores for the main trial 
Medication Endpoint 
Intervention 
(n= 58) 
Mean±SD 
Control 
(n= 59) 
Mean±SD 
Significance 
All AR 
medication 
score 
Baseline 3.14±5.504 5.33±11.599 p= 0.195 
At the end of 
treatment 
period 
2.37±5.752 1.93±4.629 p= 0.674 
At the end of 
follow-up 
period 
4.18±8.362 3.66±8.818 p= 0.773 
Antihistamine 
medication 
score 
Baseline 2.45±4.289 2.52±5.499 p= 0.947 
At the end of 
treatment 
period 
0.91±3.282 1.35±4.362 p= 0.57 
At the end of 
follow-up 
period 
4.18±8.362 3.66±8.818 p= 0.773 
 
 
8.2.7 Adverse events 
There was no significant difference between the two groups in terms of the adverse 
events reported during the treatment period and the follow-up period (Table 41). 
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Table 41: Summary of adverse events for the main trial  
Adverse events Intervention (n= 58) 
Control 
(n= 59) 
Sore on the ear with pellets attached  11 mild, 4 moderate 8 mild, 2 moderate 
Pressed too hard, pricked skin 1 mild 1 mild 
Ear points inflamed 1 mild 0 
Itchiness on the ear with pellets 
attached 8 mild, 3 moderate  3 mild, 1 moderate 
Feeling bothering with pellets on 
when need to wear ear plugs 1 mild 0 
Headache  1 mild, 5 moderate 3 mild, 1 moderate 
Dizziness  1 moderate 1 moderate 
All adverse events reported in 
treatment and follow-up period 23 mild, 13 moderate 15 mild, 5 moderate 
Number of participants reported 
adverse events (n= ) 17 21 
 
The proportion of participants who reported mild or moderate adverse events was not 
significantly different between the treatment and sham groups (29.0% vs. 21.9%, X2= 
0.526, p= 0.468). The most frequent events reported were soreness on the ear due 
to pressure (15 real and 10 sham treatment participants) and itchiness on the ear (11 
and 4 participants respectively). All the adverse events reported by participants were 
during the eight-week treatment period. In total, participants in the real treatment 
group reported 36 adverse events (23 mild and 13 moderate) with 20 adverse events 
being reported by the sham group (15 mild and 5 moderate). These mild or moderate 
discomforts were short-term and were effectively managed by refinement of the 
pressing techniques by the participants, without any medical assistance being 
required. No severe adverse event was reported during the treatment and follow-up 
periods.   
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8.2.8 Credibility of blinding 
The credibility of blinding question which allowed participants estimate which group 
they were assigned into was included in the treatment week 1 and week 8 CRFs. 
There was no significant difference between the two groups in the credibility of 
blinding. Details are in Table 42: 
Table 42: Credibility of blinding for the main trial  
 Intervention 
(n= 58) 
Mean±SD 
Control 
(n= 59) 
Mean±SD 
Significance 
Credibility of 
blinding 
Week 1 
Real  14 14 
X2= 1.962 p= 0.375 
Sham 11 6 
Not sure 33 39 
Total  58 59 
Credibility of 
blinding 
Week 8 
 
Real 18 10 
X2= 3.200 p= 0.202 
Sham 8 10 
Not sure 23 29 
Total 49 49 
 
 
 
8.3 Discussion  
This main trial is investigated the efficacy and safety of ear-acupressure in the 
treatment of AR. Based on the literature review, the pilot studies and the main trial 
are the first single-blinded, sham-controlled RCTs on ear-acupressure for AR which 
attempted to meet the challenge of fulfilling the requirements of conventional RCT 
methodology. The results from the main trial suggest that ear-acupressure was an 
effective and safe therapy for treating AR. 
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8.3.1 Methodology 
Methodological deficiencies in acupuncture and CHM studies are a major concern in 
clinical research (Ernst, 1994). As discussed in Chapter 4 (section 4.2), Systematic 
review 1 which was conducted prior to the trial concluded that the previous clinical 
studies on ear-acupuncture/ear-acupressure for AR (Gao, Zhang, Zhu, & Zhang, 
2008; Huo, 2003; Kong, Ren, & Lu, 2006; Qi & Wang, 2008; Rao & Han, 2006; 
Wang, 2004; Ye, Luo, & Xia, 2008) suffered methodological flaws (Zhang et al., 
2010). The main trial followed a rigorous methodology to avoid the methodological 
weaknesses evident in previous studies.  
 
8.3.1.1 Randomisation 
Randomisation numbers were generated by an independent statistician. The 
randomisation was stratified based on the TNSS score to ensure the severity of 
major symptoms in the two groups was comparable. However, some other symptom 
scores at baseline between two groups was not comparable (Juniper watery eyes, 
Spector total nasal symptom, and Spector Global nasal and non-nasal symptom, see 
Table 36, Page 217). Overall, the participants in real group had more severe 
symptoms compare with those in the sham group.  
 
8.3.1.2 Blinding 
Being derived from acupuncture, ear-acupressure is a physical stimulus that requires 
individualised point selection and stimulation. Hence, in the research on body 
acupuncture or ear-acupuncture/ear-acupressure, it is impossible to meet all the 
requirements of a double blind design (Lewith, 1994). Therefore a single blind design, 
in which the participants are unaware of whether they were receiving the real or 
sham treatment, was chosen. In this trial, except for the acupuncturist, all other 
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personnel were blinded including participants, the personnel who assessed the 
eligibility of the participants, those who performed the randomisation and the 
personnel who conducted the data entry and data analysis.  The credibility of blinding 
test conducted at the end of the first treatment week and at the end of the eight-week 
treatment period in this trial demonstrated that the blinding of this sham method was 
successful and the participants were properly blinded. In contrast, in previous ear-
acupuncture/ear-acupressure for AR RCTs (Gao, Zhang, Zhu, & Zhang, 2008; Huo, 
2003; Kong, Ren, & Lu, 2006; Qi & Wang, 2008; Rao & Han, 2006; Wang, 2004; Ye, 
Luo, & Xia, 2008) there was no participant blinding as a sham control method was 
not involved in any of these studies (Chapter 4, section 4.2.3). 
 
8.3.1.3 Drop-outs and intention-to-treat analysis 
Participants were free to drop-out at any time during the whole trial. All cases were 
analysed using intention-to-treat method to minimise bias due to withdrawals, which 
means, all the participants who began the treatment were considered to be part of 
the trial regardless of whether he or she finished the study. In this study, given that 
participants’ AR symptom severity may increase or decrease along with the change 
of weather and environment, the commonly used last-observation-carried-forward 
method may not have appropriately reflected the natural history of the disease. 
Therefore, all missing data were dealt with using the worst-case-scenario method in 
the intention-to-treat analysis. None of the previous ear-acupuncture/ear-acupressure 
trials for AR RCTs employed intention-to-treat analysis, so the results of this main 
trial are more accurate and reliable.   
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8.3.1.4 Selection of control method 
This study adopted the most commonly used sham method employed in previous 
ear-acupuncture/ear-acupressure RCTs (Chapter 4, section 4.3). Five non-specific 
ear acupoints were selected for the treatment in the sham group. Except for the 
points’ location, the pellets, the treatment procedure, the intensity of points’ 
stimulation and other relevant details were the same as in the real treatment. Thus, it 
was difficult for the participants to find out their treatment allocations. This approach 
resulted in effective blinding and reduced bias.  
 
There are a number of other advantages of using this method. Firstly, since the 
points used in the control group are all real points, the acupuncturist has no difficulty 
in locating them and consequently the sham treatment can be performed as naturally 
as the real treatment. Secondly, the sham treatment can be clearly specified and is 
consequently readily reproducible in other trials. 
 
 
8.3.1.5 Sample size 
Inadequate sample size threatens the validity of the findings and this has been a 
common problem for clinical trials. None of the previous ear-acupuncture/ear-
acupressure studies reported appropriate sample size estimations. In the main trial, 
the expected sample size was calculated based on the results from Pilot study II. 
Being a multi-centre study, this main trial targeted 116 participants in each group with 
232 in total allowing for a dropout rate of up to 18% (Chapter 7, section 7.3.3). The 
Australian trial centre recruited 117 participants to fulfil the targeted sample size.  
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8.3.1.6 Symptom severity and quality of life instruments employed in this trial 
This trial employed three validated instruments in the CRFs to record participants’ 
symptom severity and quality of life data including:  
 Simple 4 point rating scale (Juniper et al., 2005 ) 
 Spector 7 point VAS (Spector et al., 2003) 
 RQLQ(S) (Juniper, Thompson, Ferrie, & Roberts, 1999) 
The details of these three validated instruments have been provided in Chapter 5 
(section 5.7.2.1). These instruments have been frequently employed in previous AR 
clinical studies in the English literature (Brinkhaus et al., 2004; Brinkhaus et al., 2008; 
Xue et al., 2007; Xue, Thien, Zhang, Da Costa, & Li, 2003; Ng et al., 2004; Matkovic 
et al., 2010). The questions in these three questionnaires comprehensively assessed 
all problems relevant to AR, such as individual and total nasal symptoms, non-nasal 
symptoms, mental function, overall quality of life assessment, participants’ sleep, 
practical problems and emotions. By applying these three questionnaires in the CRFs, 
the effectiveness of ear-acupressure could be investigated in more detail compared 
with most of the previous ear-acupuncture/ear-acupressure for AR RCTs which only 
used “Total effective rate” as their outcome measure (Gao, Zhang, Zhu, & Zhang, 
2008; Huo, 2003; Kong, Ren, & Lu, 2006; Wang, 2004; Ye, Luo, & Xia, 2008) (see 
4.2.3.2).  
 
Thus, the rigorous methodology supports the reliability of the results of the main trial. 
 
8.3.2 Efficacy 
8.3.2.1 Summary of efficacy  
This main trial demonstrated that ear-acupressure treatment was effective in 
controlling AR symptoms in the following aspects: 
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 Short-term effect (at the end of the eight-week treatment period) 
The ear-acupressure treatment used in this trial was effective in controlling AR 
participants’ symptoms including: total nasal symptoms, sneezing, blocked nose, 
itchy nose, watery eyes, global nasal and non-nasal symptoms; and in improving 
participants’ quality of life in terms of the global quality of life, activity and sleep.   
 Long-term effect (at the end of the 12-week follow-up period) 
The long-term effects of the ear-acupressure treatment were: controlling the severity 
of total nasal symptoms, alleviating blocked nose, and improving participants’ sleep 
quality.  
 
Although there were no statistical differences between groups for a number of 
outcome measures, there were no instances where the sham control was superior to 
the treatment group at the end of the treatment period or at the end of follow up. 
Moreover, there are numerous examples of trends in which the treatment group is 
consistently superior to control from treatment week 3 onwards but this does not 
reach significance at p< 0.05 (see Figure 29 as example). Similar trends were 
evident in Pilot II. There are a number of likely reasons for these trends not reaching 
significance.  
 
Firstly, the overall symptom severity in participants was not high for any of the 
measures and for some symptoms the scores were very low (see Figure 29 as 
example). In such a situation, the ability of participants to detect a difference in their 
symptoms is reduced.  
 
Secondly, it is notable that the severity of many symptoms (see Figures 25 to 46) 
tends to rise in the sham group over the treatment period. This suggests a 
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background seasonal effect was operating and it was only when this background 
effect was at its maximum that significant differences between groups were 
detectable. Another possibility is that the ear-acupressure effect is delayed and 
gradually increases over time so it becomes most apparent in week 8. The lack of a 
difference between groups in the early weeks of treatment would support such an 
interpretation. Also there appears to be a ‘washout’ effect during follow up (see 
Figures 25 to 54). 
 
Thirdly, participants continued to use relief medications throughout the study and this 
is likely to have created a ceiling effect by preventing symptom severity rising too 
high in either group.  
 
Fourthly, conservative statistical approaches (Non-parametric test and intention-to-
treat with worst-case-scenario) were used so some real differences may not have 
been detected. 
 
Both the direction of the statistical differences and the trends suggest that there was 
a real effect for the real acupressure group and that a larger number of statistical 
differences would have been obtained had the sample size been larger. In fact, the 
results of the main trial presented in this thesis were based on the data in Australia 
site only. It might make some of the results under-powered. Including the data from 
the China site would give sample sizes which would enhance the power of the 
combined study. Further data analysis will be conducted for finalising further 
publication once the data from both sites are combined.   
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8.3.2.2 Relationship between the efficacy and the point selection 
In this trial, the five specific ear points used for AR are: Shenmen (TF4), Internal Nose 
(TG4), Lung (CO14), Wind Stream (SF1,2i) and Adrenal Gland (TG2p). Theoretically, 
Shenmen (TF4) is considered to relieve stress and calm the mind; Internal Nose 
(TG4) and Lung (CO14) are used to relieve nasal symptoms; Wind Stream (SF1,2i) and 
Adrenal Gland (TG2p) are used to non-specifically target allergy relief. Therefore, 
nasal symptoms such as sneezing, blocked nose, itchy nose and total nasal 
symptoms may be reduced by the function of the Internal Nose (TG4) and Lung 
(CO14) points. The sleeping quality’s improvement was possibly caused by the 
function of Shenmen (TF4) point. None of the ear points were specific for eye 
symptoms, throat symptoms or cough. 
 
8.3.2.3 Symptom control  
Consistent with Pilot study II, this trial demonstrated that real ear-acupressure was 
more effective than sham ear-acupressure for alleviating some AR symptoms. During 
the treatment and follow-up periods, the symptom severity of most outcome 
measures increased in both groups due to the impact of the change of the season. 
Although this trial was conducted in the non-peak pollen season in Melbourne and 
the pollen count data is not provided during the period of February to August, as the 
entire trial period was 22 weeks, participants recruiting and the run-in period was 
scheduled in the winter season while the end of the treatment period and the follow-
up period fell into the early spring season when pollen count was starting to rise. 
Given the fact that most PAR participants included in this trial are allergic to not only 
dust mite, mould or animal, but also pollen allergens and as a result, participants’ 
symptoms worsened when spring started. In the main trial, the symptoms in the sham 
ear-acupressure group were more severe compared with those in the real group in 
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terms of most of the outcomes which indicated that the real ear-acupressure 
treatment was more effective than the sham ear-acupressure treatment for the 
management of AR. For a condition like AR, the symptom severity may vary 
according to the change of climate or environment. The treatment efficacy cannot be 
precisely explained only by comparing the symptom severity before and after 
treatment, but by comparing the symptom severity between the real and sham 
groups.  
 
Compared with previous acupuncture RCTs on AR, the main trial demonstrated 
similar efficacy for ear-acupressure treatment. For example, a sham-controlled 
acupuncture RCT for PER participants conducted in Hong Kong between November 
2001 and August 2002 reported similar results in terms of rhinitis symptom scores 
(Ng et al., 2004). In this study, 72 children with PER were recruited. Participants 
received real or sham acupuncture twice weekly for eight weeks then followed by 
twelve weeks of monitoring. Four nasal symptoms’ severity was recorded using a 4 
point scale. The overall rhinitis symptom severity scores in the real group at the 
baseline, the end of treatment and the end of follow-up period were 6.58±3.21, 
5.25±3.57 and 5.43 ±3.94; while those in the sham group were 6.51±3.32, 6.44±3.33 
and 7.19±3.96 respectively. Although the rhinitis symptom severity in the real group 
did not achieve significant decrease compared with the baseline, when the between 
group analysis was conducted, there was significant difference between the two 
groups at the end of the follow-up period (p= 0.03). The effect size of acupuncture in 
terms of the overall rhinitis symptoms severity at the end of treatment was MD: -1.19; 
95%CI: -2.78, 0.40, while the effect size of ear-acupressure in this main trial in terms 
of the TNSS was MD: -1.19; 95%CI: -2.44, 0.06. In other words, this main trial proved 
that ear-acupressure has similar effects as to acupuncture on symptom control for 
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AR. It was inconsistent with the Xue et al., 2007 study of acupuncture for PAR which 
demonstrated that real acupuncture achieved greater symptom reduction comparing 
with sham acupuncture. In the Xue et al., 2007 study, the symptom reduction induced 
by acupuncture does not seem to have any relationship with change of season. 
Whether this inconsistency is due to the different form of intervention or by different 
timing of trial conduct is yet to be confirmed. A pilot study (Fleckenstein et al., 2009) 
including 24 participants suggested that acupuncture was effective in reducing the 
nasal symptom score of vasomotor rhinitis. However, vasomotor rhinitis is not an 
allergic condition, the symptom severity does not vary along with the change of 
pollen count. Furthermore, the sample size of this study was relatively small to draw 
any conclusions. 
 
8.3.2.4 Medication usage 
This trial did not provide evidence of ear-acupressure treatment reducing allergic 
rhinitis participants’ anti-allergy medication usage related to allergic rhinitis. In this 
trial, participants were allowed to take their own allergic rhinitis relief medication, as 
long as they recorded the usage in the CRFs. This was both an ethical 
considerations as well as recognition of the likely situation in the ‘real world’. In fact, 
there are many different types of allergy control medications including natural 
products available in the market. The large variety of medications used by 
participants made the analysis difficult. Therefore, the medication score was 
clustered as “all allergic rhinitis medication score” and “antihistamine medication 
score” for the data analysis (see Table 40). This approach is likely to have reduced 
the sensitivity of the measurements. No significant difference between two groups 
was observed. This result is consistent with previous studies of acupuncture for 
allergic rhinitis (Ng et al., 2004; Xue et al., 2007).  
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8.3.2.5 Efficacy and participants’ expectation 
As discussed in 8.3.5, the participants in the sham ear-acupressure group had a 
higher expectation of symptoms improvement (6.042±1.693) than those in the real 
ear-acupressure group (5.345±1.737) (p= 0.03) at the baseline. In contrast, the real 
treatment effects were in favour of the real ear-acupressure group. This supports the 
explanation that the treatment effectiveness was not caused by participants’ 
expectation. 
 
8.3.3 Safety 
Consistent with Pilot study I and Pilot study II, the main trial also demonstrated that 
ear-acupressure was safe for the clinical management of AR. The adverse events 
reported in this study were all mild or moderate discomforts, and they were liable to 
be tolerated or be managed by refining the pressing technique. Unlike acupuncture, 
there is no skin penetration involved in the acupressure method. Therefore, those 
adverse events which are often reported in acupuncture trials did not occur in this 
study. In addition, ear-acupressure is a semi-self-administered treatment. After the 
practitioner attached the pellets on the acupoints, the participants themselves were 
involved in applying pressure to the ear points by pressing the pellets three times a 
day. Therefore the strength and intensity of the pressure were controlled by the 
participants instead of by practitioner, which may have reduced the possibility of 
discomfort.  
 
As discussed in Chapter 4 (section 4.2), the previous RCTs (Gao, Zhang, Zhu, & 
Zhang, 2008; Huo, 2003; Kong, Ren, & Lu, 2006; Qi & Wang, 2008; Rao & Han, 
2006; Wang, 2004; Ye, Luo, & Xia, 2008) of ear-acupuncture/ear-acupressure for AR 
did not provide any relevant information about adverse events or reported that no 
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adverse events occurred. This is possibly because in those RCTs conducted in 
China, only severe adverse events were considered worthy of report. For example, 
the “sore feeling” was considered a normal reaction to acupuncture or acupressure 
(“De Qi” sensation). In contrast, in the main trial, participants were told to report any 
discomfort they believed was related to the treatment. Thus, all the mild and 
moderate discomforts were reported. Nobody reported any severe uncomfortable 
feeling throughout the whole trial period. All the reported adverse events were 
successfully managed in the first two weeks and no one withdrew from the trial due 
to the adverse events. Therefore, although there were some adverse events reported, 
this treatment is still considered as safe and well-tolerated.     
 
8.3.4 Implications for clinical practice 
Ear-acupressure is a semi-self-administered treatment. The practitioner is the person 
who applies pellets to certain ear acupoints while the participants themselves are the 
people who press the pellets three times daily during a whole week. During the eight-
week treatment period, participants only needed to visit the trial clinic once a week 
and it only took approximately 5 minutes to attach the pellets to the ear points during 
each visit. Therefore, this treatment is considered to be less time consuming 
compared with other physical interventions such as acupuncture, which often 
requires treatment twice a week and takes 20 to 30 minutes each treatment session. 
On the other hand, being a semi-self-administered treatment, the strength and 
duration of points stimulation are controlled by participants, instead of practitioners. If 
any unbearable uncomfortable feeling occurs, participants can easily take off the 
pellets by themselves without attending the clinic. This makes the ear-acupressure 
treatment more flexible compared with other therapies.  
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8.4 Conclusion and recommendations 
In clinical research, it is important to note that the present trial is the first randomised, 
sham controlled trial in the area of ear-acupressure for AR that followed a rigorous 
methodology. Therefore the findings from this study contribute to the body of 
knowledge in ear-acupressure practice by providing scientific evidence. It is 
suggested that the ear-acupressure protocol used in the main trial can be applied as 
a CAM method in clinical management of AR or as an adjunct to routine 
pharmacotherapy.  
 
This trial achieved some significant results in improving symptom severity and quality 
of life, but did not significantly reduce medication usage. It is recommended that 
further studies should incorporate a more defined medication use strategy. 
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Chapter 9: General Discussion and Conclusion  
This Chapter discusses the strengths and limitations related to the entire project on 
ear-acupressure for AR. In addition, recommendations are provided for further 
studies.  
 
This project investigated the efficacy and safety of ear-acupressure for the 
management of AR, by  
 systematically reviewing the current state of the clinical trial evidence from the 
English and Chinese literature on ear-acupuncture/ear-acupressure for AR; 
and 
 rigorously designing and methodically conducting a series of RCTs to address 
the methodological flaws identified in the systematic review to determine the 
short- and long-term efficacy and safety of ear-acupressure for AR. 
 
9.1 Main achievements  
The entire project contains five parts: two systematic reviews, two pilot studies and 
the main trial. 
 
Systematic review 1: Effectiveness and safety of ear-acupressure for AR  
This review of previous ear-acupuncture/ear-acupressure RCTs for AR was 
published in an international peer reviewed journal (Zhang et al., 2010). The findings 
of this systematic review suggested that although some RCTs presented positive 
results for the efficacy and safety of ear-acupuncture/ear-acupressure for AR, some 
major methodological weaknesses existed in those studies including: 
 Sham control was not included; 
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 Quality of life assessment was not used; 
 Clinical effectiveness was measured as a total effective rate;  
 Validated outcome measure were not used; 
 Adverse events were not mentioned; and  
 Intention-to-treat method was not used. 
Therefore, the findings from these RCTs could not be considered reliable due to the 
low methodological quality. Therefore a more rigorously designed RCT of ear-
acupressure for AR was required. 
 
Systematic review 2: Ear-acupuncture/ear-acupressure sham control methods 
In order to design a single-blinded, sham-controlled RCT on ear-acupressure for AR, 
a systematic review of all previous RCTs of ear-acupuncture/ear-acupressure was 
conducted to summarise and examine the sham/placebo control methods used. 
Based on the findings of this systematic review, the current trial employed the “non-
specific ear points” method for the sham control. 
 
Pilot study I: Ear-acupressure for AR RCT (feasibility study) 
Once the trial protocol was finalised, a pilot study was conducted between May and 
November 2008 to examine the feasibility of the protocol. According to feedback from 
this pilot study, a few minor changes were made to the original protocol. This was a 
critical step toward conducting the second pilot study and the main trial.  
 
Pilot study II: Ear-acupressure for AR RCT (efficacy study) 
The second pilot study was conducted between September and December 2008 in 
order to provide data for sample size estimation for the main trial. Sixty-three SAR 
participants were included in this pilot study, the results of which were published in a 
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peer reviewed journal (Xue et al., 2011) (Appendix A4.3). Based on the results of this 
study, it was estimated that the main trial required 116 participants in each group and 
232 in total. 
 
The main trial: Ear-acupressure for AR RCT 
The ear-acupressure for AR main trial was an adequately powered, international, 
multi-centre, single-blinded, RCT. This PhD project was to investigate the efficacy 
and safety of ear-acupressure for allergic rhinitis at the Australia centre of the multi-
centre trial. Therefore, only the results from the Australian trial centre were reported 
in this thesis.  The main trial at the Australia centre was conducted in the years of 
2009 and 2010. The trial recruiting and treatment period was scheduled in non-pollen 
season (between April and September); the follow-up period was ended at spring 
season (November). A total of 117 PAR participants were included in the trial. This 
main trial demonstrated that ear-acupressure was effective in relieving AR symptoms 
and improving participants’ quality of life. Short-term effectiveness was shown in: 
total nasal symptoms, sneezing, blocked nose, itchy nose, watery eyes, global nasal 
and non-nasal symptoms, global quality of life, activity and sleep; while long-term 
effectiveness was found for: total nasal symptoms, blocked nose and sleep. No 
severe adverse event was reported during the treatment and follow-up periods. Ear-
acupressure was also proven to be safe and well-tolerated for AR participants. 
However, ear-acupressure did not reduce participants’ relief medication usage. 
 
It is suggested that ear-acupressure is an effective and safe CAM method in clinical 
management of AR.   
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9.2 Strengths and limitations 
9.2.1 Strengths of the study 
This entire study was conducted following the flow of: systematic review 1→ 
systematic review 2 → Pilot study I → Pilot study II → main trial. This was a logical 
and consistent approach that firstly investigated the state of the current evidence, 
identified weakness in the existing trials and sought to refine the trial methodology 
before moving to the main trial. 
 
9.2.1.1 Systematic reviews prior to the RCT 
Two systematic reviews were conducted in 2008 before the development of the trial 
protocol. These two reviews provided the fundamentals of the clinical trial. Without 
them, the appropriate methodology including the important aspects of point selection 
and sham control method could not have been established. 
 
9.2.1.2 RCTs of ear-acupressure for AR 
Upon the finalisation and approval of the trial protocol, instead of commencing the 
main trial immediately, two pilot studies were conducted to test the feasibility and 
collect data for sample size estimation. As a result of the data and expertise gained 
in the pilot studies, it was possible to undertake the main trial as an international 
collaborative, multi-centre study to investigate the efficacy and safety of ear-
acupressure for AR.  
 
This trial assessed not only the short-term efficacy and safety (at the end of the eight 
weeks treatment period) but also the long-term efficacy and safety by including a 12-
week follow-up period.  
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Furthermore, three developed and commonly used questionnaires were used in this 
trial to evaluate the AR symptom severity and quality of life, they are: 
 Juniper 4 point symptom severity scale (Juniper et al., 2005 )  
 Spector 7 point VAS (Spector et al., 2003)  
 RQLQ(S) (Juniper, Thompson, Ferrie, & Roberts, 1999) 
RQLQ(S) was used instead of RQLQ, following the suggestion from the originator of 
this questionnaire, in order to increase the consistency and reliability of the results of 
questions about activities.  
 
With regard to the statistics, intention-to-treat analysis was employed in this trial for 
missing data to reduce bias. Given the fact that the AR symptoms may be relieved 
spontaneously along with the weather/environment change, all missing data was 
replaced using the conservative worst-case-scenario method. 
 
These aspects ensured the development of an appropriate methodology for this 
clinical trial. The results indicate that the rigorous design was also rigorously 
conducted, so the findings from the current trial are reliable, and the conclusions that 
ear-acupressure may be effective and safe for AR management are warranted.  
 
9.2.2 Limitations of the study  
9.2.2.1 Systematic reviews prior to the RCT 
Firstly, only English and Chinese language databases were searched due to 
language barriers, so some relevant studies published in other languages such as 
Korean and German may have been missed. This might have an impact on our 
conclusions. Secondly, these two systematic reviews were conducted in 2008 prior to 
designing the trial protocol and followed the Cochrane Handbook for Systematic 
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Reviews of Interventions 4.2.6 (Higgins & Green, 2006). However, there have been 
some amendments to the review methodology in the latest version of the Cochrane 
Handbook (Cochrane Handbook for Systematic Reviews of Interventions 5.1.0) 
(Higgins & Green, 2011). For instance, a PRISMA flow diagram is employed in the 
“Results of the search” section. The Jadad scale is no longer used for study 
methodological quality assessment. Instead, risk of bias assessment is employed.   
 
9.2.2.2 RCTs of ear-acupressure for AR 
There are some limitations of the RCTs, as follows: 
 The pellets used in the trial could not always be kept attached to the ear points 
throughout the whole treatment week. The pellets on the real points (such as 
Internal Nose (TG4) and Adrenal Gland (TG2p)) are more likely to be detached 
compared with those on the points used for the sham group due to the 
different locations.   
 Cost-effectiveness analysis was not performed in the current RCT. Firstly, 
instruments suitable for QALY calculation were not used. For example, SF-36 
was not employed as an outcome measure. SF-36 is a survey of patients’ 
general health. It is commonly used in health economics as a variable in the 
QALY calculation to determine the cost-effectiveness of a health intervention.  
 The symptom relief medication was not standardised. Participants were 
permitted to use their preferred symptom relief medication if needed. Although 
the medication usage data were categorised as antihistamines and others for 
the data analysis, due to the large variety of medications used by the trial 
participants, it was difficult to identify the medication type in the “others” 
category. This made it impossible to perform correlation analysis between cost 
and effectiveness. It is also possible that participants who use a preferred 
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relief medication tend to maintain use habitually even when symptoms are 
mild. By providing a different relief medication at the beginning of the trial, any 
such effect could be controlled for. 
The above mentioned limitations should be considered in future studies.  
 
9.3 Implications for future studies 
Based on the findings of the systematic reviews and the RCTs, it is suggested that 
further studies be conducted to address the following aspects. 
 
9.3.1 Cost-effectiveness of ear-acupressure 
As discussed in Chapter 2 (section 2.7), AR causes a significant impact on patients’ 
quality of life and is an economic burden that includes both the direct costs of health 
care and the indirect costs caused by patients’ incapacity for work. Therefore it is 
important to investigate the cost-effectiveness of an AR therapy rather than the 
efficacy and safety only. For example, a recent large sized study concluded that 
using acupuncture in addition to routine care to treat patients with AR was cost-
effective (Witt, Reinhold, Jena, Brinkhaus, & Willich, 2009). As a subtype of 
acupuncture, ear-acupressure is a kind of semi-self-administered technique. It 
requires less frequent clinic visits and shorter treatment duration than acupuncture. 
Thus, a separate cost-effectiveness evaluation is needed. The results may help with 
policy makers’ decision-making. It is recommended that further studies should 
include the SF-36 survey for QALY calculation.  
 
In addition, participants should be issued with a standard relief medication during the 
trial and given instructions for its use to ensure the relief medication data is more 
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accurate and avoid the bias due to unclear medication scoring. In accordance with 
this arrangement, correlation analysis between cost and effects is possible.  
 
9.3.2 Investigation of the mechanism 
The underlying mechanism of ear-acupressure requires investigation.  
 
Firstly, whether the effectiveness of ear-acupressure treatment was induced by the 
combination of the five points or was due only to specific points needs to be further 
assessed. Future studies may consider isolating the five ear points into subgroups 
and investigating the specific point function. 
 
Secondly, similar to acupuncture for the management of AR, the physiological 
mechanisms of ear-acupressure’s action on AR are yet to be elucidated. In recent 
years, a number of animal experiments and clinical trials have been conducted to 
investigate the anti-inflammatory effects of acupuncture (section 3.4.4). Being similar 
to acupuncture, ear-acupuncture/ear-acupressure may produce similar effects by 
means of similar pathways. For example, a study tested both ear-electroacupuncture 
and body electroacupuncture concluded that these two approaches both can 
effectively relieve endometriosis-induced dysmenorrhea, which may be closely 
related to their effects in reducing plasma PGE2 and increasing 6-Keto-PGF1alpha 
level (Jin, Sun, & Jin, H. F. 2009). Another study compared body acupuncture and 
ear-acupuncture for anxiety and concluded that both ear-acupuncture and body 
acupuncture treatment methods were effective in decreasing anxiety in preoperative 
patients (Wu, Liang, Zhu, Liu, & Miao 2011). However, the exact mechanism of ear-
acupuncture/ear-acupressure remains unclear. A RCT on ear-acupuncture for 
migraine suggested that the therapeutic specificity of auricular points exists and is 
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linked to the somatotopic representation of our body on the ear (Allais et al., 2011). 
When treating AR, an RCT demonstrated that ear-acupressure and body 
acupuncture had similar symptomatic relief effects and caused similar changes in 
cytokines (IL-4) and serum total IgE level in AR participants (Rao & Han, 2006). 
 
Further well-designed studies on ear-acupressure for AR will be needed to confirm 
any anti-inflammatory effects of ear-acupressure.  
 
9.4 Implications for clinical practice  
As discussed in Chapter 8 (section 8.3.4), ear-acupressure is a semi-self-
administered treatment. It is considered to be a less time-consuming and safer 
approach compared with the traditional acupuncture technique. Once the cost-
effectiveness of this therapy is established, it is anticipated that practitioners should 
consider this treatment once a week for at least eight weeks for AR management. 
Practitioners should give patients clear instructions with regard to the proper way of 
pressing pellets and maintaining their adhesion.  
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2. What you have to do if you participate 
If you would like to participate in this research project, you must be between 18 and 70 years 
of age and have had hay fever for more than two years. You will not be able to participate if 
you are currently under systemic corticosteroid therapy or have a current active respiratory 
disease such as asthma. We will need to know your medical history in relation to allergies, 
respiratory diseases and other conditions relevant to hay fever.  
 
This is a randomised, single blind, sham controlled clinical trial. You will be joining more 
than 200 other hay fever sufferers. You will have 50% chance of being randomly assigned to 
either the active ear-acupressure group or the control ear-acupressure group. This design 
allows us to compare the therapeutic effects of the active treatment with the control treatment. 
If the results of this study show that ear-acupressure is effective in the treatment of hay fever, 
then we will be happy to provide free active ear-acupressure treatment at the completion of the 
study to those who were in the control group. 
 
Your participation will involve an initial interview, a two-week run-in period, an eight-week 
treatment (real or sham) period and a twelve-week follow-up period. In total your involvement 
in this research project will continue for 22 weeks but you will only need to come to RMIT on 
nine occasions. 
 
During the initial assessment interview, you will be asked to attend the Clinical Trial 
Laboratory once. At this time you will sign an informed consent form, complete an 
assessment questionnaire, undertake an allergy test (skin prick test) and have a nasal 
examination. 
 
During the eight-week treatment period, you will be asked to attend the Clinical Trial 
Laboratory once a week for ear-acupressure treatment. The ear-acupressure will be done using 
commercially available stainless steel press-pellet tapes. The press-pellet measures 1 mm in 
diameter and is attached to a round adhesive tape in a tan colour which is close to skin colour 
and measures 5 mm in diameter. During the treatment, you will be seated comfortably in an 
arm chair and the practitioner will tape the pellets on the real or sham ear points on one of 
your ears. Once taped, the practitioner will show you how to press each pellet to achieve the 
therapeutic effects. There is no skin penetration in the treatment. In the subsequent treatment 
session, the other ear will be used for taping. Thus, the two ears will be used alternately on a 
weekly basis.  
 
You will be asked to press the five pellets three times a day once they have been taped on 
your ear. The practitioner will show you how to do this. The pressing technique is to promote 
the desired stimulation on the points used for hay fever. Over the week, some pellets may 
become unstuck and fall off. 
 
You will also be asked to:  
 record your medication usage using the diary form provided;  
 record the medical expenses related to your hay fever (ie. medical practitioner visits, 
diagnostic testing, purchase of home aids and services); 
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 complete the fortnightly assessment forms,  
 record how many press-pellets remain stuck to your ear per day using the diary form 
provided,  
 record your opinions about the ear-acupressure at the end of week 1 and the end of 
week 8, and record any adverse events you experience relating to ear-acupressure.  
 
These forms are designed to be easy to fill in and should not require much of your time. 
 
You should stay at the same address or in the same suburb for the whole 22 week since hay 
fever is affected by the environment and the allergens can be different in different areas. Such 
changes can influence the results of the research project. 
 
3. Potential risks of ear-acupressure treatment 
All the ear points to be used in this research project have been used in previous clinical 
studies and no adverse events have been reported. Generally, pain or discomfort associated 
with ear-acupressure is very minor. However, some individuals may experience some minor 
pain after prolonged pressing. Others may find the surface of their skin becomes temporarily 
sticky after the pellets are removed from the ear. If any unforeseen event occurs, please 
record it on the form provided and report it to the investigators as soon as possible.  
 
4. Skin prick test   
During the initial interview, you will be asked to have a Skin Prick Test. This test is to find 
out which allergen(s) cause your allergic reactions. A trained practitioner will perform the 
test following the standard procedure used in everyday practice. In order to obtain an accurate 
outcome of the Skin Prick Test it is preferable that you do not take oral medications for hay 
fever three (3) days prior to the test. Except for the three days prior to the skin prick test, you 
are expected to continue to take your medication as needed, and record the medication taken 
on the diary form.  
 
5. Physical Examination 
This involves physical examination of the nose during the initial interview. It will be carried 
out by a qualified medical practitioner. The examination includes a visual inspection of the 
anatomical position of the septal cartilage, the appearance of the mucosa of the nasal cavities, 
the physical nature and colour of the nasal turbinates, inspection of nasal secretions, and an 
assessment of the flow of air through the nasal passages. 
 
6. Confidentiality of information you provide 
All information provided by you and the data collected through this research project will be 
stored in a password protected computer program. All files will be kept securely in a locked 
filling cabinet at RMIT and will be retained for 15 years and then will be shredded and 
disposed of as required by the Therapeutic Goods Administration (TGA). Your records may 
be inspected by authorised persons for the purpose of an original data audit. In all 
publications, all your personal information will be removed so your identity will not be 
revealed. You have the right to access your personal data at a time prearranged with the 
investigators. 
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7. Your rights as a participant 
Participation in this project is voluntary. You may discontinue your participation at any time. 
You may ask the investigators any questions concerning the project at any time. Please 
contact me, Claire Shuiqing Zhang, on 9925 7002 or 0402103088 when you have any 
questions about this project. 
 
Yours sincerely, 
 
Claire Shuiqing Zhang,  
PhD Candidate 
The RMIT Chinese Medicine Research Group 
Any complaints about your participation in this project may be directed to the Executive Officer, RMIT Human Research Ethics Committee, 
Research & Innovation, RMIT, GPO Box 2476V, Melbourne, 3001.  The telephone number is (03) 9925 2251.   
Details of the complaints procedure are available from the above address.   
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10. Please list the regular medicine you use for Hay Fever and/or other drugs you take 
for other diseases/symptoms. 
 
Name of Medication Medical condition Dosage 
Frequency 
(times/day or 
week) 
How long 
have you 
been taking 
it? 
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4. Which allergic diseases do you suffer from? 
 Hay fever  Asthma             Eczema/Dermatitis    
 Others (please 
specify):              
 
     
     
5. At what age did your allergy occur for the first time? 
Hay fever: Age     
Asthma: Age     
Eczema/Dermatitis: Age     
Others (please specify):  
     
     
6. Your opinion of the cause of your hay fever  
 
     
     
     
7. Your hay fever symptoms are worse when: 
 Outdoors  At home  At night  During the day  On waking 
 Others (please specify):  
  
  
8. Do your hay fever symptoms occur in certain months or over the whole year? 
 In certain months  Whole year     
  
If your hay fever symptoms occur in certain months:  
(1). in which month(s) do your symptoms occur each year, and  
(2). which are the worst months? (Please circle the months) 
 
(1). Occur 
in months Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 
(2). Worse 
in months Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 
             
11. Does the severity of your hay fever symptoms relate to the environment? If yes, 
please specify. 
 Yes:  Garden     Outdoors  At home  Windy days  Smoke 
  Pollution  Cats  Dogs   
  Others (specify)  
   
 No   
 
 
  
12. Age of your house:  years 
      Period of residence:  months/years 
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13. Bedroom environment   
Pillow: Age  Filling type   
Mattress: Age  Filling type   
Type of bed cover:  Quilt/ Doona/ Eiderdown  Blankets 
   
14. Material used to make/fill bed 
cover:   
 Feathers  Wool  Cotton  Synthetic 
 
15. Do you have carpet in your house? If yes, what kind of material is it made of? 
 Yes:  Wool  Synthetic  Cotton 
 No  
  
16. Which of the following animals do you have regular contact with? 
 Dog  Cat  Horse  Rabbit  Sheep  Cow 
 Others 
(specify) 
    
Please estimate frequency and length of exposure  
  
17. Are there any foods that you avoid (please list):  
      Why?  
  
18. Do your hay fever symptoms occur for: 
 Less than 4 days per week 
 More than 4 days per week  
 
 
19. Do your hay fever symptoms occur for: 
 Less than 4 consecutive weeks 
 More than 4 consecutive weeks 
 
 
20. What is the severity of your current hay fever nasal symptoms, on a 4 point scale? 
(Please circle one number for each symptom to indicate its severity)  
 
Hay Fever Symptom 
Severity of Symptom 
(please circle one number for each symptom) 
None Mild Moderate Severe 
Sneezing 0 1 2 3 
Stuffy / blocked nose 0 1 2 3 
Runny nose 0 1 2 3 
Itchy nose 0 1 2 3 
Itchy eyes 0 1 2 3 
Watery eyes 0 1 2 3 
Redness of eyes 0 1 2 3 
Itchiness of ears and/or 
throat/palate 0 1 2 3 
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21. What is the severity of your current hay fever symptoms on a 7 point scale? (Please 
circle one number for each symptom to indicate its severity)  
*1 = None- to an occasional limited episode; 
  2 = Between 1 and 3;                                                                       
    3 = Mild- Steady symptoms but easily tolerable;             
  4 = Between 3 and 5;                                                                 
  5 = Moderately Bothersome- Symptoms hard to tolerate, may interfere with activities of daily living 
and/or sleep;                 
      6 = Between 5 and 7;                      
   7 = Unbearably severe- Symptoms are so bad, person can’t function all the time. 
 
 
22. What is the global assessment of nasal and non-nasal symptoms severity?   
Score = _______  (from 1 to 7) 
 
N.B. Please note this particular question assesses your combined nasal and non-nasal 
symptoms. Also, the scale is the reverse of the previous assessment scales: So 1 means 
unbearably severe; and 7 means no symptoms*. See below:   
*Key to symptoms: 
1 = Unbearably severe- Symptoms are so bad, person can’t function all the time 
2 = Between 1 and 3 
3 = Moderately Bothersome- Symptoms hard to tolerate, may interfere with 
activities of daily living and/or sleep 
4 = Between 3 and 5 
5 = Mild- Steady symptoms but easily tolerable 
6 = Between 5 and 7 
7 = None- to an occasional limited episode 
 
 
  
Hay Fever Symptom Severity of Symptom (see below)* 
Sneezing 1 2 3 4 5 6 7 
Runny nose 1 2 3 4 5 6 7 
Congestion 
(stuffiness)
1 2 3 4 5 6 7 
Itchy nose  1 2 3 4 5 6 7 
Postnasal drip 1 2 3 4 5 6 7 
Eye symptoms 1 2 3 4 5 6 7 
Throat symptoms 1 2 3 4 5 6 7 
Chronic cough 1 2 3 4 5 6 7 
Ear symptoms 1 2 3 4 5 6 7 
Headache 1 2 3 4 5 6 7 
Mental function 1 2 3 4 5 6 7 
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23. What treatment can ease your hay fever symptoms?  
      Please specify the name of any medications you find effective: 
     
     
      Please specify any other treatments you find effective for your hay fever symptoms: 
     
     
     
     
24. Have you been taking long acting antihistamines (such as Astemizole, Cetirizine, 
Loratadine) within the last three months? 
Yes    Please specify  
 When did you last take 
them 
               /                 /  
 No  
 
 
25. Have you been treated by oral cortisone/steroid tablets/cortisone injections within 
the last three years for hay fever or other conditions? 
 Yes Please specify  
 When                  /                   /  
 No 
 
 
26. Did you have Immunotherapy within the last three years for your hay fever? 
 Yes     Please specify 
when 
          /             /  
 No   
 
 
 
27. Have you changed your regular medication for hay fever in the last three months?  
 Yes     Please specify  
 When  
 No 
 
 
28. Have you ever been diagnosed with nasal polyps? 
 Yes In which year  
 No   
   
   
29. Do you have any other respiratory diseases? 
 Yes      TB       Asthma     Bronchiectasis    
  Others, specify   
 No   
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30. Do you have any other diseases including infectious diseases? 
 Yes Please specify  
 No 
 
 
31. If you are female, are you currently pregnant? 
 Yes     Please specify how many 
months 
 
 No  
 
32. What is your smoking status? 
 Current           Former              Never 
If current, how many cigarettes per day and for how 
many years? 
 per 
day 
 years
   
   
33. Are you wearing hearing aid? 
 Yes           
 No   
   
   
34. Have you been treated by ear-acupressure? If yes, for what condition? 
 Yes When   
 Please specify  
 No  
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Section II: 
Chinese medicine syndrome differential diagnosis questionnaire (please tick yes or no in the 
box): 
 
Differentiation of Hay Fever Syndrome Yes No 
A1 Is your nose blocked?    
A2 Do you have an itchy nose?    
A3 Do you sneeze a lot?    
A4 Do you have a running nose? Is the nasal discharge clear? Or white in colour?   
A5 Is your sense of smell reduced?   
A6 Do you catch cold easily or is it difficult for you to recover from colds?   
A7 Do you sweat easily, even when you are not doing exercise?   
A8 Do you often cough?   
B1 Do you get headaches or feel heavy headed?   
B2 Do you feel tired or exhausted?   
B3 Do your limbs feel heavy?   
B4 Do you lose your appetite?   
B5 Do you often have loose bowels?    
B6 Do you feel full in the stomach even when you haven’t just eaten?   
C1 Are you sensitive to the cold?    
C2 Do your limbs feel cold?   
C3 Do you feel weak, especially in the lumbar area, or the knees?   
C4 Do you usually get up in the night to pass urine frequently?   
C5 Do you get short of breath easily after slight physical exercise?   
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8. Physical Examination of Nose: 
 Septal Cartilage 
  Normal midline anatomic position   Abnormal anatomic position 
(Deviated) 
  Deviated to left   Deviated to right 
  Deviated to both sides 
 
 Nasal Cavities Mucosal Appearance 
  Normal nasal mucosa   Pale nasal mucosa 
  Hyperaemic nasal mucosa   Dehydrated nasal mucosa (dry nasal 
mucosa) 
  Hypertrophied nasal mucosa  
  Others  
 
 Nasal turbinates 
  Normal superior, middle and inferior turbinates 
  Hypertrophied turbinates   Atrophic turbinates 
  Swollen turbinates 
  Others  
 
 Nasal turbinates colour 
  Normal pink mucosal colour   Abnormal mucosal colour 
  Pale colour   Purplish, congested colour 
  Hyperaemic colour  
  Others  
 
 Nasal secretion 
  Normal thin mucoid nasal secretion 
  Abnormal nasal secretion 
  Watery discharge:     Serous 
   Seromucinous 
  Purulent discharge:   Yellow 
   Green 
   Yellow Green 
   Mucopurulent discharge 
   Post nasal discharge 
  
 Patient’s Nasal Pathway Situation 
  Patient breathes easily via nose 
  Patient cannot easily breathe via nose 
  Patient feels total nasal block 
  Others  
 
 Patient’s other associated clinical symptoms 
  Disturbed sleep   Pharyngitis 
  Tonsillitis   Snoring 
  Smelling function disorders 
  Others  
 
 330 
 
Clinical Diagnosis:_____________________________________________________ 
 
Recorder name:________________________________Date:_______/_______/_____
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A2.4 Fortnightly/Weekly 7 Point Visual Analogue Scale (VAS) 
7 Point Visual Analogue Scale (VAS) 
 
Please indicate your response on the following visual analogue scales by circling the 
appropriate number following the keys given below. As an example, if your sneezing is 
“Mild- Steady symptoms but easily tolerable” (= 3), then answer by circling number 
“3”as shown below. 
Sneezing 
 
1 2 3 4 5 6 7 
   
 
Now, please answer the following five questions by circling a number with the help of 
the Keys below the questions: 
 
Question 1.  Assessment of nasal symptom severity (during the 
last week). 
 
Sneezing 
 
1 2 3 4 5 6 7 
   
    
Runny nose 
 
1 2 3 4 5 6 7 
   
    
Congestion 
(stuffiness) 
1 2 3 4 5 6 7 
   
               
Itchy nose 
 
1 2 3 4 5 6 7 
   
               
Postnasal drip 
 
1 2 3 4 5 6 7 
   
               
Total nasal 
symptoms 
1 2 3 4 5 6 7 
   
 
Key to symptoms: 
1 = None- to an occasional limited episode 
2 = Between 1 and 3 
3 = Mild- Steady symptoms but easily tolerable 
4 = Between 3 and 5 
5 = Moderately Bothersome- Symptoms hard to tolerate, may interfere with 
activities of daily living and/or sleep 
6 = Between 5 and 7 
7 = Unbearably severe- Symptoms are so bad, person can’t function all the time 
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Question 2.  Assessment of non-nasal symptom severity (during 
the last week). 
 
 
Eye symptoms  1 2 3 4 5 6 7 
   
    
Throat symptoms  1 2 3 4 5 6 7 
   
    
Chronic cough 1 2 3 4 5 6 7 
   
               
Ear symptoms  1 2 3 4 5 6 7 
   
               
Headache  1 2 3 4 5 6 7 
   
               
Mental function 1 2 3 4 5 6 7 
   
 
 
Key to symptoms: 
 
1 = None- to an occasional limited episode 
2 = Between 1 and 3 
3 = Mild- Steady symptoms but easily tolerable 
4 = Between 3 and 5 
5 = Moderately Bothersome- Symptoms hard to tolerate, may interfere with 
activities of daily living and/or sleep 
6 = Between 5 and 7 
7 = Unbearably severe- Symptoms are so bad, person can’t function all the time 
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Question 3.  Global assessment of nasal and non-nasal symptom 
severity (during the last week).  
 
N.B.  Please note Question 3 assesses your combined / overall nasal and non-nasal 
symptoms. Also, the scale is the reverse of the previous assessment scales: So “1” means 
severe; and “7” means no symptoms.    
 
 
 
1 2 3 4 5 6 7 
   
Unbearable                                                                                             No symptoms 
 
 
 
Special key to Question 3 above: 
 
1 = Unbearably severe- Symptoms are so bad, person can’t function all the time 
2 = Between 1 and 3 
3 = Moderately Bothersome- Symptoms hard to tolerate, may interfere with 
activities of daily living and/or sleep 
4 = Between 3 and 5 
5 = Mild- Steady symptoms but easily tolerable 
6 = Between 5 and 7 
7 = None- to an occasional limited episode 
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Question 4.  Quality-of-life assessment of rhinitis (hay fever) 
severity (during the last week).  
 
 
 
1 2 3 4 5 6 7 
   
Severely 
affected 
     Excellent 
 
 
 
 
Key to Quality of life: 
 
1 = Quality of life is terribly affected in terms of sleep disturbance at night and/or 
impairment of social and/or recreational activities. 
2 = Quality of life is affected almost all the time in terms of sleep disturbance at 
night and/or impairment of social and/or recreational activities. 
3 = Quality of life is affected often in terms of sleep disturbance at night and/or 
impairment of social and/or recreational activities. 
4 = Quality of life is affected occasionally but it is tolerable in terms of sleep 
disturbance at night and/or impairment of social and/or recreational activities. 
5 = Quality of life is hardly affected in terms of sleep disturbance at night and/or 
impairment of social and/or recreational activities. 
6 = Quality of life is hardly noticed in terms of sleep disturbance at night and/or 
impairment of social and/or recreational activities. 
7 = Excellent quality of life in terms of sleep disturbance at night and/or 
impairment of social and/or recreational activities. 
 
 
  
 
 
References:  
Spector, S. L., Nicklas, R. A., Chapman, J. A., Bernstein, I. L., Berger, W. E., Blessing-Moore, J., . . . Tilles, S. 
A. (2003). Symptom severity assessment of allergic rhinitis: part 1. Ann Allergy Asthma Immunol, 91(2), 105-
114.  
 
 340 
 
A2.5 Fortnightly Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) 
Rhinoconjunctivitis Quality of Life Questionnaire 
 
PLEASE FILL IN THIS QUESTIONNAIRE BY TICKING [√] THE APPROPRIATE 
BOX 
ACTIVITIES 
We would like you to think of ways in which your nose/eye symptoms trouble you in your 
life. We are particularly interested in activities that you do but which are limited by your 
nose/eye symptoms. You may be limited because you do these activities less often, or less 
well, or because they are less enjoyable. These should be activities which you do frequently 
and which are important in your day-to-day life. These should also be activities that you 
intend to do regularly throughout the study. 
 
Here is a list of activities in which some people with nose/eye symptoms are limited. We hope 
that this will help you to identify the 3 most important activities in which you have been 
limited by your nose/eye symptoms during the last two weeks. Please fill in this form once 
a week. 
 
1. BICYCLING 16. SINGING 
2. READING 17. DOING REGULAR SOCIAL ACTIVITIES 
3. SHOPPING 18. HAVING SEXUAL RELATIONS 
4. DOING HOME MAINTENANCE 19. TENNIS 
5. DOING YOUR HOUSE WORK 20. TALKING 
6. GARDENING 21. EATING 
7. WATCHING TV 22. VACUUMING 
8. EXERCISING OR WORKING 23. VISITING FRIEND OR RELATIVES 
9. GOLF 24. GOING FOR A WALK 
10. USING A COMPUTER 25. WALKING THE DOG 
11. MOWING THE LAWN 26. OUTSIDE ACTIVITIES 
12. PLAYING WITH PETS 27. SITTING OUTSIDE 
13. PLAYING WITH CHILDREN OR GRANDCHILDREN 28. 
CARRYING YOUR ACTIVITIES AT 
WORK 
14. PLAYING SPORTS 29. TAKING CHILDREN TO THE PARK
15 DRIVING 30. OTHER NAME AN ACTIVITY OF YOUR CHOICE 
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(1)   SELECTED ACTIVITIES 
 
Please write your 3 most important activities in the box below and then tell us how much 
TROUBLED you have been by each co these activities during the last two weeks as a result 
of your nose/eye symptoms by checking the box [X] with the appropriate rating. Once you 
have chosen the 3 activities, stick to them throughout the entire study, so we can monitor 
any changes, if any. 
 
Activities 
Not 
troubled 
0 
Hardly 
troubled 
1 
Somewhat 
troubled 
2 
Moderately 
troubled 
3 
Quit a bit 
troubled 
4 
Very 
troubled 
5 
Extremely 
troubled 
6 
1. 
 
 
       
2. 
 
 
       
3. 
 
 
       
 
 
 
 
(2)  SLEEPING 
 
How TROUBLED have you been by each of these sleep problems during the last two 
weeks as a result of your NOSE/EYE SYMPTOMS? 
 
Sleep 
Not 
troubled 
0 
Hardly 
troubled 
1 
Somewhat 
troubled 
2 
Moderately 
troubled 
3 
Quit a bit 
troubled 
4 
Very 
troubled 
5 
Extremely 
troubled 
6 
4. 
Difficulty 
getting to 
sleep 
       
5. Wake up 
during the 
night 
       
6. Lack of 
good 
night’s 
sleep 
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(3)  NON-NOSE/ EYE SYMPTOMS 
 
How TROUBLED have you been by these problems during the last two weeks as a result of 
your NON-NOSE/EYE SYMPTOMS? 
 
Non-
nose/eye 
symptoms 
Not 
troubled 
0 
Hardly 
troubled 
1 
Somewhat 
troubled 
2 
Moderately 
troubled 
3 
Quit a bit 
troubled 
4 
Very 
troubled 
5 
Extremely 
troubled 
6 
7. Fatigue        
8. Thirst        
9. Reduced 
productivity  
       
10. Tiredness        
11. Poor 
concentration 
       
12. Headache        
13. Worn out 
       
 
 
(4) PRACTICAL PROBLEMS 
 
How TROUBLED have you been by each of these sleep problems during the last two 
weeks as a result of your NOSE/EYE SYMPTOMS? 
 
Practical 
problems 
Not 
troubled 
0 
Hardly 
troubled 
1 
Somewhat 
troubled 
2 
Moderately 
troubled 
3 
Quit a bit 
troubled 
4 
Very 
troubled 
5 
Extremely 
troubled 
6 
14. 
Inconvenience 
of having to 
carry tissues or 
handkerchief 
       
 
15. Need to 
rub 
nose/eyes 
 
       
16. Need to 
blow nose 
repeatedly 
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(5) NASAL SYMPTOMS 
 
How TROUBLED have you been by each of these symptoms during the last two weeks? 
 
Nasal 
symptoms 
Not 
troubled 
0 
Hardly 
troubled 
1 
Somewhat 
troubled 
2 
Moderately 
troubled 
3 
Quit a bit 
troubled 
4 
Very 
troubled 
5 
Extremely 
troubled 
6 
17.  
Stuffy/ 
blocked 
       
18. Running 
 
       
19. Sneezing 
 
       
20. Catarrh 
(drainage of 
mucous 
down the 
back of your 
nose) 
       
 
 
 
(6) EYE SYMPTOMS 
 
How TROUBLED have you been by each of these symptoms during the last two weeks? 
 
Eye 
symptoms 
Not 
troubled 
0 
Hardly 
troubled 
1 
Somewhat 
troubled 
2 
Moderately 
troubled 
3 
Quit a bit 
troubled 
4 
Very 
troubled 
5 
Extremely 
troubled 
6 
21. Itchy 
eyes  
       
22. Watering 
eyes 
       
23. Sore eyes 
       
24. Swollen 
eyes 
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(7) EMOTIONAL 
 
How TROUBLE have you been by each of these emotions during the last two weeks as a 
result of your  
NOSE/EYE SYMPTOMS? 
 
Emotional 
Not 
troubled 
0 
Hardly 
troubled 
1 
Somewhat 
troubled 
2 
Moderately 
troubled 
3 
Quit a bit 
troubled 
4 
Very 
troubled 
5 
Extremely 
troubled 
6 
25. 
Frustrated 
       
26. Impatient 
or restless 
       
27. Irritable 
 
       
28. 
Embarrassed 
by your  
symptoms 
       
 
 
References: 
Juniper, E. F., & Guyatt, G. H. (1991). Development and testing of a new measure of health status for clinical 
trials in rhinoconjunctivitis. Clin Exp Allergy, 21(1), 77-83.
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A2.6 Weekly Rhinoconjunctivitis Quality of Life Questionnaire with 
Standardised Activities/ RQLQ(S) 
Rhinoconjunctivitis Quality of Life Questionnaire 
with Standardised Activities / RQLQ(S) 
PLEASE COMPLETE ALL QUESTIONS IN THIS QUESTIONNAIRE BY CIRCLING 
THE NUMBER DURING THE LAST WEEK AS A RESULT OF YOUR NOSE/EYE 
SYMPTOMS. 
 
(1) ACTIVITIES 
How TROUBLED have you been by each of activities during the last week as a result of 
your NOSE/EYE SYMPTOMS? 
 
Activities Not troubled  
Hardly 
troubled 
at all  
Somewha
t troubled 
 
Moderatel
y troubled  
Quit a bit 
troubled  
Very 
troubled  
Extremel
y troubled 
1. Regular Activities at 
Home and at Work (your 
occupation or tasks that 
you have to do regularly 
around your home)  
0 1 2 3 4 5 6 
2. Social Activities (e.g., 
activities with your family 
and friends, playing with 
children and pets, sex, 
hobbies) 
0 1 2 3 4 5 6 
3. Outdoor Activities 
(e.g., gardening, mowing 
the lawn, sitting outdoors, 
sports, going for a walk). 
0 1 2 3 4 5 6 
 
(2) SLEEP 
How TROUBLED have you been by each of these sleep problems during the last week as a 
result of your NOSE/EYE SYMPTOMS? 
 
Sleep Not troubled  
Hardly 
troubled at 
all  
Somewhat 
troubled  
Moderately 
troubled  
Quit a bit 
troubled  
Very 
troubled  
Extremely 
troubled  
4. Difficulty 
getting to sleep 0 1 2 3 4 5 6 
5. Wake up 
during the 
night 
0 1 2 3 4 5 6 
6. Lack of 
good night’s 
sleep 
0 1 2 3 4 5 6 
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(3) NON-NOSE/ EYE SYMPTOMS 
 
How TROUBLED have you been during the last week as a result these symptoms? 
 
Non-
nose/eye 
symptoms 
Not 
troubled  
Hardly 
troubled  
at all  
Somewhat 
troubled  
Moderately 
troubled  
Quit a bit 
troubled  
Very 
troubled  
Extremely 
troubled  
7. Fatigue 
 0 1 2 3 4 5 6 
8. Thirst 
 0 1 2 3 4 5 6 
9. Reduced 
productivity  0 1 2 3 4 5 6 
10. 
Tiredness 0 1 2 3 4 5 6 
11. Poor 
concentratio
n 
0 1 2 3 4 5 6 
12. 
Headache 0 1 2 3 4 5 6 
13.  
Worn out 0 1 2 3 4 5 6 
 
 
 
(4) PRACTICAL PROBLEMS 
 
How TROUBLED have you been by each of these problems during the last week as a result 
of your NOSE/EYE SYMPTOMS? 
 
Practical 
problems 
Not 
troubled  
Hardly 
troubled 
 at all  
Somewhat 
troubled  
Moderately 
troubled  
Quit a bit 
troubled  
Very 
troubled  
Extremely 
troubled  
14. Inconvenience 
of having to carry 
tissues or 
handkerchief 
0 1 2 3 4 5 6 
 
15. Need to rub 
nose/eyes 
 
0 1 2 3 4 5 6 
16. Need to 
blow nose 
repeatedly 
0 1 2 3 4 5 6 
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(5) NASAL SYMPTOMS 
 
How TROUBLED have you been by each of these symptoms during the last week? 
 
Nasal 
symptoms 
Not 
troubled  
Hardly 
troubled 
 at all  
Somewhat 
troubled  
Moderately 
troubled  
Quit a bit 
troubled  
Very 
troubled  
Extremely 
troubled  
17.  
Stuffy/ 
blocked 
0 1 2 3 4 5 6 
18. Runny 
 0 1 2 3 4 5 6 
19. Sneezing 
 0 1 2 3 4 5 6 
20. Post nasal 
drip  0 1 2 3 4 5 6 
 
 
 
(6) EYE SYMPTOMS 
 
How TROUBLED have you been by each of these symptoms during the last week? 
 
Eye symptoms Not troubled  
Hardly 
troubled 
 at all  
Somewhat 
troubled  
Moderately 
troubled  
Quit a bit 
troubled  
Very 
troubled  
Extremely 
troubled  
21. Itchy eyes  0 1 2 3 4 5 6 
22. Watering 
eyes 0 1 2 3 4 5 6 
23. Sore eyes 0 1 2 3 4 5 6 
24. Swollen 
eyes 0 1 2 3 4 5 6 
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(7) EMOTIONAL 
 
How often during the last week have you been TROUBLED by these emotions as a result of 
your NOSE/EYE SYMPTOMS?  
 
Emotional None of the time 
Hardly 
any time 
at all 
A small 
part of 
the time 
Some of 
the time 
A good 
part of 
the time 
Most of 
the time 
All of 
the time
25. Frustrated 0 1 2 3 4 5 6 
26. Impatient or 
restless 0 1 2 3 4 5 6 
27. Irritable 0 1 2 3 4 5 6 
28. 
Embarrassed by 
your symptoms 
0 1 2 3 4 5 6 
 
 
 
 
References: 
 
Juniper, E. F., Stahl, E., Doty, R. L., Simons, F. E., Allen, D. B., & Howarth, P. H. (2005). Clinical outcomes 
and adverse effect monitoring in allergic rhinitis. J Allergy Clin Immunol, 115(3 Suppl 1), S390-413.  
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SET II 
 
For this set, close your eyes for a few moments and try to identify what you really feel 
about the treatment and its likely success. Then answer the following questions. 
 
1. At this point, how much do you really feel that therapy will help you to reduce your 
hay fever symptoms? 
 
1 2 3 4 5 6 7 8 9 
Not at 
all 
useful 
   Somewhat 
useful 
   Very 
useful 
 
 
2. By the end of the therapy period, how much improvement in your hay fever symptoms 
do you really feel will occur? 
  
1 2 3 4 5 6 7 8 9 
Not at 
all  
   Somewhat     Very 
much 
 
 
 
 
 
References: 
Deviliya, G. J., & Borkovecb, T. D. (2000). Psychometric properties of the credibility/expectancy questionnaire. 
J Behav Ther Exp Psychiatry, 31(2), 73-86.  
 
 
 
Additional Question: 
 
For the assessment of the effectiveness of the blinding procedure we used in this study, please 
indicated that the treatment that you believe you have received is (please √): 
 
□ Real ear-acupressure treatment 
 
□ Sham ear-acupressure treatment 
 
□ Not sure 
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Appendix three: Treatment effects for Pilot study II 
A3.1 Juniper 4 point symptom scores for Pilot study II 
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A3.2 Spector 7 point VAS for Pilot study II 
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A3.3 RQLQ 7 domains for Pilot study II 
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